FINAL PROGRAMME

57TH ANNUAL MEETING OF THE

EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
Content Page
EASD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
EASD Community Plaza . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Programme at a Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Ask the EASD e-Learning Expert Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . 28
EFSD Mentorship Programme . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
EUDF Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Tuesday, 28 September . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Claude Bernard Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Short Oral Discussion Event A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Short Oral Discussion Event B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Camillo Golgi Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Albert Renold Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Rising Star Symposium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Wednesday, 29 September .................................... 56
Short Oral Discussion Event C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
Short Oral Discussion Event D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Diabetes Prize for Excellence Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Thursday, 30 September . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
Short Oral Discussion Event E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
Short Oral Discussion Event F . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
Minkowski Lecture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Friday, 1 October . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Short Orals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Index of Presenting Authors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
Index of Symposium Speakers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
European Foundation for the Study of Diabetes (EFSD) . . . . . . . . . . . . . . . 208
Symposia on the occasion of the 57th EASD Annual Meeting . . . . . . . . . . . 212
Industry Symposia and Meet the Expert Sessions on the occasion
of the 57th EASD Annual Meeting (organised by INTERPLAN) . . . . . . . . . . 227
58th EASD Annual Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 300
 DEAR MEMBERS AND GUESTS,

It will be my great honour and pleasure to

welcome you to the 57th Annual Meeting of the
European Association for the Study of Diabetes,
which will take place from 27 September to
1 October 2021.

Due to the ongoing global impact of the COVID-19

pandemic, and the continued uncertainty
EASD

regarding travel, events, public gatherings and

public health, we have decided to run the EASD
Annual Meeting in 2021 again as an online event.

Last year the Virtual Meeting was a success with more than 20,000
participants, many of whom have expressed their appreciation of the
Scientific Programme and the increased opportunity for a flexible
participation. We have learned a lot and we have done our best to
take advantage of that lesson to develop a new, improved, virtual
EASD Annual Meeting 2021 platform to offer state-of-the-art diabetes
science along with a state-of-the-art virtual get together to connect
the global diabetes community and to provide educational
opportunities.

I look forward to welcoming you online – where the global diabetes

community will be united to experience the wealth of scientific content
provided in the EASD 2021 Scientific Programme – and wish you a
very successful and inspiring virtual EASD Annual Meeting 2021.

Stefano Del Prato

President EASD/EFSD

2
WELCOME ADDRESS

On behalf of the 2021 Scientific Programme

Committee, I have the pleasure of inviting you to
join us for the 57th EASD Annual Meeting and
look forward to welcome you online.

The EASD Annual Meeting has a longstanding

tradition of not only presenting science of the
highest calibre, but also of bringing researchers

EASD
and clinicians of the highest calibre together.

This year will be no exception and will be even more accommodating

thanks to our virtual platform offering ample opportunities to socialise
and network with peers from all over the world.

The scientific programme will comprise of stimulating symposia,

numerous oral presentations and short oral discussion sessions as
well as prize lectures, honouring the achievements of both
distinguished researchers and promising research talents.

I look forward to seeing you virtually from 27 September to

1 October 2021.

Mikael Rydén
Honorary Secretary EASD

3
 BOARD
S. Del Prato, IT President
C. Mathieu, BE Senior Vice-President
F. Gribble, UK Board Member
P.-H. Groop, FI Board Member
H. Mulder, SE Board Member
EASD

M. Roden, DE Board Member

M. Rydén, SE Board Member
P. Schrauwen, NL Board Member
M. Solimena, DE Board Member
C.D.A. Stehouwer, NL Board Member
P. Wilson, BE Board Member
W. Winzer, DE Board Member

HEADQUARTERS DÜSSELDORF
Managing Director and Chief Medical Officer
M. Grüsser
Rheindorfer Weg 3
40591 Düsseldorf
Germany
Email: [email protected]
Phone: +49-211-7584690
www.easd.org

4
HISTORY OF THE EASD ANNUAL MEETINGS

1965 Montecatini 2000 Jerusalem

1966 Aarhus 2001 Glasgow
1967 Stockholm (IDF) 2002 Budapest
1968 Louvain 2003 Paris (IDF)

EASD
1969 Montpellier 2004 Munich
1970 Warsaw 2005 Athens
1971 Southampton 2006 Copenhagen
1972 Madrid 2007 Amsterdam
1973 Brussels (IDF) 2008 Rome
1974 Jerusalem 2009 Vienna
1975 Munich 2010 Stockholm
1976 Helsinki 2011 Lisbon
1977 Geneva 2012 Berlin
1978 Zagreb 2013 Barcelona
1979 Vienna (IDF) 2014 Vienna
1980 Athens 2015 Stockholm
1981 Amsterdam 2016 Munich
1982 Budapest 2017 Lisbon
1983 Oslo 2018 Berlin
1984 London 2019 Barcelona
1985 Madrid (IDF) 2020 Virtual Conference
1986 Rome
1987 Leipzig
1988 Paris
1989 Lisbon
1990 Copenhagen
1991 Dublin
1992 Prague
1993 Istanbul
1994 Düsseldorf
1995 Stockholm
1996 Vienna
1997 Helsinki (IDF)
1998 Barcelona
1999 Brussels

5
 The mission of EASD is to promote excellence in diabetes care through
research and education

Since its foundation in 1965, EASD has been organising an Annual Meeting,
which has become the largest international annual conference on diabetes
research worldwide. Although the meetings have grown so dramatically,
they are still driven by the academic traditions of the founding members.
The EASD Meeting is a meeting of members where guests are welcome.
EASD

Chairpersons of oral presentations and poster sessions are chosen

exclusively from the EASD membership. The abstracts are evaluated on a
strictly anonymous basis and the selection is based exclusively on the
quality of the science, regardless of the place of work. The EASD Honorary
Secretary is solely responsible for inviting speakers and chairpersons for
symposia and lectures. Comments, advice and proposals from the
membership and the Programme Committee are welcome. None of the
speakers or chairpersons at the EASD Annual Meeting receives an
honorarium; reimbursement of their travel costs is exclusively provided by
the Association.

EASD and its Foundation EFSD are academic charities dedicated to

diabetes research. As an academic society, EASD encourages cooperation
with industry and other institutions conducting and funding diabetes
research. EASD is committed to transparency. In 2005, its Annual Meeting
endorsed the following policy with respect to duality of interest: prior to the
Meeting speakers invited to symposia or lectures declare to EASD the
existence of any relationship or arrangement that could be reasonably
considered to affect the content of the presentation. Invited speakers who
declare a duality of interest are asked by EASD to disclose this on a slide
of their presentation.

Any occasional, positive balance resulting from the Annual Meeting is used
to encourage further diabetes research in Europe. Increasingly, major end-
point related trials are carried out to evaluate diabetes treatments. EASD
encourages these trials and provides an outstanding forum to announce
their results to the scientific community.

6
The EASD regulations on the presentation of major clinical trials state that
all data of the trial must be openly available, and clear information should be
provided on the role of the funding source/sponsor on study design, data
collection, analysis and interpretation of the data. Moreover, a commentator,
nominated by the EASD Honorary Secretary, must have prior access to the
data in order to prepare an unbiased review. EASD Meetings are organised
in such a way as to ensure the academic independence of physicians and
scientists as the patients’ advocates.

EASD
Article 1, Section 2
Statutes of the European Association for the Study of Diabetes,
Diabetologia 1, 256-260 (1965):

The aims of the Association are to encourage and support research in the
field of diabetes, to rapidly spread acquired knowledge and to facilitate its
application.

7
 EASD HAS THE FOLLOWING STUDY GROUPS
AIDPIT - Artificial Insulin Delivery, Pancreas and Islet Transplantation Study Group
D&CVD - Diabetes and Cardiovascular Disease Study Group
DCSG - Diabetes and Cancer Study Group
DESG - Diabetes Education Study Group
EASD

DFSG - Diabetic Foot Study Group

DIAB IMAGE - Biomedical Imaging in Diabetes Study Group
DNSG - Diabetes and Nutrition Study Group
DPSG - Diabetes Pregnancy Study Group
EASDec - Eye Complications Study Group
EDEG - European Diabetes Epidemiology Group
EDNSG - European Diabetic Nephropathy Study Group
EGIR - European Group for the Study of Insulin Resistance
ExPAS - Exercise and Physical Activity Study Group
HSRHE-SG - Health Services Research and Health Economics Study Group
IHSG - International Hypoglycaemia Study Group
INCSG - Incretin Study Group
ISG - Islet Study Group
MSSG - Study Group on Metabolic Surgery
NAFLD - Non-alcoholic fatty liver disease
NEURODIAB - Diabetes Neuropathy Study Group
PCDE - Study Group on Primary Care Research in Diabetology
PSAD - Psychosocial Aspects of Diabetes Study Group
RM-SG - Reactive Metabolites in Diabetes Study Group
SGGD - Study Group on Genetics of Diabetes

8
JOIN EASD ““Join EASD and you will become a member of the
European diabetes family. This way, you can easily
improve your knowledge about all aspects of the
disease and follow the latest developments in the

THE GLOBAL world of diabetes available from both scientific as

well as clinical practice. It’s really worth it!”

DIABETES Prof. Krzysztof Strojek, Poland

COMMUNIT Y

EASD
“Being a diabetologist, a clinical researcher and
a basic researcher, becoming a member of the
EASD was and is the perfect thing to do: the EASD
combines these different facets in its activities in
order to promote the best clinical care and excel-
lence in diabetes research. Join the international
diabetes community!”

Prof. Miriam Cnop, Belgium

MEMBERSHIP

““I originally joined for professional reasons but

quickly realised that EASD offers much more.
Through EASD I have expanded my professional
network and joined a community of passionate
peers that is not just shaping the future of
diabetes research, care and education but also
working to ensure that, one day, a life-changing
breakthrough will be made.”

Asst. Prof. Dario Rahelić, Croatia

CONTACT EASD
The EASD Membership Department is ready to assist:

Phone: +49 211 758 469 0

Email: [email protected]

Web: easd.org/membership.html

9
 GENERAL INFORMATION

Format:
The 57th EASD Annual Meeting will take place online as a virtual event from
27 September to 1 October 2021. Registered delegates can access the
virtual EASD Annual Meeting via their personal MyEASD account by using
the personalised link or login details (both provided in their registration
confirmation).

All sessions in the scientific programme will take place live and interactive at
the time indicated in the programme (all references to a date or deadline
EASD

mentioned here refer to the Central European Time Zone (CEST).

Recordings of all sessions will be available afterwards, access will be limited
to registered delegates until 31 October 2021.

Registration:
Early Registration fees are € 100 for paid-up EASD members and € 215 for
non-members (until 27 July 2021).Late registration fees are € 150 for paid-
up EASD members and € 265 for non-members.
All registrations have to be made by means of the secured online
registration system either prior to or during the virtual EASD Annual Meeting
dates. For more information, please visit:
https://www.easd.org/annual-meeting/easd-2021.html.

Children under the age of 18 are not permitted to access the virtual EASD
Annual Meeting 2021.

Technical requirements:
Delegates must ensure at their own expense that they meet the technical
requirements necessary for participation in the virtual EASD Annual Meeting.
In addition to the necessary hardware, the following requirements will be
needed:
• A stable internet connection with a minimum of 5 MBITs (data speed)
to follow the online programme,
• A browser in an up-to-date version e.g. Chrome©, Firefox© or Safari©.

EASD recommends the participation via PC/Mac Computers and a

resolution of Full HD 1920x1080 pixels or higher. Cookie and Pop-Up
blocking measures may lead to problems. On smartphone/tablet devices
only basic viewing features are being supported. It is recommended to use
the Safari© browser for Apple© devices.

10
For Presenters and Chairpersons it is mandatory to connect through desktop
computers or notebooks with plugged in power supply.

EASD is not responsible if delegates are unable to successfully access the

virtual EASD Annual Meeting if they do not fulfil the technical requirements.

Delegates receive:
• Admission to live-streamed and recorded Scientific Programme
• Admission to the virtual Industry Exhibition
• Admission to the virtual EASD Community Plaza with EASD/EFSD
booth, Diabetologia and EASD Postgraduate Education booths as well

EASD
as the Associations’ Village
• Admission to interactive chat/discussion hubs

Certificates:
Kindly note, that your watch time will be monitored via your MyEASD
account, which will be the basis of your certification.
Certificates will be available for download via your MyEASD account. It will
be mandatory to complete the congress evaluation survey to receive
certification.
• Certificate of Attendance available from 4 October 2021
• EACCME Certificate available from 2 November 2021
• CME Certificate for German delegates (Teilnahmebescheinigung)
available between 4 October and 22 October 2021

Certificate of Attendance
The criteria for this certification is a minimum watch time of 60 minutes from
27 September to 31 October 2021.

EACCME Certificate
The virtual 57th EASD Annual Meeting 2021 has been accredited by the
European Accreditation Council for Continuing Medical Education
(EACCME®) to provide Continuing Medical Education for a maximum of 21
European CME credits (ECMEC®s).
Kindly note, that only the sessions within the scope of the EASD Scientific
Programme are considered for EACCME® Accreditation (colour code: dark
blue as shown in the online programme).
EACCME credits will be given per hour per day for EASD scientific sessions
watched live and on demand between 28 September 10:00 hrs and 31
October 2021 23:59 hrs.

11
 Tuesday, 28 September 2021 max. 5 ECMEC®s
Wednesday, 29 September 2021 max. 6 ECMEC®s
Thursday, 30 September 2021 max. 6 ECMEC®s
Friday, 1 October 2021 max. 4 ECMEC®s

EACCME® awards 1 ECMEC® for one hour of CME with a maximum of 6

ECMEC®s per day.
Kindly note that you will NOT automatically receive maximum
accreditation. Credits will be based on your monitored watch time.

CME Certificate for German delegates – Teilnahmebescheinigung

EASD

The virtual 57th EASD Annual Meeting 2021 has been accredited with 24
CME credits of category B by the Ärztekammer Nordrhein. 3 credits will be
given per half day for EASD scientific sessions (colour code: dark blue as
shown in the online programme) watched live and on demand between 28
September 10:00 hrs and 1 October 2021 17:30 hrs.

Tuesday, 28 September 2021 10:00 - 13:00 3 credits

13:15 - 17:20 3 credits
Wednesday, 29 September 2021 10:00 - 13:15 3 credits
13:30 - 18:00 3 credits
Thursday, 30 September 2021 10:00 - 13:15 3 credits
13:30 - 17:55 3 credits
Friday, 1 October 2021 10:00 - 13:30 3 credits
13:45 - 17:30 3 credits

The Ärztekammer Nordrhein is a national institution. German doctors need

to enter their EFN number when downloading their certificate. This EFN
Number will be automatically forwarded to the Ärztekammer Nordrhein after
the virtual meeting.

Teilnahmebescheinung für deutsche Teilnehmer

Das virtuelle 57. EASD Annual Meeting 2021 wurde von der Ärztekammer
Nordrhein mit 24 Fortbildungspunkten der Kategorie B anerkannt.
Für Vorträge innerhalb des wissenschaftlichen Programmes der EASD
(Farbcode: dunkelblau im online Programm) die zwischen dem 28.
September 10:00 Uhr und dem 1. Oktober 2021 17:30 Uhr live oder auf
Abruf verfolgt werden, werden pro halber Tag 3 Fortbildungspunkte
vergeben.

12
Dienstag, 28. September 2021 10:00 - 13:00 3 Punkte
13:15 - 17:20 3 Punkte
Mittwoch, 29. September 2021 10:00 - 13:15 3 Punkte
13:30 - 18:00 3 Punkte
Donnerstag, 30. September 2021 10:00 - 13:15 3 Punkte
13:30 - 17:55 3 Punkte
Freitag, 1. Oktober 2021 10:00 - 13:30 3 Punkte
13:45 - 17:30 3 Punkte

Die Ärztekammer Nordrhein ist eine nationale Einrichtung. Deutsche

Teilnehmer müssen beim Herunterladen ihres Zertifikats ihre EFN-Nummer

EASD
eingeben. Diese EFN-Nummer wird nach der Veranstaltung automatisch an
die Ärztekammer Nordrhein weitergeleitet.

Press Registration:
Press delegates can register online through the press registration system.
Registered journalists/media will have access to the EASD 2021 online
Press Centre and will receive press releases throughout the Meeting.
The entire scientific programme during the virtual EASD Annual Meeting
is open to registered journalists.

EASD/EFSD Booth:
The EASD/EFSD Booth is located in the virtual EASD Community Plaza.

Associations' Village:
The Associations' Village is located in the virtual EASD Community Plaza.

Presenters and Chairpersons:

All sessions in the scientific programme will take place live and interactive at
the time indicated in the programme schedule. Symposia and OP presenters
should present live and participate in follow-up Q&A session.

Short Oral presenters must pre-record their presentation and should be

present to view their session and be available for the follow-on discussions
and Q&A.

All presenters and chairpersons will receive detailed instructions and will be
invited to individual trial presentations with admin staff prior to the virtual
EASD Annual Meeting to test the presentation and Q&A system. In case of
any questions, please contact: [email protected].

13
 Short Oral Discussion Events
Short oral discussions rank equally with oral presentations. A short pre-
recorded PowerPoint presentation including audio must be uploaded to the
EASD virtual meeting platform by the indicated deadline prior to the start of
the virtual meeting; this will allow attendees to pre-view the short
presentation and thus be able to follow the short summary by the presenter
and engage in the discussion during the live/ interactive and moderated
short oral discussion session.

All short oral discussion sessions will take place during six Events which will
be held on Tuesday, Wednesday and Thursday from 11:30 to 15:00.
EASD

Short Oral Discussion Event A Tuesday 11:30 - 13:00

Short Oral Discussion Event B Tuesday 13:15 - 14:45
Short Oral Discussion Event C Wednesday 11:45 - 13:15
Short Oral Discussion Event D Wednesday 13:30 - 15:00
Short Oral Discussion Event E Thursday 11:45 - 13:15
Short Oral Discussion Event F Thursday 13:30 - 15:00

Exhibition:
For the duration of the virtual EASD Annual Meeting, delegates receive
access to the virtual Industry Exhibition. Delegates can select, before
accessing industry areas, which personal information can be passed to
companies – to this extent a list of companies will be available for viewing.

Disclaimer:
All efforts will be made to adhere to the programme as provided. However,
EASD and its agents reserve the right to alter or cancel, without prior notice,
any of the arrangements, timetables, plans or other items relating directly
or indirectly to the Meeting, for any case beyond their reasonable control.
EASD and conference organisers are not liable for any other loss or
inconvenience caused as a result of such changes.

Advisory Note to Delegates:

EASD is the official registration provider and all EASD activities are handled
via the official EASD website: www.easd.org.
Please be aware of “fraudulent” third party companies offering EASD
services e.g. registration.

14
EASD COMMUNITY PLAZA

The virtual EASD Community Plaza provides the EASD/EFSD Booth,

Diabetologia Booth and the EASD Postgraduate Education Booth as well as
the EASD Associations’ Village.

EASD ASSOCIATIONS’ VILLAGE

The EASD Associations’ Village brings together EASD Study Groups,

international diabetes associations and societies. Each represented
association has an exhibition stand displaying its current activities and

EASD
highlighting its work and practices.

The EASD Associations’ Village is a multinational networking platform which

aims to further increase and facilitate the exchange of knowledge and
experiences among diabetes associations, and to provide information to
physicians and researchers from all over the world on the existing
associations.

FOLLOW THE DISCUSSION

LIVE ON TWITTER

Tweet live
#EASD2021
and follow
@EASDnews

#EASD2021 15
 ABSTRACT SELECTION

All abstracts accepted for inclusion in the scientific programme were

considered anonymously and were scored by 40 Abstract Review
Committee Members. 17 Programme Committee Members designed the
programme and created Oral and Short Oral Discussion Sessions based
upon the anonymous abstracts.

Publication of Abstracts
Accepted abstracts are published in the Volume of Abstracts which is part
of Diabetologia, the official journal of the Association. Abstracts are available
EASD

online in the EASD Virtual Meeting.

Embargo Policies
Information contained in abstracts may not be released until 1 July when
the abstracts are published online. Oral Presentations are under embargo
until one (1) minute following the commencement of the speakers’
presentation. Short Oral Discussion Presentations are under embargo until
11:30 CEST on Tuesday, 28 September 2021.

16
 Abstract Review Committee

Paul W. Franks, SE Erik Serné, NL

Christian Herder, DE Björn Eliasson, SE
Adam G. Tabák, HU Jan Westerink, NL
Sarah Wild, UK Jan W. Eriksson, SE
Dorte Vistisen, DK Thomas Nyström, SE

EASD
Miriam Cnop, BE Raimund Weitgasser, AT
Lorenzo Pasquali, ES Helen Colhoun, UK
Meritxell Rovira, ES Martin Rutter, UK
Lorella Marselli, IT Daniël van Raalte, NL
Susanne J. Ullrich, DE Kåre I. Birkeland, NO
Alexandra Kautzky-Willer, AT Peter Rossing, DK
Patrick Schrauwen, NL Lena M. Thorn, FI
Francesca Amati, CH Samy Hadjadj, FR
Brendan Egan, IE Luigi Gnudi, UK
Martin Clodi, AT Frederik Persson, DK
Stephan Herzig, DE Steven E. Kahn, US
Mikael Rydén, SE Amalia Gastaldelli, IT
Maria Rohm, DE Martin Haluzik, CZ
Nicolas Venteclef, FR John Petrie, UK
Kirsi Virtanen, FI Maria Paula Macedo, PT

17
 PROGRAMME COMMITTEE
EASD

Patrick Schrauwen, Björn Eliasson, Miriam Cnop,

NL SE BE

Paul W. Franks, Amalia Gastaldelli, Helen Colhoun,

SE IT UK

Martin Haluzik, Lena M. Thorn, Stephan Herzig,

CZ FI DE

18
 EASD
Steven E. Kahn, Alexandra Kautzky- Peter Rossing,
US Willer, DE DK

Mikael Rydén, Erik Serné, Christian Herder,

SE (Chair) NL DE

©Spar_MirjaGeh_Photography

Lorenzo Pasquali, Raimund

ES Weitgasser, AT

19
 Tuesday, 28 September

Time Moscow Hall Paris Hall London Hall Madrid Hall

Opening
and
10:00
Presidential
EASD

Address

53rd Claude
10:30
Bernard Lecture

11:30 OP 1 OP 2 OP 3 OP 4

13:15 OP 7 OP 8 OP 9 OP 10

36th Camillo 15th Albert

Golgi Lecture Renold Lecture Rising Star
15:00
Symposium

16:40 Daily roundup / wrap up

20
 Tuesday, 28 September

Barcelona Hall St Petersburg Hall Rome Hall Athens Hall

EASD
Short Orals
OP 5 OP 6
Event A

Short Orals EFSD Mentorship

OP 11 OP 12
Event B Programme

Daily roundup / wrap up

21
 Wednesday, 29 September

Time Moscow Hall Paris Hall London Hall Madrid Hall

EASD/ADA Diabetologia
EASD

Symposium: Symposium: EASD/JDRF

Hypoglycaemia:
Optimising diabetes Learning from Symposium: Beta
10:00 unanswered
diagnosis, prevention machines – AI in cell (dys)function in
and care: Is precision diabetes research questions
type 1 diabetes
medicine the answer? and care

11:45 OP 13 OP 14 OP 15 OP 16

13:30 OP 19 OP 20 OP 21 OP 22

EASD/Novo Nordisk
15:15 Foundation Diabetes
Prize for Excellence

Adipose tissue as a
SARS-CoV-2 in
therapeutic target
human islets: a More from closed
16:30 in type 2 diabetes:
diabetes epidemic loops
What should we
in the making?
aim for?

17:30 Daily roundup / wrap up

22
 Wednesday, 29 September

St Petersburg
Barcelona Hall Rome Hall Athens Hall Milan Hall
Hall
EASD/AASD
The liver, heart
Joint
and kidney EASD e-

EASD
Symposium:
triangle: Fifty shades of Learning:
Medical nutrition
linking major ectopic fat in Insulin@100:
therapy, physical
organs in the diabetes insulin in specific
activity and
complications of populations
exercise for
dysglycaemia
diabetes

EASD e-Learning:
Short Orals
OP 17 OP 18 Fear of
Event C hypoglycaemia

EASD e-Learning:
Short Orals
OP 23 OP 24 EUDF Non-alcoholic fatty
Event D liver disease
Symposium:
It takes more
than just a
New data from registry to
Dapa-CKD improve care

EASD e-
Learning:
Results from Insulin@100:
TriMASTER:
a 3-way cross-over
insulin and
100 years insulin It is time to be exercise
trial of precision
treatment active medicine strategy of
2nd/3rd line therapy
in type 2 diabetes

Daily roundup / wrap up

23
 Thursday, 30 September

Time Moscow Hall Paris Hall London Hall Madrid Hall

EASD/ESC
Symposium:
EASD

Prediabetes: How come not Perspectives of the New ways to

10:00 Does it really every patient with diabetic foot understand kidney
matter? diabetes develops syndrome disease in diabetes
vascular
complications?

11:45 OP 25 OP 26 OP 27 OP 28

13:30 OP 31 OP 32 OP 33 OP 34

56th Minkowski
15:15
Lecture

Michael Berger
Will human-first
Debate:
The future of approaches finally
Who suffers more: Devices support
16:15 incretin-based get to the root
Are women with diabetes treatment
treatments cause of diabetic
diabetes at higher
vascular disease?
cardiovascular risk?

17:15 Daily roundup / wrap up

24
 Thursday, 30 September

St Petersburg
Barcelona Hall Rome Hall Athens Hall Milan Hall
Hall

5 years of
Inter-organ cardiovascular

EASD
EASD/ESE Next step in EASD e-
communication benefits of GLP-1
receptor agonists: Symposium: incretin therapy: Learning:
in diabetes and
evidence from Diabetes and from single to Obesity and type
systemic energy recent bone dual agonism 2 diabetes
homeostasis cardiovascular
outcomes trials

EASD e-Learning:
Insulin@100: in
Short Orals
OP 29 OP 30 combination with
Event E GLP-1 RAs and fixed
ratio combinations

Short Orals EASD e-Learning:

OP 35 OP 36 Diabetic neuropathy
Event F

New data from

Dapa-CKD
Small vessels, EASD e-
INNODIA -
big problems: Learning:
Translational
cerebral small- Harnessing Insulin@100:
approaches to
vessel disease - intracellular EMPEROR insulin in hospital
disease
a potential pathways for Preserved Study settings
modifying
microvascular therapy
therapy of type 1
complication of
diabetes
diabetes

Daily roundup / wrap up

25
 Friday, 1 October

Time Moscow Hall Paris Hall London Hall Madrid Hall

Debate: Preventing
Importance of diabetic
EASD

Current guidelines insulin clearance in complications –

Retinopathy and
10:00 on diabetes the regulation of 100 years on from
artificial intelligence
management glucose insulin: Which of
metabolism the newer classes
will prevail?

11:15 OP 37 OP 38 OP 39 OP 40

12:30 OP 43 OP 44 OP 45 OP 46

What do the cells

talk about and
Management of type
how? Extracellular My cells are getting
1 diabetes: ADA- Going to bed with
13:45 vesicles: old!
EASD Consensus diabetes
Report 2021 biomarker, Ageing in diabetes
diagnostic tool or
therapeutic vehicle

15:15 Daily roundup / wrap up

16:15

26
 Friday, 1 October

Barcelona Hall St Petersburg Hall Rome Hall Milan Hall

In-hospital EASD-Lancet
management of COVID-19 infection Symposium:

EASD
hyperglycaemia: still in people with Treatment of obesity:
a Cinderella of diabetes: a risky the future
diabetes combination of diabetes
management? treatment?

OP 41 OP 42 Finerenone: a new
approach to kidney
protection in patients
EASD e-Learning:
with type 2 diabetes
OP 47 Insulin@100: novel
technologies

Major results from the

Glycaemia Reduction A novel approach to
Approaches in
Turning stem cells problematic
Diabetes: a
into beta cells Comparative
hypoglycaemia:
EASD e-Learning:
Effectiveness (GRADE) the HARPdoc RCT Real World Evidence
Study

Daily roundup / wrap up

EASD General
Assembly

27
 ASK THE EASD E-LEARNING EXPERT SESSIONS

In these sessions you will be able to interact live with the EASD e-Learning
authors and ask all your questions in relation to the topic. We invite you to
join the discussion.

Wednesday, 29 September 2021, Milan Hall

10:00 - 11:30 Chair: E. Patrakeeva, Russia

P. Jarosz-Chobot, Poland and C. de Beaufort;

EASD

Luxembourg:
Insulin@100: diabetes in kids

12:00 - 13:30 Chair: P. Choudhary, UK

F. Snoek, Netherlands:
Fear of hypoglycaemia

14:00 - 15:30 Chair: B. Wolffenbuttel, Netherlands

M. Roden, Germany:
Non-alcoholic fatty liver disease

16:15 - 17:30 Chair: M. Cnop, Belgium

M. Riddell, Canada:
Insulin@100: insulin and exercise

Thursday, 30 September 2021, Milan Hall

10:00 - 11:30 Chair: P. Gaede, Denmark

N. Sattar, UK:
Obesity and type 2 diabetes

12:00 - 13:30 Chair: C. Mathieu, Belgium

T. Vilsboll, Denmark:
Insulin@100: in combination with GLP-1 RAs
and fixed ratio combinations

28
Thursday, 30 September 2021, Milan Hall

14:00 - 15:30 Chair: S. Dinneen, Ireland

S. Tesfaye, UK:
Diabetic neuropathy

16:00 - 17:30 Chair: E. Noctor, Ireland

G. Umpierrez, USA:
Insulin@100: insulin in hospital settings

EASD
Friday, 1 October 2021, Milan Hall

10:00 - 11:30 Chair: B. Wolffenbuttel, Netherlands

E. de Koning, Netherlands:
Insulin@100: physiological replacement

12:00 - 13:30 Chairs: E. Patrakeeva, Russia and P. Choudhary, UK

T. Battelino, Slovenia and M. Phillip, Israel:

Insulin@100: novel technologies

14:00 - 15:30 Chair: A. Tsapas, Greece

M. Evans, UK:
Real World Evidence

29
 EFSD MENTORSHIP PROGRAMME MEETING

Tuesday, 28 September 2021, 13:00 - 14:00, Athens Hall

A.J.M. Boulton, Chairman EFSD Mentorship Programme:

Welcome and Introduction of the Mentorship Programme

S. Del Prato, President EASD/EFSD:

Introduction of the Mentees

Presentation of the Mentees:

EASD

Giuseppe Daniele, Mentee 2017 cohort

Ernesto Maddaloni, Mentee 2107 cohort

Teresa Mezza, Mentee 2017 cohort

Shivani Misra, Mentee 2017 cohort

Rumyana Boykova Dimova-Draganova, Mentee 2018 cohort

Peter van Dijk, Mentee 2020 cohort

S. Del Prato, President EASD/EFSD:

Closing remarks

Questions and Answers

About the EFSD Mentorship Programme:

The major goal of the EFSD Mentorship Programme is to identify and

promote the advancement of the next generation of leading clinical
diabetologists in Europe. Through its various activities the Programme will
help award recipients (“Mentees”) develop into leaders by refining their skills
in the three cardinal areas of clinical diabetes, research and communication,
thereby keeping them in the field of diabetes and facilitating their
appointment to senior academic positions at major European institutions.

30
EUROPEAN DIABETES FORUM (EUDF) SYMPOSIUM

IT TAKES MORE THAN JUST A REGISTRY TO IMPROVE CARE: HOW

CAN WE USE DATA TO RAISE AWARENESS AND INITIATE ACTION TO
IMPROVE OUTCOMES FOR PEOPLE WITH DIABETES?

Wednesday, 29 September 2021, 14:00 - 16:00, Athens Hall

Chairs: C. Mathieu, Belgium, D.R. Matthews, UK

D.R. Matthews, UK:

EASD
Welcome and introduction

B. Mikkelsen, Norway:
Developing missing targets: the diabetes treatment target

R.J. Heine, USA:

Recommendations for implementation from the Strategic Forum Data &
Registries

Best practices – Using registries to improve quality of care and outcomes

T. Danne, Germany: SWEET
K. Eeg-Olofsson, Sweden: The Swedish National Diabetes Register

A. Rys, Poland:
How to re-use health data for the benefit of public health, research and
innovation?

Panel discussion and questions

B. Hauck, Germany: What’s in it for people with diabetes?
K. Khunti, UK: How to use feedback from registries in the clinical practice?
J. Soderberg. Sweden: What are the opportunities for research?
T. Sokol, Croatia: What is the perspective of the European Parliament?
M. Bujas-Bobanovic, Croatia: What are the perspectives from industry?

D.R. Matthews, UK:

Closing remarks

31
 CLAUDE BERNARD LECTURE

The Claude Bernard Lectureship recognises

contributions to the advancement of knowledge
in the field of diabetes mellitus and related
metabolic diseases. The Claude Bernard Award
is presented to the lecturer by the President of
Tuesday, 28 September

the EASD at the Award Ceremony immediately

preceding this lecture.

CLAUDE BERNARD LECTURERS

1969 Montpellier C. DE DUVE, BE 1995 Stockholm M. BERGER, DE
1970 Warsaw E.W. SUTHERLAND, US 1996 Vienna J.D. WARD, UK
1971 Southampton M. DEROT, FR 1997 Helsinki C.E. MOGENSEN, DK
1972 Madrid K. LUNDBAEK, DK 1998 Barcelona C. WOLLHEIM, CH
1973 Brussels A.E. DONIACH, CH 1999 Brussels J.P. ASSAL, CH
1974 Jerusalem T.R. FRASER, UK 2000 Jerusalem W. MALAISSE, BE
1975 Munich R.G. SPIRO, US 2001 Glasgow P.E. CRYER, US
1976 Helsinki H.G. HERS, BE 2002 Budapest M.R. TASKINEN, FI
1977 Geneva D.L. COLEMAN, US 2003 Paris M. BROWNLEE, US
1978 Zagreb W. CREUTZFELDT, DE 2004 Munich C.R. KAHN, US
1979 Vienna D.A. PYKE, UK 2005 Athens J.J. HOLST, DK
1980 Athens R.H. UNGER, US 2006 Copenhagen L. GROOP, SE
1981 Amsterdam G.R.E. MEYER-SCHWICKERATH, DE 2007 Amsterdam E. VAN OBBERGHEN, FR
1982 Budapest J. MIROUZE, FR 2008 Rome R.A. DEFRONZO, US
1983 Oslo C. HELLERSTRÖM, SE 2009 Vienna O. PEDERSEN, DK
1984 London P.J. LEFEBVRE, BE 2010 Stockholm M. KASUGA, JP
1985 Madrid E.F. PFEIFFER, DE 2011 Lisbon E. FERRANNINI, IT
1986 Rome W. K. WALDHÄUSL, AT 2012 Berlin D.J. DRUCKER, CA
1987 Leipzig H. KEEN, UK 2013 Barcelona M. LAAKSO, FI
1988 Paris T. DECKERT, DK 2014 Vienna D. ACCILI, USA
1989 Lisbon G. TCHOBROUTSKY, FR 2015 Stockholm H.-U. HÄRING, DE
1990 Copenhagen K.G.M.M. ALBERTI, UK 2016 Munich M.E. COOPER, AU
1991 Dublin E. SHAFRIR, IL 2017 Lisbon B. THORENS, CH
1992 Prague P.H. BENNETT, US 2018 Berlin J. TUOMILEHTO, KW
1993 Istanbul D. ANDREANI, IT 2019 Barcelona S.E. KAHN, US
1994 Düsseldorf G. REAVEN, US 2020 Virtual T. KADOWAKI, JP

32
10:00 OPENING CEREMONY AND Moscow Hall
PRESIDENTIAL ADDRESS
S. Del Prato, President, EASD and EFSD
followed by

10:30 53RD CLAUDE BERNARD LECTURE

Tuesday, 28 September
Chair: S. Del Prato, President, EASD and EFSD

Speaker: J.R. Zierath, Sweden

Title: Sending the right signals - How exercise keeps the

rhythm in metabolism

Juleen R. Zierath is a native of Milwaukee Wisconsin.

She is Professor of Experimental Physiology at
Karolinska Institutet, Stockholm, Sweden and
Professor of Integrative Physiology and Executive
Director at the Novo Nordisk Foundation Center for
Basic Metabolic Research at University of
Copenhagen, Denmark. She performs translational
research to delineate mechanisms for the development
of insulin resistance in type 2 diabetes. Current work is
focused on the role of epigenetic modifications in the
development of insulin resistance and the interaction between circadian
rhythms and exercise training in the control of metabolism.
Zierath is a member of the Nobel Assembly and Nobel Committee for
Physiology or Medicine. She is a Member of the Royal Swedish Academy of
Science and Academia Europaea. She is former Chairman of the Nobel
Committee, Chairman of the Board of Directors of the Keystone Symposia,
and President of the European Association for the Study of Diabetes. She is
past Editor-in-Chief of Diabetologia and currently holds editorial positions
with several scientific journals in the fields of endocrinology, metabolism,
and interdisciplinary sciences.
Zierath has received the Minkowski Prize from the European Association for
the Study of Diabetes, the Datta Lectureship Award for outstanding
achievement from the Federation of European Biochemical Society, the
Harold Rifkin Award for Distinguished International Service in the Cause of
Diabetes, the Knud Lundbaek Award from the Scandinavian Society for the
Study of Diabetes, J.B. Wolffe Memorial Lectureship Award from the
American College of Sports Medicine, The Nordic Medicine Prize for
Research in Diabetes, and a Distinguished Alumnus Award and Honorary
Doctorate of Science from University of Wisconsin-River Falls.
33
 11:30 - 13:00 Moscow Hall

OP 01 Macrovascular disease: large cohorts and large trials

Chair: P. Novodvorsky, Slovakia

1 Association of increased intima media thickness and arteriosclerosis

Tuesday, 28 September

with elevated fasting insulin levels in middle-aged persons

M. Röhling, K. Kempf, H. Kolb, M. Schneider, S. Martin, Germany

2 Kidney function measures and cardiovascular outcomes in people

with diabetes: the Hoorn Diabetes Care System cohort
E. Dal Canto, A.A. Van der Heijden, A.J. Van Ballegooijen, B.I. Lissenberg-
Witte, F. Rutters, P. Elders, J.J. Beulens, Netherlands

3 Comparative evaluation of GLP-1 receptor agonists and SGLT-2

inhibitors neuroprotective properties in transient brain ischaemia
A. Simanenkova, N. Timkina, O. Fuks, A. Khalzova, A. Shimshilashvili, V.
Timofeeva, T. Karonova, T. Vlasov, Russian Federation

4 Insulin resistance and risk of first stroke in type 2 diabetes: a

nationwide cohort study
A. Zabala, V. Darsalia, M. Lind, A.-M. Svensson, S. Franzén, B. Eliasson, C.
Patrone, M. Jonsson, T. Nyström, Sweden

5 Gender differences in cardiovascular risk, treatment, and outcomes:

a post-hoc analysis from the REWIND trial
G. Ferrannini, J.M. Maldonado, S. Raha, P. Rao-Melacini, R. Khatun, C.
Atisso, L. Shurzinske, H. Gerstein, L. Rydén, M.A. Bethel, Sweden, USA,
Canada

6 The importance of addressing multiple risk markers in type 2

diabetes: results from LEADER and SUSTAIN 6
E. Hein Zobel, B.J. Von Scholten, T.W. Hansen, F. Persson, S. Rasmussen,
B. Wolthers, P. Rossing, Denmark

34
11:30 - 13:00 Paris Hall

OP 02 Deep and shallow looks at human beta cell gene expression

Chair: L. Marselli, Italy

7 About time: functional and molecular effects of prolonged ex vivo

Tuesday, 28 September
human islet culture
M. Suleiman, E. Bosi, A. Piron, C. De Luca, M. Tesi, S. Del Guerra, D.L.
Eizirik, M. Cnop, P. Marchetti, L. Marselli, Italy, Belgium, USA

8 Identification of mRNA and microRNA transcripts that differ in

expression across islet donor sex, age and BMI
W.K. Wong, M.V. Joglekar, A.E. Sørensen, Y. Chew, F. Cheng, T. Loudovaris,
H.E. Thomas, R.C. Ma, W.J. Hawthorne, L.T. Dalgaard, A.A. Hardikar,
Australia, Denmark, Hong Kong

9 A single cell atlas of de novo beta cell regeneration in adult zebrafish

identifies hybrid cell states that facilitates diabetes reversal
P. Chawla, S.P. Singh, L.D. Silva, A. Hnatiuk, M. Kamel, B. Spanjaard, J.P.
Junker, N. Ninov, Germany, Belgium

10 An integrated analysis of human pancreatic islet single cells reveals

autocrine and paracrine interactions
E. Bosi, L. Marselli, M. Suleiman, M. Tesi, C. De Luca, S. Del Guerra, M.
Cnop, D.L. Eizirik, P. Marchetti, Italy, Belgium, USA

11 The transcription factor CEBPG regulates beta cell function

A. Lopez-Pascual, A. Lindqvist, J.A. Martínez-López, J. Hjerling-Leffler, N.
Wierup, Sweden

12 A long non-coding RNA that harbors a SNP associated with insulin

levels regulates TGM2 gene expression in pancreatic beta cells
I. González-Moro, M. Sebastián-delaCruz, H. Rojas-Márquez, A.
Olazagoitia-Garmendia, J. Mentxaka, L.M. Mendoza, A. Lluch, J.M.
Fernández-Real, F.J. Ortega, A. Castellanos-Rubio, I. Santin, Spain

35
 11:30 - 13:00 London Hall

OP 03 Many faces of diabetic pregnancy

Chair: R. Corcoy Pla, Spain

13 Sweet pregnancy: digital solutions for an effective management of

Tuesday, 28 September

diabetic pregnancies
M. Löhnert, S. Stichling, C. Eberle, Germany

14 Decreased insulin sensitivity during pregnancy after assisted

reproductive therapy in women in the Stork cohort
E. Qvigstad, S.D. Steintorsdottir, K. Godang, M.-C.P. Roland, T. Lekva, Norway

15 Maternal C-peptide reappearance in type 1 diabetes pregnancy:

Evidence of beta cell regeneration or fetal hyperinsulinism?
C.L. Meek, R. Oram, T. McDonald, D.S. Feig, A.T. Hattersley, H.R. Murphy,
UK, Canada

16 Maternal efficacy, safety, and pregnancy outcomes with degludec vs

detemir in the treatment of pregnant women with type 1 diabetes: an
international, multicentre, randomised trial
E.R. Mathiesen, R. Corcoy, F. Dunne, M. Ekelund, D.S. Feig, M. Hod, T. Jia,
B. Kalyanam, S. Kar, A. Kautzky-Willer, P. Damm, on behalf of the EXPECT
study group, Denmark, Spain, Ireland, Canada, Israel, India, Austria

17 Epigenetic alterations in offspring born to mothers with type 1

diabetes (the EPICOM study)
S. Knorr, A. Skakkebæk, J. Just, C. Trolle, S. Vang, Z. Lohse, B. Bytoft, P.
Damm, K. Højlund, D.M. Jensen, C.H. Gravholt, Denmark

18 Maternal exercise in gestational diabetes has sex-specific effects on

offspring adiposity and beta cell function
N. Boonpattrawong, S. Schaffner, A. Jang, M.S. Kobor, I. Laher, A.M. Devlin,
Canada

36
11:30 - 13:00 Madrid Hall

OP 04 GLP-1 receptor agonism: higher dose, combination therapy,

or both?

Chair: T. Nyström, Sweden

Tuesday, 28 September
19 Effect of semaglutide 2.4 mg on glucose metabolism and body
weight in adults with overweight or obesity and type 2 diabetes in the
STEP 2 trial
S.D. Pedersen, M. Davies, L. Færch, O.K. Jeppesen, A. Pakseresht, L.
Perreault, J. Rosenstock, I. Shimomura, A. Viljoen, T. Wadden, I. Lingvay,
Canada, UK, Denmark, USA, Japan

20 Tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and

safe when added to basal insulin for treatment of type 2 diabetes
(SURPASS-5)
D. Dahl, Y. Onishi, P. Norwood, R. Huh, H. Patel, A. Rodriguez, Germany,
Japan, USA

21 Semaglutide reduced cardiovascular events regardless of metformin

use: a post hoc exploratory subgroup analysis of SUSTAIN 6 and
PIONEER 6
M. Husain, A. Consoli, A. De Remigis, A.S. Meyer, S. Rasmussen, S. Bain,
Canada, Italy, Denmark, UK

22 Efficacy and safety of tirzepatide versus semaglutide once weekly as

add-on therapy to metformin in people with type 2 diabetes (SURPASS-2)
M.J. Davies, J.P. Frias, J. Rosenstock, F. Pérez Manghi, L. Fernández
Landó, B.K. Bergman, B. Liu, X. Cui, K. Brown, UK, USA, Argentina

23 Efficacy and safety of GLP-1RAs with or without baseline SGLT-2i:

post hoc analysis of the SUSTAIN 10 trial
M. Capehorn, A.-M. Catarig, O. Frenkel, M. Marre, H. Price, A.L.
Søndergaard, R. Pratley, UK, Denmark, France, USA

24 Adherence and persistence in patients with type 2 diabetes initiating

once-weekly versus once-daily injectable GLP-1 RAs in US clinical
practice (STAY study)
W.H. Polonsky, R. Arora, M. Faurby, J. Fernandes, A. Liebl, USA, India,
Denmark, Germany

37
 11:30 - 13:00 Barcelona Hall

OP 05 Epidemiology of diabetes complications

Chair: J.E. O'Reilly, UK

25 The natural history of 786 episodes of diabetic ketoacidosis in

Tuesday, 28 September

adults with type 1 and type 2 diabetes

K. Nash, E. Ooi, L. Rengarajan, E. Melson, L. Thomas, A. Johnson, D. Zhou,
L. Wallett, S. Ghosh, P. Narendran, P. Kempegowda, UK, Malaysia

26 Burden of established cardiovascular disease in people with type 2

diabetes and matched controls: hospital-based care, days absent from
work, costs, and mortality
S. Persson, K. Nilsson, K. Karlsdotter, J. Skogsberg, S. Gustavsson, J.
Jendle, K. Steen Carlsson, Sweden

27 One-year trajectories of impaired hypoglycaemia awareness in

young people with type 1 diabetes
A. Messaaoui, S. Tenoutasse, L. Hajselova, L. Crenier, Belgium

28 Association and familial co-aggregation of type 1 diabetes with

depression, anxiety and stress-related disorders: a population-based
cohort study
S. Liu, M. Leone, H. Larsson, P. Lichtenstein, B.M. D'Onofrio, S.E. Bergen,
R. Kuja-Halkola, A. Butwicka, Sweden, USA

29 High adherence to recommended diabetes follow-up procedures by

general practitioners is associated with lower estimated cardiovascular
risk
K. Nøkleby, T.J. Berg, I. Mdala, E.S. Buhl, T. Claudi, J.G. Cooper, K.F.
Løvaas, S. Sandberg, A.K. Jenum, Norway

30 Assessment of the effect of the COVID-19 pandemic on HbA1c

testing: implications for diabetes management and diagnosis
D. Holland, A.H. Heald, C.J. Duff, A.A. Fryer, UK

38
11:30 - 13:00 Saint Petersburg Hall

OP 06 Insights into diabetic retinopathy

Chair: H.-P. Hammes, Germany

31 Evaluation of maculopathy deep learning prediction models using

Tuesday, 28 September
the SDRNT1BIO cohort J
. Mellor, A. Storkey, P.M. McKeigue, H.M. Colhoun, SDRNT1BIO
Investigators, Diabetic Retinopathy Clinical Research Network, UK

32 Whole exome- and whole genome sequencing reveals novel rare

genetic variants for severe diabetic retinopathy in type 1 diabetes
N. Vuori, J. Haukka, A. Antikainen, V. Harjutsalo, C. Forsblom, N. Sandholm,
P.-H. Groop, FinnDiane Study Group, Finland

33 Mapping the daily rhythmic transcriptome in the diabetic retina

H.R. Winter, R. Silk, V. Tiwari, D. Simpson, A. Stitt, E. Beli, UK

34 Transcriptional and post-transcriptional impact of methylglyoxal in

human retinal endothelial cells: New players in diabetic retinopathy?
M. Aprile, A. Leone, S. Cataldi, F. Scognamiglio, C. Perfetto, A. Nicolò, C.
Nigro, V. Costa, C. Miele, A. Ciccodicola, Italy

35 Two-year progression of retinal neurodegeneration in paediatric

patients with type 1 diabetes: the role of glycaemic variability
M. Menduni, F. Picconi, M.C. Parravano, B. Russo, L. Chioma, S. Cianfarani,
D. Ylli, P.I. Patera, S. Frontoni, Italy, USA

36 Effect of calcium dobesilate in patients with subclinical diabetic

macular oedema: the CADODIAME study
O. Simo-Servat, E. Cordero-Vázquez, H. Brosa, A. Simó-Servat, M. Barraso,
X. Valldeperas, M. Barahona, J. García-Arumí, M. Rivas, C. Hernández, L.
Lehr, D. Zingg, R. Simó, Spain, Switzerland

39
 Short Oral Discussion Events

Short oral discussions rank equally with oral presentations. A short pre-
recorded PowerPoint presentation including audio must be uploaded to the
EASD virtual meeting platform by the indicated deadline prior to the start of
the virtual meeting; this will allow attendees to pre-view the short
presentation and thus be able to follow the short summary by the presenter
Tuesday, 28 September

and engage in the discussion during the live/ interactive and moderated
short oral discussion session.

All short oral discussion sessions will take place during six events which will
be held on Tuesday, Wednesday and Thursday from 11:30 to 15:00.

Short Oral Discussion Event A Tuesday 11:30 - 13:00

Short Oral Discussion Event B Tuesday 13:15 - 14:45
Short Oral Discussion Event C Wednesday 11:45 - 13:15
Short Oral Discussion Event D Wednesday 13:30 - 15:00
Short Oral Discussion Event E Thursday 11:45 - 13:15
Short Oral Discussion Event F Thursday 13:30 - 15:00

During the Short Oral Discussion Events, the presenting author must
be available or make arrangements for somebody with knowledge of
pre-uploaded presentation to discuss their work with the Chairperson
and the participants. The Short Oral Discussion event Chairperson is
a scientist with knowledge of the respective field of work. He/she will
elaborate on the findings together with the author.

Delegates are invited to discuss and comment on the short oral

discussions using the Virtual Conference Tool.

40
11:30 - 13:00 Short Oral Discussion Event A Page

SO 01 Diabetes epidemiology at scale: registries and 125

large databases

SO 07 Risk factors and consequences of poor glycaemic control 132

Tuesday, 28 September
SO 13 From pregnant women and mice 138

SO 19 Gastro-entero pancreatic factors 144

SO 25 Interaction of digestive system and glucose metabolism 150

SO 31 Clinical aspects of semaglutide 158

SO 37 New approaches to health care delivery 165

SO 43 Insulin pumps 171

SO 49 Neuropathy: from mechanisms to memory 177

SO 55 Not so sweet: cancer and diabetes 183

SO 61 Fatty liver always hides some complications 189

41
 13:15 - 14:15 Short Oral Discussion Event B Page

SO 02 Diabetes across generations 126

SO 08 Preservation versus destruction of beta cell mass 133

SO 14 Exercise effects beyond blood glucose 139

Tuesday, 28 September

SO 20 Carbohydrate and protein metabolism 145

SO 26 Cardiorenal consequences of SGLT2 inhibition 152

SO 32 Different aspects of SGLT2 inhibition 159

SO 38 Psychological aspects of diabetes care 166

SO 44 Glycaemic management in special settings 172

and popolations

SO 50 Nephropathy interventions: from blueberries to SGLT2 178

SO 56 Looking at the brain and its function 184

SO 62 Cardiovascular complications and drugs 190

42
13:15 - 14:45 Moscow Hall

OP 07 When men are mice: the study of human physiology in humans

Chair: M. Blüher, Germany

37 Exogenous LEAP2 improves postprandial glucose tolerance and

Tuesday, 28 September
reduces ad libitum food intake in men
C.A. Hagemann, M.S. Jensen, S. Holm, L.S. Gasbjerg, M.B. Christensen,
S.M. Heimbürger, F. Dela, T. Vilsbøll, B. Holst, F.K. Knop, Denmark

38 Effect of a hypercaloric diet on brain insulin sensitivity and liver fat

in normal-weight men
S. Kullmann, L. Wagner, R. Veit, J. Machann, A. Fritsche, H. Preissl, A.L.
Birkenfeld, M. Heni, Germany

39 Effect of lowering branched-chain amino acid levels in patients with

type 2 diabetes using sodium-phenylbutyrate
F. Vanweert, E. Erazo Tapia, T. Van de Weijer, J. Hoeks, V.B. Schrauwen-
Hinderling, P. Schrauwen, M.K. Hesselink, M. Blair, M. Neinast, Z. Arany, E.
Phielix, Netherlands, USA

40 Comparative effects of acute hypertriglyceridaemia with or without

elevation of non-esterified fatty acids on glucose tolerance, insulin
kinetics and beta cell function
D. Trico, B. Astiarraga, M. Seghieri, A. Mengozzi, L. Nesti, S. Baldi, A. Mari,
A. Natali, Italy, Spain

41 Pathophysiological changes during weight-loss induced remission

of type 2 diabetes in non-obese people
A. Al-Mrabeh, A. Barnes, K. Irvine, T. Kelly, K.G. Hollingsworth, D. Romeres,
C. Cobelli, R. Taylor, UK, Italy

42 The Single-Point Insulin Sensitivity Estimator (SPISE) in the

prediction of abnormal glucose metabolism in obese children: a long
term follow-up study
S. Dule, I. Barchetta, L. Bertoccini, F. Cimini, F. Sentinelli, G. Marini, S.
Loche, E. Cossu, M. Baroni, M. Cavallo, Italy

43
 13:15 - 14:45 Paris Hall

OP 08 Bugs on fire

Chair: M.P. Gillum, Denmark

43 Leukocyte counts and T cell frequencies differ between novel

Tuesday, 28 September

subgroups of diabetes
J.M. Ratter, H. Maalmi, S. Trenkamp, O.-P. Zaharia, W. Rathmann, N.C.
Schloot, K. Straßburger, J. Szendroedi, C. Herder, M. Roden, GDS Group,
Germany

44 Visceral adipose tissue-derived PD1-1+ Tconv from obese patients

with type 2 diabetes are pro-inflammatory cells with the potential to
recirculate to the blood stream
A. Giovenzana, E. Bezzecchi, C. Socci, M. Bissolati, C. Corsini, A. Terulla,
G.M. Scotti, S. Cardellini, A. Saibene, M. Morelli, E. Ruggiero, A. Petrelli,
Italy

45 Plasma lipopolysaccharide levels and its relationship with

glycaemic status and gut microbiota changes associated with H. pylori
infection
M. Clemente-Postigo, G.M. Martin-Nuñez, M.M. Roca-Rodriguez, L. Coin-
Araguez, I. Moreno-Indias, I.M. Cornejo-Pareja, F.J. Tinahones, Spain

46 TNFA mediates inflammation-induced effects on PPARG splicing in

adipose tissue and mesenchymal precursor cells
S. Cataldi, M. Aprile, C. Perfetto, D. Melillo, S. Giorgetti-Peraldi, M. Cormont,
P. Italiani, M. Blüher, J.-F. Tanti, A. Ciccodicola, V. Costa, Italy, France,
Germany

47 Empagliflozin-induced gut microbiota alternation reduces obesity in

high-fat diet-fed mice
J. Shi, H. Qiu, N. Hou, Y. Liu, F. Han, C. Kan, X. Sun, China

48 Heat shock 70 kDa protein 4 declines after bariatric surgery in

association with markers of inflammation and glycaemia
H. Fachim, Z. Iqbal, M. Gibson, I. Baricevic-Jones, A. Campbell, B. Geary, R.
Donn, A. Syed, A. Whetton, H. Soran, A. Heald, UK

44
13:15 - 14:45 London Hall

OP 09 SGLT2 inhibitor trials

Chair: J. Eriksson, Sweden

49 Safety and efficacy of SGLT2-inhibitors in over 70 years old type 2

Tuesday, 28 September
diabetic patients: 1 year of follow up
M.E. Lunati, M. Trevisan, A. Gandolfi, C. Pace, N. Betella, G. Favacchio, M.
Bulgheroni, L. Bucciarelli, G. Massari, C. Mascardi, A. Girelli, P.S. Morpurgo,
M. Mirani, C. Berra, P. Fiorina, Italy

50 Cardiorenal outcomes with ertugliflozin by baseline cardiorenal

medications: an analysis from VERTIS CV
C.P. Cannon, F. Cosentino, D.K. McGuire, B. Charbonnel, S. Dagogo-Jack,
R.E. Pratley, W.J. Shih, M. Maldonado, A. Pong, I. Gantz, R. Frederich, J.P.
Mancuso, U. Masiukiewicz, D.Z. Cherney, USA, Sweden, France, UK,
Canada

51 Efficacy and safety of dapagliflozin on kidney and cardiovascular

outcomes by baseline albuminuria: a secondary analysis of the DAPA-
CKD trial
H.J. Lambers Heerspink, S.W. Waijer, P. Vart, D.Z. Cherney, G. Chertow,
A.M. Langkilde, J.J. McMurray, P. Rossing, R. Correa-Rotter, B.V.
Stefansson, R. Toto, D. Wheeler, Netherlands, Canada, USA, Sweden, UK,
Denmark, Mexico

52 Ertugliflozin in older patients with type 2 diabetes: an analysis from

VERTIS CV
R.E. Pratley, C.P. Cannon, B. Charbonnel, D.Z. Cherney, F. Cosentino, D.K.
McGuire, W.J. Shih, M.N. Essex, D. Lawrence, P.L. Jones, J. Liu, I.A.
Adamsons, S. Dagogo-Jack, USA, France, Canada, Sweden, UK

53 Empagliflozin versus dapagliflozin for type 2 diabetes in

combination with metformin, dipeptidyl peptidase-4 inhibitor and
sulfonylurea: 3-year prospective study
E. Ku, H. Jeon, D.-H. Lee, T. Oh, Korea, Republic of

54 Effects of empagliflozin on uric acid levels and gout: observations

from the EMPA-REG OUTCOME trial
J.P. Ferreira, S.E. Inzucchi, B. Zinman, M. Mattheus, T. Meinicke, D. Steubl,
C. Wanner, France, USA, Canada, Germany

45
 13:15 - 14:45 Madrid Hall

OP 10 Peripheral neuropathy: pathophysiology and intervention

Chair: R. Malik, Qatar

55 Advanced glycation end-products are associated with diabetic

Tuesday, 28 September

neuropathy in young adults with type 1 diabetes

E.F. Al-Saoudi, M.M. Christensen, P. Nawroth, T. Fleming, E.E. Hommel,
M.E. Jørgensen, J. Fleischer, C.S. Hansen, Denmark, Germany

56 Progression and regression of small and large nerve fiber pathology

and dysfunction in recent-onset type 1 and type 2 diabetes: a 5-year
prospective study
G.J. Bönhof, A. Strom, K. Straßburger, Y. Karusheva, J. Szendroedi, M.
Roden, D. Ziegler, GDS group, Germany

57 Dys- but not demyelination is the hallmark of diabetic neuropathic

lesions
M. Le Marois, R. Longuespee, D. Schwarz, J. Szendrödi, P. Nawroth, T.
Fleming, Germany

58 Morphometric abnormalities of the brain in diabetic peripheral

neuropathy
G. Sloan, D. Selvarajah, K. Teh, M. Greig, P. Shillo, I.D. Wilkinson, S.
Tesfaye, UK

59 Pain processing areas of the brain demonstrate altered

microvascular perfusion during spontaneous neuropathic pain
M. Greig, G. Sloan, P. Shillo, D. Selvarajah, I.D. Wilkinson, S. Tesfaye, UK

60 Long-term high frequency (10 kHz) spinal cord stimulation in painful

diabetic neuropathy: a randomised controlled trial
E. Petersen, SENZA-PDN Investigators, USA

46
13:15 - 14:45 Barcelona Hall

OP 11 Cardiac complications: mechanisms and possible treatments

Chair: M. Haluzik, Czech Republic

61 Identifying myocardial insulin resistance by positron emission

Tuesday, 28 September
tomography combined with hyperinsulinaemic euglycaemic clamp: a
new strategy for phenotyping type 2 diabetes
R. Simo, M. Velasquez, O. Simó-Servat, A. Rojano, B. Paun, R. Marés, C.
Hernández, S. Aguadé, J.R. Herance, Spain

62 Do cardiovascular risk prediction models developed in primary care

patients with type 2 diabetes perform better than the general
population models? PREDICT cohort study
R. Pylypchuk, New Zealand

63 Autonomic dysfunction is associated with the development of

arterial stiffness: the Whitehall II cohort
J.F. Schaarup, M.S. Christensen, A. Hulman, L. Bjerg, C.S. Hansen, D.
Vistisen, A.G. Tabák, D.R. Witte, Denmark, UK, Hungary

64 Metabolically healthy obese and cardiovascular events in a

nationwide cohort study
G. Fauchier, A. Bisson, C. Semaan, J. Herbert, A. Bodin, D. Angoulvant, G.
Lip, P. Ducluzeau, L. Fauchier, France, UK

65 Distribution of cardiovascular risk in type 2 diabetes: results of an

analysis using data from CAPTURE study
J. Westerink, H. Bleken Oestergaard, E. Margo Hengeveld, J. Broe Honore,
V. Humphreys, F. Mach, G. Yadav, O. Mosenzon, Netherlands, Denmark,
Ireland, Switzerland, India, Israel

66 Association of circulating metabolomic biomarkers with incident

cardiovascular disease in type 2 diabetes: analysis from the Hong
Kong Diabetes Biobank
Q. Jin, A. Luk, C. Lim, E. Lau, R. Ozaki, H. Lee, W. So, Y. Huang, J. Chan,
Hong Kong Diabetes Biobank Study Group, R. Ma, China

47
 13:15 - 14:45 Saint Petersburg Hall

OP 12 The long and winding road to prevention and treatment of

diabetes

Chair: Z. Semnani-Azad, Canada

Tuesday, 28 September

67 Predicting sensitivity and resilience to modifiable risk factors for

cardiometabolic disease
H. Pomares-Millan, N. Atabaki-Pasdar, A. Poveda, I. Johansson, P.W.
Franks, Sweden, USA

68 Epidemiology of hypoglycaemic episodes leading to

hospitalisations in Denmark over the last two decades
M.H. Jensen, O. Hejlesen, P. Vestergaard, Denmark

69 The association of hypoglycaemia exposure with subsequent

adverse events and severe hypoglycaemia: preliminary results from
Hypo-RESOLVE
J.E. O'Reilly, A. Jeyam, T.M. Caparrotta, P. McKeigue, H. Colhoun, the Hypo-
RESOLVE consortium, UK

70 Heterogeniety in the effects of two anti-diabetic drugs evaluated

using machine learning applied to registry data
S. Franzén, A.-M. Svensson, M. Miftaraj, K. Eeg-Olofsson, B. Eliasson,
Sweden

71 Alendronate use and risk of type 2 diabetes: a Danish population-

based case-control study
R. Viggers, P. Vestergaard, Denmark

72 Sex-specific differences in patients deceased after bariatric surgery:

a retrospective, registry analysis
H. Beiglböck, E. Mörth, B. Reichardt, T. Stamm, B. Itariu, J. Harreiter, M.
Hufgard-Leitner, P. Fellinger, J. Eichelter, G. Prager, A. Kautzky, A. Kautzky-
Willer, P. Wolf, M. Krebs, Austria, Norway

48
EFSD European Foundation
for the Study of Diabetes

FU N D ING
DIABETES RESEARCH
SINCE 2000

GRANTS & FELLOWSHIPS

AVAILABLE THROUGHOUT THE YEAR

www.EuropeanDiabetesFoundation.org

49
 CAMILLO GOLGI PRIZE

Camillo Golgi (1843 - 1926) was awarded the

Nobel Prize in 1906 for his studies on the
nervous system and kidney physiology.
The EASD Camillo Golgi Prize is awarded for
outstanding contributions in the field of the
Tuesday, 28 September

histopathology, pathogenesis, prevention and

treatment of the complications of diabetes
mellitus, which have been carried out in Europe
by a member of EASD normally resident in
Europe. The awardee delivers a lecture named
in honour of Camillo Golgi at the EASD Annual
Meeting in the year of the award.

CAMILLO GOLGI LECTURERS:

1986 Rome G.C. VIBERTI, UK 2004 Munich A. CERIELLO, IT

1987 Leipzig D.J. EWING, UK 2005 Athens C. STEHOUWER, NL
1988 Paris C.E. MOGENSEN, DK 2006 Copenhagen M. LAAKSO, FI
1989 Lisbon G.B. BOLLI, IT 2007 Amsterdam P. FIORETTO, IT
1990 Copenhagen P.J. WATKINS, UK 2008 Rome A. AVOGARO, IT
1991 Dubln R. OSTERBY, DK 2009 Vienna P.-H. GROOP, FI
1992 Prague E. KOHNER, UK 2010 Stockholm D. ZIEGLER, DE
1993 Istanbul K.F. HANSSEN, NO 2011 Lisbon A. BIERHAUS, DE
1994 Düsseldorf J.E. TOOKE, UK 2012 Berlin G. PUGLIESE, IT
1995 Stockholm R. LANDGRAF, DE 2013 Barcelona T. LAURITZEN, DK
1996 Vienna M.-R. TASKINEN, FI 2014 Vienna S. TESFAYE, UK
1997 Helsinki H.-H. PARVING, DK 2015 Stockholm H.-P. HAMMES, DE
1998 Barcelona D.R. TOMLINSON, UK 2016 Munich P. ROSSING, DK
1999 Brussels E. STANDL, DE 2017 Lisbon B.M. FRIER, UK
2000 Jerusalem U. DI MARIO, IT 2018 Berlin P.P. NAWROTH, DE
2001 Glasgow A. FLYVBJERG, DK 2019 Barcelona R.A. MALIK, QA
2002 Budapest J. TUOMILEHTO, FI 2020 Virtual N. SATTAR, UK
2003 Paris A.J.M. BOULTON, UK

50
15:00 36TH CAMILLO GOLGI LECTURE Moscow Hall

Chair: S. Del Prato, President, EASD and EFSD

Speaker: H.J. Lambers Heerspink, Netherlands

Title: Personalising the treatment for patients with type 2

Tuesday, 28 September
diabetes: the mean is meaningless

Hiddo Lambers Heerspink is Professor of Clinical

Trials and Personalized Medicine and a clinical
trialist at the Department of Clinical Pharmacy and
Pharmacology at the University Medical Center
Groningen.

He is also visiting professor at the University of New

South Wales in Sydney. He studied pharmacy at the
University of Groningen and received his PhD from
the University Medical Center Groningen.

L. Heerspink’s research interests focus on optimsing

current treatment strategies and finding new therapeutic approaches to halt
the progression of kidney and cardiovascular diseases in patients with
diabetes with a specific focus on personalized medicine.

He leads numerous clinical trials with new interventions to reduce diabetes

related kidney and cardiovascular complications. His main expertise includes
clinical trial design, personalized medicine and methodological aspects and
statistical analyses of clinical trials.

L. Heerspink has authored and co-authored over 350 peer-reviewed

publications and is editorial board member of Diabetes Obesity and
Metabolism and the Clinical Journal of the American Society of Nephrology.

51
 ALBERT RENOLD PRIZE

The Albert Renold Prize and Lecture honours the

memory of A. Renold, the distinguished diabetologist
and researcher. The aim of the Lectureship is to
recognise an individual's outstanding contribution to the
advancement of knowledge in the field of research on
Tuesday, 28 September

the islets of Langerhans. Not only do many generations

of scientists consider A. Renold their principal mentor,
but he was also one of the founding fathers of EASD,
serving as Honorary Secretary (1965-1969) and
President (1974-1977). He trained with the eminent
diabetologist, E.P. Joslin, and was the first full-time
director of the Joslin Research Laboratory in the
mid-1950s. In 1963, he returned to Geneva, where
he founded the lnstitut de Biochimie Clinique. Under A. Renold
his leadership, it became an international centre of 1923 - 1988
excellence in islet research until his death in 1988.
P. Langerhans Jr. began medical studies at the
University of Jena and completed them in Berlin. The
discovery of the islets of Langerhans was published in
his thesis in 1869. Later he became Professor of
Pathology in Freiburg. He also gained fame due to his
discovery of the Langerhans cells in the skin. In 1887,
while living on the island of Madeira, progressive renal
failure brought his medical activities to an end and he
died of uraemia in 1888.
ALBERT RENOLD LECTURERS
2007 Amsterdam F. ASHCROFT, UK
2008 Rome J.-C. HENQUIN, BE
2009 Vienna B. THORENS, CH
2010 Stockholm S. SEINO, JP P. Langerhans Jr.
2011 Lisbon M. PRENTKI, CA 1847 - 1888
2012 Berlin D.L. EIZIRIK, BE
2013 Barcelona P. RORSMAN, UK
2014 Vienna S.E. KAHN, US
2015 Stockholm A. HATTERSLEY, UK
2016 Munich M.S. GERMAN, US
2017 Lisbon J. FERRER, UK
2018 Berlin R.N. KULKARNI, US
2019 Barcelona T. OTONKOSKI, FI
2020 Virtual G.A. RUTTER, UK

52
15:00 15TH ALBERT RENOLD LECTURE Paris Hall

Chair: C. Mathieu, Belgium

Speaker: P.L. Herrera, Switzerland

Title: Diabetes remission through insulin secretion by islet

Tuesday, 28 September
non-beta cells

Pedro Herrera is Full Professor at the Faculty of Medicine

of Geneva University (Switzerland) where he also heads
the Transgenic Core Facility, which he created in 2004, in
order to provide other laboratories with access to cutting-
edge mouse transgenic techniques.
Professor Herrera performed his first experiments of
selective in vivo cell ablation to study the formation of the
different pancreatic endocrine cell types in developing
mouse embryos under the guidance of Jean-Dominique
Vassalli, in the Department led by Lelio Orci. Thanks to the
Juvenile Diabetes Research Foundation, he rapidly
became an independent young investigator and he was
the first to report how to irreversibly “tag” with Cre
recombinase any specific type of cell in a mouse embryo, in order to follow its
progeny in the adult. This procedure quickly became the standard approach to study
the lineages of cells, from embryo to adult, in health and disease. What he did is to
selectively “activate” a gene that he called “reporter”, in order to label cells in mouse
tissues. The single-authored seminal paper (published in 2000) was regarded as
bringing ground-breaking discoveries with elegant experiments.
During the following years, he showed that there is a population of embryonic
pancreatic islet precursors that is multipotent as a cell population but, interestingly, at
the single cell level, they are strictly unipotent, i.e., they give rise to only one
endocrine cell type. Also, his work on pancreas biology shed light on the origin of
adipose tissue during degeneration associated with ageing, and more broadly, on
adult cell plasticity as well.
Most recently, observations made in his lab and published in Nature (2010, 2014 and
2019), Nature Cell Biology (2018) and Nature Communications (2021), have led to
an innovative breakthrough in the approach to developing new cell replacement
therapies for diabetes. Still an early discovery, he has shown that the adult pancreas
retains the ability to generate new insulin-producing cells after the near total loss of
functional β-cells. This unexpected finding revealed a high degree of cell plasticity, for
nearly all the reconstituted β-like cells were indeed adult specialized mature non-β
cells (α-, δ- and γ-cells), which had spontaneously reprogrammed to produce insulin.
This is particularly striking as his laboratory has now shown that the cellular plasticity
is also a feature of human pancreatic islet cells. Beyond diabetes, any degenerative
disease will likely benefit from this paradigm shift.

53
 15:00 RISING STAR SYMPOSIUM London Hall

Chair: M. Rydén, Sweden

The Rising Star Symposium aims to identify promising and innovative keen
Tuesday, 28 September

researchers who are developing their research activities in Europe. Selected

candidates will have the opportunity to present an overview of their past and
ongoing research activities during a multidisciplinary research symposium at
the EASD Annual Meeting. Four candidates have been selected.

Rising Star Awardees

2005 Athens P.-O. CARLSSON, SE 2013 Barcelona A. ROSENGREN, SE
A.L. GLOYN, UK J.A. POSPISILIK, DE
M. CNOP, BE D.J. PREISS, UK
N. MARX, DE G. SUMARA, FR
2006 Copenhagen G. DA SILVA XAVIER, UK 2014 Vienna G.H. GOOSSENS, NL
M. FLODSTRÖM-TULLBERG, SE H.J. HEERSPINK, NL
M. FEDERICI, IT L. PASQUALI, ES
J.J. MEIER, DE R. STIENSTRA, NL
2007 Amsterdam T. FRAYLING, UK 2015 Stockholm M. HENI, DE
A. TENGHOLM, SE D. HODSON, UK
E.R. PEARSON, UK R. NOGUEIRAS, ES
N. STEFAN, DE R.A. SCOTT, UK
2008 Rome R. MALLONE, FR 2016 Munich S. KOOIJMAN, NL
P. SCHRAUWEN, NL F. D.’ADDIO, IT
M. BLÜHER, DE N.K.A. SANDHOLM, FI
E. ZEGGINI, UK A.G. JONES, UK
2009 Vienna V. GAULT, UK 2017 Lisbon G. CHRISTOFFERSSON, SE
G.P. FADINI, IT T. MEZZA, IT
C. HERDER, DE A.R. WOOD, UK
V. LYSSENKO, SE Y. YAGHOOTKAR, UK
2018 Berlin M.R. BOON, NL
2010 Stockholm P. FRANKS, SE
E. DE FRANCO, UK
F. KNOP, DK
N. DE LEU, BE
C. LINDGREN, UK
N.R. GANDASI, SE
K. BOUZAKRI, CH
2019 Barcelona S. AHMAD, SE
2011 Lisbon I. PROKOPENKO, UK I. MIGUEL-ESCALADA, ES
M. RAVIER, FR I. NIKOLIC, ES
A.N.E. AKO, UK D. TRICO, IT
A.L. BIRKENFELD, DE 2020 Virtual B. MERINO ANTOLIN, ES
2012 Berlin A. BONNEFOND, FR L. DOLLET, SE
J. BEULENS, NL P. LARRAUFIE, FR
L. HERRERO, ES A. SMINK, NL
H. SELL, DE

54
Speaker: R. Pirzgalska, Portugal
Title: Neuroimmune regulation of tissue
physiology

Tuesday, 28 September
Speaker: I. Sen, Sweden
Title: Role of ncRNAs in the regulation of skeletal
muscle metabolism, growth and insulin
sensitivity

Speaker: B.N. Stocks, Denmark

Title: Proteomics in the study of metabolism and
type 2 diabetes

Speaker: O.P. Zaharia, Germany

Title: Refining novel diabetes classifications by
using markers of adipogenesis and adipose
tissue distribution

55
 10:00
Moscow Hall

EASD/ADA Symposium: Optimising diabetes diagnosis, prevention and

care: Is precision medicine the answer?
Wednesday, 29 September

Chair: P.W. Franks, Sweden; R.A. Gabbay, USA

M.S. Udler, USA:

Why precision medicine is the future of diabetes medicine

S.J. Griffin, UK:

Why precision medicine is not the future of diabetes medicine

J. Dennis, UK:
Precision diabetes medicine: the devil is in the details

Paris Hall

Diabetologia Symposium: Learning from machines – AI in diabetes

research and care

Chair: H. Mulder, Sweden; J. Busik, USA

F. Theis, Germany:
AI in research: the revenge of algebra?

A. Viñuela, UK:
Large scale multi-omics and genomics research

G. Hartvigsen, Norway:
AI applied in diabetes research and care: glucose control

R.A. Malik, Quatar:

AI applied in diabetes research and care: diabetic neuropathy

S. Wang, Canada:
AI applied in diabetes research and care: wound healing

Discussion

56
10:00
London Hall

EASD/JDRF Symposium: Beta cell (dys)function in type 1 diabetes

Chair: S.J. Richardson, UK; A.J. Kowalski, USA

Wednesday, 29 September
C. Evans-Molina, USA:
The role of beta cells in the pathogenesis of type 1 diabetes

R. Mallone, France:
Beta cell stress increases their autoimmune vulnerability

R. Mirmira, USA:
Reviving stunned beta cells: Is it possible?

Madrid Hall

Hypoglycaemia: unanswered questions

Chair: P. Choudhary, UK

R.A. Gubitosi-Klug, USA:

Persistent beta cell function and hypoglycaemia: What do we know?

A. Iqbal, UK:
CGM detected hypoglycaemia: What is its clinical relevance?

S.A. Amiel, UK:

Hypoglycaemic unawareness: Strategies to prevent and manage it?

57
 10:00
Barcelona Hall

The liver, heart and kidney triangle: linking major organs in the
complications of dysglycaemia
Wednesday, 29 September

Chair: C. Wanner, Germany

A. Sanyal, USA:
Liver

P. Nuutila, Finland:
Heart

P. Fioretto, Italy:
Kidney

Saint Petersburg Hall

Fifty shades of ectopic fat in diabetes

Chair: E. Serné, Netherlands

L.V.C. Valenti, Italy:

MAFLD versus NAFLD: Let the contest begin!

E. Eringa, Netherlands:
Perivascular fat and control of perfusion

A. Gemmink, Netherlands:
Skeletal muscle lipid droplets and insulin resistance; it is all about
dynamics!

S.J. Ullrich, Germany:

What role do fat cells play in the pancreas?

58
10:00
Rome Hall

EASD/AASD Joint Symposium: Medical nutrition therapy, physical

activity and exercise for diabetes

Wednesday, 29 September
Chair: B. Ukropcova, Slovakia; D. Zhu, China

A.-M. Aas, Norway:

Medical nutrition therapy in Europe

D. Yabe, Japan:
Medical nutrition therapy in Asia

D.H. Pesta, Germany:

Physical activity guidelines: East meets West!

C.-H. Kuo, Taiwan:

Exercise in the prevention and treatment of obesity and diabetes for
Asians

59
 11:45 - 13:15 Moscow Hall

OP 13 Diverse landscape of type 1 diabetes risk

Chair: T. Klupa, Poland

Wednesday, 29 September

73 Dietary factors and risk of islet autoimmunity and type 1 diabetes: a

systematic review and meta-analysis
A.-M. Lampousi, S. Carlsson, J.E. Löfvenborg, Sweden

74 Alterations in biomarkers of carbohydrate and lipid metabolism up

to 20 years before the diagnosis of type 1 diabetes: findings from the
AMORIS cohort
K. Herzog, V.E. Grill, N. Hammar, H. Malmström, M. Talbäck, G. Walldius, S.
Carlsson, Sweden, Norway

75 Decreasing age-at-onset of type 1 diabetes in a unique

multigenerational cohort
P. Leete, R.J. Aitken, I.V. Wilson, A.E. Long, K.M. Gillespie, UK

76 Follow up of a French cohort of children with a family history of type

1 diabetes
A. Vambergue, T. Lemoine, M. Kyheng, I. Fajardy, C. Leroy, P. Pigny, P.
Fontaine, France

77 Large socioeconomic differences in life expectancy and years spent

with complications of diabetes: a cohort study in the Scottish
population with type 1 diabetes, 2013-2018
A. Höhn, S.J. McGurnaghan, T.M. Caparrotta, A. Jeyam, J.E. O'Reilly, L.A.
Blackbourn, S. Hatam, C. Dudel, P.M. McKeigue, H.M. Colhoun, on behalf of
SDRN-Epi, UK, Germany

78 Risk of incident obstructive sleep apnoea in patients with type 1

diabetes: a population-based matched controlled cohort study
A.A. Tahrani, Z. Alshehri, A. Subramanian, N.J. Adderley, K.M. Gokhale, M.
Karamat, C.J. Ray, P. Kumar, K. Nirantharakumar, UK, Saudi Arabia

60
11:45 - 13:15 Paris Hall

OP 14 "Humanomics" in diabetes

Chair: N. Krahmer, Germany

Wednesday, 29 September
79 Fasting lipidomic analysis: a tool to unveil type 2 diabetes
heterogeneity
A.F. Pina, M.J. Meneses, R. Patarrão, R.T. Ribeiro, J.F. Raposo, L. Gardete-
Correia, R. Duarte, J.M. Boavida, J.L. Medina, F. Carli, B. Patrício, A.
Gastaldelli, M.P. Macedo, Portugal, Italy

80 Metabolite differences between type 2 diabetes and type 3c diabetes

secondary to chronic pancreatitis based on an untargeted
metabolomics approach
L. Qi, L. Li, China

81 Regional adipose tissue differences of the proteome reveals an

enhanced antioxidative and chaperone activity as a feature of lower
body fat in humans
M. Ahmed, M. Todorcevic, A. Van Dam, F. Karpe, Sweden, UK

82 Distinct associations of plasma methionine and cysteine with

regional fat distribution: the CODAM and the Maastricht studies
E.C. Tore, M.C. Brouwers, P.C. Dagnelie, A. Elshorbagy, S.J. Eussen, J.F.
Jansen, C.J. Van der Kallen, E. Kooi, S.J. Meex, T. Olsen, H. Refsum, C.G.
Schalkwijk, C.D. Stehouwer, K. Vinknes, M.M. Van Greevenbroek,
Netherlands, UK, Norway

83 Thrifty energy phenotype predicts weight regain: results of a

randomised controlled trial
K. Mai, L. Spranger, J. Bredow, U. Zeitz, U. Grittner, M. Boschmann, S.
Dickmann, N. Stobäus, R. Jumpertz-von Schwartzenberg, J. Spranger,
Germany

84 Cardiovascular risk of former obesity in healthy-weight Americans

M.P. Smith, W. Mansour, B. De Gale, Grenada

61
 11:45 - 13:15 London Hall

OP 15 Fat in the liver: where it comes from and how it can be prevented

Chair: A. Gastaldelli, Italy

Wednesday, 29 September

85 Long-term effect of a diet high in unsaturated fat and dietary protein

on intrahepatic lipids and circulating FGF21 levels: results of a
randomised controlled trial
C. Wernicke, A. Pohrt, L. Pletsch-Borba, N. Meyer, J. Machann, C.
Gerbracht, A.F. Pfeiffer, J. Spranger, K. Mai, Germany

86 Fructose intake from fruit juice and sugar sweetened beverages, but
not from fruit, is associated with higher intrahepatic lipid content: The
Maastricht Study
A.M. Buziau, S.J. Eussen, M. Kooi, C.J. Van der Kallen, M.C. Van Dongen,
N.C. Schaper, R.M. Henry, M.T. Schram, D.C. Pieter, M.M. Van
Greevenbroek, A. Wesselius, C.G. Schalkwijk, C.D. Stehouwer, M.C.
Brouwers, Netherlands

87 Hepatic glycogen and whole-body fat oxidation are not modulated by

one night of prolonged fasting in people with non-alcoholic fatty liver
K.H. Roumans, P. Veeraiah, J. Mevenkamp, B. Havekes, H.P. Peters, L.
Lindeboom, P. Schrauwen, V.B. Schrauwen-Hinderling, Netherlands

88 Visceral adipose tissue mitochondrial function is reduced in

humans with non-alcoholic fatty liver disease and correlates with
insulin resistance
K. Pafili, S. Kahl, D. Pesta, K. Strassburger, L. Mastrototaro, J. Pützer, B.
Dewidar, T. Sarabhai, I. Esposito, M. Schlensak, M. Roden, Germany, Egypt

89 Multi-organ multiparametric magnetic resonance imaging reveals

distinct ectopic fat distribution in type 2 diabetics with and without co-
existing obesity
T. Waddell, A. Bagur, D. Cunha, H. Thomaides-Brears, R. Banerjee, M. Brady, UK

90 Inferring causal pathways between metabolic processes and liver fat

accumulations: an IMI DIRECT study
N. Atabaki Pasdar, H. Pomares-Millan, R.W. Koivula, L.Z. Agudelo, G.N.
Giordano, A. Viñuela, E. Thomas, A. Mari, R. Hartmut, M. Ohlsson, J.D. Bell,
I. Pavo, E. Pearson, P.W. Franks, IMI DIRECT Consortium, Sweden, UK,
USA, Italy, Germany, Austria

62
11:45 - 13:15 Madrid Hall

OP 16 CKD in diabetes - a costly complication

Chair: P.-H. Groop, Finland

Wednesday, 29 September
91 Inside CKD: modelling the clinical and economic impact of routine
screening for albuminuria in people with type 2 diabetes
S. Nolan, J. Ärnlöv, M.C. Batista, S. Chadban, G.M. Chertow, L. De Nicola,
J.-M. Halimi, E. Kanda, G. Li, F.S. Mennini, J.F. Navarro-González, A. Power,
L. Retat, N. Tangri, J. Wish, UK, Sweden, Brazil, Australia, USA, Italy,
France, China, Spain, Canada

92 Hyper-filtration most strongly predicts decline in estimated

glomerular filtration rate: results from analysis of 73,583 person-years
S. Katoh, K. Yokoyama, M. Zeniya, Y. Sakamoto, K. Utsunomiya, R.
Nishimura, Japan

93 Metabolic syndrome, and not obesity, is associated with chronic

kidney disease in the general US population
E. Muraca, C. Ballabeni, R. Trevisan, G. Perseghin, S. Ciardullo, Italy

94 Non-dipping of nocturnal blood pressure is associated with

increased risk of mortality and kidney disease in type 1 diabetes
H. Hjortkjær, F. Persson, S. Theilade, S. Winther, N. Tofte, T. Ahluwalia, P.
Rossing, Denmark

95 High plasma concentrations of folic acid are associated with

increased risk of graft failure in renal transplant recipients with type 2
diabetes
J.L. Flores-Guerrero, M.C. Osté, A. Gomes Neto, M.F. Eisenga, G. Navis,
R.P. Dullaart, S.J. Bakker, Netherlands

96 Fully automated closed-loop versus standard insulin therapy in

adults with type 2 diabetes requiring dialysis: a randomised controlled
trial
L. Bally, C.K. Boughton, A. Tripyla, S. Hartnell, A. Daly, D. Herzig, M.E.
Wilinska, C. Czerlau, A. Fry, R. Hovorka, Switzerland, UK

63
 11:45 - 13:15 Barcelona Hall

OP 17 Don't stop moving: beneficial effects of exercise on diabetes and

beyond

Chair: F. Amati, Switzerland

Wednesday, 29 September

97 Regular exercise training improves skeletal muscle glucose uptake

in monozygotic twin pairs discordant for body weight
J. Hentilä, R. Ojala, M.S. Lietzén, M.A. Heiskanen, S.M. Honkala, R.
Lautamäki, E. Löyttyniemi, T. Malm, L. Lahti, J.O. Rinne, K.H. Pietiläinen, J.
Kaprio, J.C. Hannukainen, Finland

98 Dynamic profiling of the metabolic response to endurance exercise

M. Hoene, X. Zhao, C. Hu, A. Moller, P. Schneeweiss, M. Heni, A. Birkenfeld,
A.M. Niess, A. Peter, R. Lehmann, G. Xu, C. Weigert, Germany, China

99 Effects of regular exercise and carnosine on muscle energy

metabolism and cognitive performance in the overweight elderly
population
J. Ukropec, M. Nemec, M. Schon, L. Slobodova, V. Tirpakova, P. Krumpolec,
J. Cvecka, P. Turčáni, M. Sedliak, P. Valkovič, B. Ukropcová, Slovakia

100 Resistance exercise training protects beta cell from apoptosis in

an in vitro model of type 1 diabetes
G.A. Bronczek, G.M. Soares, E.M. Carneiro, A.C. Boschero, J.M. Costa-
Júnior, Brazil

101 High intensity interval training improves insulin sensitivity and

affects mitochondria dynamics in skeletal muscle of type 2 diabetes
humans
L. Mastrototaro, M. Apostolopoulu, D. Pesta, K. Strassburger, Y. Karusheva,
S. Gancheva, J. Szendroedi, M. Roden, Germany

102 TGFβ/mir143/145 associated mis-differentiation affects exercise

response
S.I. Dreher, S. Höckele, C. Hoffmann, P. Huypens, A. Moller, A.L. Birkenfeld,
A. Peter, J. Beckers, M. Hrabe de Angelis, C. Weigert, Germany

64
11:45 - 13:15 Saint Petersburg Hall

OP 18 Stressed out beta cell organelles

Chair: A. Zorzano, Spain

Wednesday, 29 September
103 Boosting the pancreatic beta cell function: the influence of
nanotopographical cues on cell clustering and organelles crosstalk
A. Galli, A. Marku, N. Dule, P. Marciani, M. Castagna, P. Milani, C. Lenardi,
G. Tedeschi, C. Perego, Italy

104 Bcl-xl limits transcriptional and functional decompensation of beta

cell mitochondria during chronic exposure to high glucose
D.J. Pasula, R. Shi, A.Z. Shih, A. Chaudry, B. Vanderkruk, B.G. Hoffman,
D.S. Luciani, Canada

105 The fate of intracellular sphingosine-1 phosphate regulates beta

cell response to fatty acids
Y. Tang, E. Gurgul-Convey, Germany

106 Manf overexpression in pancreatic beta cells protects from

streptozotocin-induced beta cell death and diabetes in mice
H. Li, T. Danilova, E. Palm, E. Hakonen, T. Otonkoski, M. Lindahl, Finland

107 Loss of autophagy, Transcription Factor EB (TFEB) and lysosomal

homeostasis limit beta cell function and survival under ER stress in
vitro and in vivo
Y. Zou, D.J. Pasula, M. Tang, D.L. Dai, G. Soukhacheva, B.C. Verchere, D.S.
Luciani, Canada

108 Cell biology of stress granules in pancreatic beta cells

E. Quezada, J. Vasiljevic, M. Solimena, Germany

65
 11:45 - 13:15 Short Oral Discussion Event C Page

SO 03 Diet, lifestyle and behaviour 127

SO 09 The ins and outs of insulin secretion 134

Wednesday, 29 September

SO 15 Novel methods to study metabolism in diabetes 140

SO 21 Metabolic control during and after pregnancy 146

SO 27 Glucose-lowering agents: Real World Evidence 153

SO 33 Non-insulin treatment in type 1 and type 2 diabetes 160

SO 39 Apps, devices and tools and their impact on diabetes care 167

SO 45 Seeing the full picture of diabetic retinopathy 173

SO 51 Burdens and bones in CKD and diabetes 178

SO 57 All you need to know about atherosclerosis and diabetes 185

SO 63 COVID-19: from the known to the unknown 192

66
13:30 - 15:00 Short Oral Discussion Event D Page

SO 04 Prediction models and precision medicine 129

SO 10 Beta cells to the grave in type 1 diabetes 135

Wednesday, 29 September
SO 16 The many faces of insulin sensitivity 141

SO 22 News from the drug pipeline 147

SO 28 GLP-1 receptor agonists and weight loss 154

SO 34 News from new insulins 162

SO 40 CGM 168

SO 46 Diabetic foot: from cost to COVID 174

SO 52 Predictors of diabetic kidney disease 180

SO 58 Brain, kidney and vascular complications 186

SO 64 Cardiac complications in diabetes and prediabetes 193

67
 13:30 - 15:00 Moscow Hall

OP 19 Diet and nutrition

Chair: M.A. Schroijen, Netherlands

Wednesday, 29 September

109 Reduced carbohydrate and increased protein and fat during weight
loss improve the atherogenic lipid profile in type 2 diabetes
M.N. Thomsen, M.J. Skytte, A. Samkani, A. Astrup, J. Frystyk, E.
Chabanova, B. Hartmann, J.J. Holst, T.M. Larsen, S. Madsbad, F. Magkos,
H.S. Thomsen, R.L. Walzem, T. Krarup, S.B. Haugaard, Denmark, USA

110 Intra-organ fat content during weight loss-induced remission of

type 2 diabetes in people with normal or raised BMI
R. Taylor, A.C. Barnes, K.M. Irvine, T.L. Kelly, K.G. Hollingsworth, N. Sattar,
M.E. Lean, A. Al-Mrabeh, UK

111 Habitual intake of dietary methylglyoxal is associated with less low-

grade inflammation, but also with impaired retinal microvascular
function: The Maastricht Study
K. Maasen, S.J. Eussen, P.C. Dagnelie, A.J. Houben, C.A. Webers, M.T.
Schram, T.T. Berendschot, C.D. Stehouwer, A. Opperhuizen, M.M. Van
Greevenbroek, C.G. Schalkwijk, Netherlands

112 Very-low dose pre-meal whey protein microgels reduce

postprandial glucose in type 2 diabetes: a randomised, placebo-
controlled crossover study
O. Johansen, I.J. Neeland, R.L. Zagury, B. Ahrén, J. Neutel, E. Perrin, K.
Reyes, E. Berk, M. Von Eynatten, L.H. De Gregório, Switzerland, USA,
Brazil, Sweden

113 Investigation of sex-dependent effects of a one-year low-carb- vs

low-fat intervention in patients with high-risk prediabetes - a
randomised controlled trial
S. Kabisch, A. Hustig, U. Dambeck, M. Kemper, C. Gerbracht, C. Honsek, J.
Machann, M.A. Osterhoff, A.F. Pfeiffer, Germany

114 The effect of dietary carbohydrate restriction beyond weight loss

on health-related quality of life and cognition
N.J. Jensen, H.Z. Wodschow, M.J. Skytte, A. Samkani, A. Astrup, J. Frystyk,
B. Hartmann, J.J. Holst, T.M. Larsen, S. Madsbad, F. Magkos, K.W.
Miskowiak, J. Rungby, S.B. Haugaard, M.N. Thomsen, Denmark

68
13:30 - 15:00 Paris Hall

OP 20 Keeping the balance in islet secretion

Chair: A. Tengholm, Sweden

Wednesday, 29 September
115 Re-internalised Phogrin/IA-2beta is targeted to multigranular
bodies devoted to degradation of young insulin secretory granules
I. Kalaidzidis, K.-P. Knoch, J.M. Torkko, A. Sönmez, K. Ganss, Y. Kalaidzidis,
M. Solimena, Germany

116 The importance of islet δ-cell ATP-sensitive K+channel (KATP)

function for somatostatin secretion and islet hormone balance
T.G. Hill, Q. Zhang, A.I. Tarasov, L.J. Briant, C. Guida, R. Terron Exposito, P.
Rorsman, F.M. Ashcroft, UK

117 Islet beta cell synchrony and second phase activity are governed
by α cells upon physiological nutrient mixtures
M. Raoux, M. Jaffredo, K. Leal Fischer, J. Gaitan, A. Pirog, S. Renaud, J.
Lang, France

118 Pancreatic alpha and beta cells are globally phase-locked

H. Ren, Y. Li, C. Han, Y. Yu, B. Shi, X. Peng, S. Wu, X. Yang, L. Chen, C.
Tang, China

119 Investigating the presence of proglucagon-derived peptides in

human pancreas
T. Mezza, N. Wewer Albrechtsen, G. Di Giuseppe, C. Cefalo, S. Moffa, F.
Cinti, U. Capece, S. Menchi, G. Quero, S. Alfieri, A. Giaccari, J.J. Holst, Italy,
Denmark

120 Modulation of cholesterol homeostasis via pancreatic LDL receptor

alteration: impact on beta cell secretory activity
A. Marku, L. Da Dalt, A. Galli, N. Dule, D. Norata, A.L. Catapano, C. Perego,
Italy

69
 13:30 - 15:00 London Hall

OP 21 The adipocentric angle

Chair: N. Venteclef, France

Wednesday, 29 September

121 Yes-associated protein 1 in adipocytes plays an important role in

glucose homeostasis
D.J. Han, R. Aslam, T. Ojha, D.A. Yuen, C.T. Luk, Canada

122 Aberrant overexpression of HOTAIR inhibits abdominal

adipogenesis through the epigenetic remodelling of genome-wide DNA
methylation and transcription
F.-C. Kuo, Y.-C. Huang, P.-Y. Chen, Taiwan

123 The type 2 diabetes gene RREB1 plays a role in high-fat diet
induced adipogenesis in mice
G.Z. Yu, L. Bentley, N.A. Krentz, R. Casero, Y. Bai, K.K. Mattis, S. Holliman,
J.M. Torres, A. Mahajan, A.L. Gloyn, R.D. Cox, UK, USA

124 Deletion of CD44 promotes adipogenesis and insulin signalling in

adipocytes
X. Weng, S.M. Warburton, C.K. Hennayake, L. Kang, UK

125 The role of CDKN2C in the regulation of human adipocyte

metabolism
M. Vranic, S. Hetty, P.G. Kamble, E. Holbikova, H. Jernow, S. Skrtic, M.K.
Svensson, J.W. Eriksson, M.J. Pereira, Sweden

126 Zmat3 hypomethylation contributes to early senescence of adipose

precursor cells from healthy individuals with a family history of type 2
diabetes
R. Spinelli, P. Florese, L. Parrillo, F. Zatterale, M. Longo, M. Pastorino, A.
Desiderio, G.A. Raciti, C. Miele, B. Gustafson, A. Nerstedt, U. Smith, F.
Beguinot, Italy, Sweden

70
13:30 - 15:00 Madrid Hall

OP 22 Understanding kidney disease in diabetes

Chair: G. Gruden, Italy

Wednesday, 29 September
127 Meta-analysis of whole exome and whole genome sequencing data
for diabetic nephropathy in individuals with type 1 diabetes
J. Haukka, A. Antikainen, E. Valo, V. Harjutsalo, C. Forsblom, N. Sandholm,
P.-H. Groop, on behalf of the FinnDiane Study Group, Finland

128 Long non-coding RNA from cells derived from urine in biopsy
confirmed kidney disease with diabetes to differentiate diabetic kidney
disease from non-diabetic kidney disease
S. Ghosh, M. Basu, A. Raychaudhuri, N.P. Bhattacharyya, India

129 Novel cross-species transcriptional networks, effective genes and

signalling pathways of diabetic nephropathy in human and mouse
kidney
B.A. Bhat, T. Habib, I. Ahmed, S.S. Jeya, K.A. Fakhro, A.A. Akil, Qatar

130 Soluble Nogo-B upregulates Tie1 receptor: implication for

vegfa/vegfr2 signalling in diabetic nephropathy
C. Ricciardi, L. Gnudi, UK

131 Novel compounds found to regulate VEGF-A splicing in diabetic

podocytes
M.L. Ayine, Y. Liu, M. Stevens, S. Oltean, UK

132 Circulating tenascin-C levels predict renal progression in type 2

diabetes
D.T. Lui, C. Lee, C.Y. Cheung, C.H. Fong, W. Chow, Y. Woo, K.S. Lam, Hong
Kong

71
 13:30 - 15:00 Barcelona Hall

OP 23 Advances in insulin therapy

Chair: T. Heise, Germany

Wednesday, 29 September

133 Ado09, a co-formulation of pramlintide and insulin A21G improves

post-prandial glucose and body weight versus insulin aspart in type 1
diabetes
G. Meiffren, G. Andersen, R. Eloy, C. Seroussi, C. Mégret, S. Famulla, Y.-P.
Chan, M. Gaudier, O. Soula, J.H. DeVries, T. Heise, France, Germany

134 Once weekly basal insulin Fc is safe and efficacious in patients

with type 2 diabetes previously treated with basal insulin
J. Frias, J. Chien, Q. Zhang, E. Chigutsa, W. Landschulz, P. Wullenweber, A.
Haupt, C. Kazda, USA

135 Similar hypoglycaemia duration with once-weekly insulin icodec vs

insulin glargine U100 in insulin naive or experienced patients with type
2 diabetes
R. Silver, M. Asong, K. Begtrup, S.R. Heller, L. Liu, J. Rosenstock, USA,
Denmark, UK

136 A first in human, single ascending dose study to assess the safety
and tolerability, pharmacokinetics, and pharmacodynamics of AB101 in
subjects with type 1 diabetes
B.K. Roberts, X. Wang, B. Franey, M. Hernandez, M. Hompesch, USA

137 Final data from a long-term observational study of continuous

intraperitoneal insulin infusion in a vulnerable population with diabetes
B. Gehr, N. Oliver, E. Renard, D. Hilgard, K. Mueller, C. Rieger, W. Mueller-
Hoffmann, A. Liebl, Germany, UK, France

138 Comparative effectiveness of insulin glargine 300 U/mL and insulin

degludec 100 U/mL in insulin naive type 2 diabetes adults: the Restore-
2 naive cohort
G.P. Fadini, R. Buzzetti, M. Larosa, M.C. Rossi, A. Nicolucci, D. Cucinotta,
Italy

72
13:30 - 15:00 Saint Petersburg Hall

OP 24 Epidemiology of diabetes complications

Chair: A.O.Y. Luk, Hong Kong

Wednesday, 29 September
139 Young-onset type 2 diabetes: clinical outcomes in Norwegian
general practice
K.L. Tibballs, A. Jenum, E.S. Buhl, Norway

140 Diabetes complications among patients from metropolitan versus

non-metropolitan cities in India: one year results of LANDMARC
S. Kalra, A.K. Das, S. Joshi, A. Mithal, K.M. Prasanna Kumar, A.G.
Unnikrishnan, H. Thacker, B. Sethi, S. Chowdhury, R. Ghosh, S. Krishnan, A.
Nair, D. Chodankar, A.H. Zargar, LANDMARC Study Group, India

141 Risk factors, incident dementia, cognitive performance and

structural brain abnormalities in individuals with type 2 diabetes
A.C. Van Gennip, C.D. Stehouwer, The Maastricht Study, A. Singh-Manoux,
T.T. Van Sloten, Netherlands, France, UK

142 Associations between chronic kidney disease, prior cardiovascular

conditions and increased mortality in 36.303 type 1 diabetes patients
between 2015-2017
L. Lyngfelt, P. Wessman, M. Miftaraj, C. Zhou, S. Franzén, K. Eeg-Olofsson,
A.-M. Svensson, B. Eliasson, Sweden

143 Heart failure and renal complications in young- and usual-onset

type 2 diabetes among white Caucasians from US and UK
S. Paul, J. Ling, O. Montvida, Australia

144 Risk of long term HbA1c variability on cancer events and cause-
specific death in 15,286 patients with type 2 diabetes (The Hong Kong
Diabetes Register 1995-2019)
D. Mao, E. Lau, H. Wu, A. Yang, B. Fan, M. Shi, E. Chow, A. Kong, R. Ma, A.
Luk, J. Chan, Hong Kong

73
 EASD-Novo Nordisk Foundation Diabetes Prize for Excellence

EASD, in partnership with the Novo Nordisk Foundation, is again pleased

to announce the “Diabetes Prize for Excellence” which was awarded for the
first time in 2015.
Wednesday, 29 September

The EASD-Novo Nordisk Foundation Diabetes Prize for Excellence is to be

awarded to an internationally recognised researcher who has contributed
significantly to our understanding of diabetes and/or its treatment. The Prize
awardee’s research may focus on prevention, treatment and/or basic
research in physiological biochemistry.

The awardee will deliver a keynote lecture after the award ceremony.

The history of the Novo Nordisk Foundation commences in 1922 when

August Krogh, who received the Nobel Prize for Physiology/Medicine in
1920, returned from Canada and the United States holding permission to
produce insulin in the Nordic countries. In 1923, the first Foundation was
formed - Nordisk Insulinlaboratorium and Nordisk Insulin Foundation which
should become the forerunners for the Novo Nordisk Foundation. Today,
the Novo Nordisk Foundation is an independent foundation with the vision
to improve the health and welfare of people by contributing to research and
development.

DIABETES PRIZE FOR EXCELLENCE LECTURER

2015 Stockholm SIR S. O’RAHILLY, UK

2016 Munich A. HATTERSLEY, UK
2017 Lisbon P.E. SCHERER, US
2018 Berlin G.S. HOTAMISLIGIL, US
2019 Barcelona D.J. DRUCKER, CN
2020 Virtual J.C. BRÜNING, DE

74
15:15 7TH EASD/NOVO NORDISK FOUNDATION Moscow Hall
DIABETES PRIZE FOR EXCELLENCE

Chair: S. Del Prato, President EASD and EFSD

Speaker: J.A. Todd, UK

Wednesday, 29 September
Title: From HLA-DQ position 57 and back again

John Todd FRS, FMedSci, FRCP Hons, PhD is

Professor of Precision Medicine at the University of
Oxford, Director of the Wellcome Centre for Human
Genetics and of the JDRF/Wellcome Diabetes and
Inflammation Laboratory (DIL), and an Emeritus
Senior Investigator of the National Institute for
Health Research.
Previously, Todd was Professor of Human Genetics
and a Wellcome Trust Principal Research Fellow at
the University of Oxford, and until 2016, Professor of
Medical Genetics at the University of Cambridge.
His PhD was in Biochemistry at the University of
Cambridge, followed by a postdoctoral fellowship at Stanford University.
Todd researches type 1 diabetes (T1D) genetics and disease mechanisms
with the goal of delivering clinical interventions. Todd helped pioneer
genome-wide genetic studies in common diseases. He then went on to study
the associations between disease-associated genetic variants and
phenotypes in T1D by founding and deploying the Cambridge BioResource.
In the latest phase of his research, to translate basic genetic and
immunological knowledge to treatment and prevention, the DIL is testing the
efficacy of ultra-low doses of interleukin-2 in newly-diagnosed children with
T1D to preserve the remaining pancreatic islet beta-cell insulin production.
Todd is also part of the international consortium, Global Platform for the
Prevention of Autoimmune Diabetes (GPPAD), aiming to establish primary
preventions of T1D in randomised placebo-controlled trials, initially by testing
the possibility that daily oral insulin given to children at high genetic risk of
T1D can inhibit the autoimmunity that causes T1D.
His research in genetics and diabetes has received several awards and
prizes, including the 1995 Minkowski Prize of the European Association for
the Study of Diabetes. Todd has supervised 35 PhD students with three in
progress and has an h-index of 130 and over 80,000 citations.

75
 15:15
Rome Hall

New data from from Dapa-CKD

Chair: P. Rossing, Denmark

Wednesday, 29 September

S.E. Inzucchi, USA:

New findings from a metabolic perspective

D.C. Wheeler, UK:

New findings from a nephrology perspective

J.J. McMurray, UK:

New findings from a cardiology perspective

16:30
Paris Hall

SARS-CoV-2 in human islets: a diabetes epidemic in the making?

Chair: A. Op de beeck, Belgium

S. Chen, USA:
Modelling SARS-CoV-2 infection using human organoids

F. Dotta, Italy:
ACE2 expression in human islets

76
16:30
London Hall

Adipose tissue as a therapeutic target in type 2 diabetes: What should

we aim for?

Wednesday, 29 September
Chair: M. Rydén, Sweden

M.D. Jensen, USA:

Modifying lipid turnover

L. Kazak, Canada:
Target intracellular metabolism

B.B. Kahn, USA:

Improve the production of signalling lipids

Madrid Hall

More from closed loops

Chair: S.E. Siegelaar, Netherlands

P. Choudhary, UK:
The advantages of a single hormone approach

A. Haidar, Canada:
A novel dual-hormone insulin-and-pramlintide artificial pancreas for
type 1 diabetes

77
 16:30
Barcelona Hall

100 years Insulin treatment

Chair: F.K. Knop, Denmark

Wednesday, 29 September

C.J. Tack, Netherlands:

Forms of insulin treatment in 2021: an individualised approach

T. Vilsbøll, Denmark:
New insulins: What could we get, true value or vague promise?

Saint Petersburg Hall

It is time to be active

Chair: P. Schrauwen, Netherlands

J.R. Zierath, Sweden:

Exercise timing and glucose control

M.K.C. Hesselink, Netherlands:

Stand up or exercise? Muscle adaptations to different forms of
physical activity

78
16:30
Rome Hall

Results from TriMASTER: a 3-way cross-over trial of precision

medicine strategy of 2nd/3rd line therapy in type 2 diabetes

Wednesday, 29 September
Chair: N. Sattar, UK

A.T. Hattersley, UK:

Precision medicine approaches in type 2 diabetes based on how
clinical features influence glycaemic treatment response

E.R. Pearson, UK:

Trial designs to test precision medicine approaches

C. Angwin, UK:
Design of the TriMASTER trial

B.M. Shields, UK:

Results of the TriMASTER trial

A.T. Hattersley, UK:

Clinical and methodological implications of TriMASTER trial results

C.M. Kistorp, Denmark:

Commentary

Panel Q&A

79
 10:00
Moscow Hall

Prediabetes: Does it really matter?

Chair: C. Herder, Germany

Thursday, 30 September

C.D.A. Stehouwer, Netherlands:

Prediabetes: innocent or guilty? Insights from the Maastricht Study

D. Ziegler, Germany:
Prediabetic neuropathies?

K. Færch, Denmark:
Cardiovascular risk in prediabetes

Paris Hall

EASD/ESC Symposium: How come not every patient with diabetes

develops vascular complications?

Chair: M. Haluzik, Czech Republic; S. Achenbach, Germany

T. Tuomi, Finland:
It’s genes

A.G. Tabak, UK:

It’s environment

J. Petrie, UK:
It’s drugs

80
10:00
London Hall

Perspectives of the diabetic foot syndrome

Chair: M. Malecki, Poland

Thursday, 30 September
K. van Acker, Belgium:
Epidemiology of diabetic foot syndrome and further prospects

E.B. Jude, UK:

Comprehensive diabetic foot care and prevention

V. Fejfarova, Czech Republic:

New diagnostic and therapeutical approaches to diabetic foot
management with a focus on PAD

Madrid Hall

New ways to understand kidney disease in diabetes

Chair: M.F. Gomez, Sweden

M. Pruijm, Switzerland:
The use of functional MRI to understand and predict progression of
CKD in diabetes

K. Susztak, USA:
Single cell transcriptomics of kidney tissue: towards a new level of
understanding of renal diseases

M. Kretzler, USA:
An integrative systems biology approach in CKD

81
 10:00
Barcelona Hall

Inter-organ communication in diabetes and systemic energy

homeostasis
Thursday, 30 September

Chair: S. Herzig, Germany

F. Villarroya, Spain:
Organ communication through adipokines: brown adipose tissue as a
novel actor

T. Müller, Germany:
Regulation of energy metabolism by CNS GIP receptor signalling

A. Georgiadi, Germany:
Novel endocrine circuits in metabolic control

82
10:00
Saint Petersburg Hall

5 years of cardiovascular benefits of GLP-1 receptor agonists:

evidence from recent cardiovascular outcomes trials

Thursday, 30 September
Chair: J. Buse, USA

D.J. Drucker, Canada:

The evolution of GLP-1 receptor agonist

S.P. Marso, USA:

Cardiovascular benefits of GLP-1 receptor agonists: evidence from
recent outcome trials

O. Mosenzon, Israel:
Renal benefits of GLP-1 receptor agonists: evidence from recent
outcome trials

N. Marx, Germany:
Mechanistic insights in the cardiorenal benefits of GLP-1 receptor
agonists

I. Lingvay, USA:
Impact of guidelines on management of type 2 diabetes and future
directions of GLP-1 receptor agonists

Panel Discussion

83
 10:00
Rome Hall

EASD/ESE Symposium: Diabetes and bone

Chair: C. Mathieu, Belgium; M. Reincke, Germany

Thursday, 30 September

N. Napoli, Italy:
Pathways that link obesity, metabolic syndrome, type 2 diabetes and
musculoskeletal diseases

R. Eastell, UK:
The impact of diabetes on fracture risk

C. Meier, Switzerland:
Antidiabetic treatments and effects on fracture risk

K. Loh, Australia:
Glucoregulatory actions of bone

Panel Discussion

84
10:00
Athens Hall

Next step in incretin therapy: from single to dual agonism

Chair: J.J. Meier, Germany

Thursday, 30 September
M.J. Davies, UK:
Introduction to the molecule

T. Heise, Germany:
Tirzepatide mechanism of action: effects on endocrine function and
insulin resistance in patients with type 2 diabetes

T. Battelino, Slovenia:
Effect of tirzepatide on glycaemic control captured with continuous
glucose monitoring in patients with type 2 diabetes (SURPASS-3 CGM)

K. Cusi, USA:
The effects of tirzepatide on liver fat content and abdominal adipose
tissue in patients with type 2 diabetes (SURPASS-3 MRI)

S. Del Prato, Italy:

SURPASS 4: Efficacy and safety of tirzepatide once weekly versus
insulin glargine in patients with type 2 diabetes and increased
cardiovascular risk

J.W. Eriksson, Sweden:

Commentary

Q&A with Speakers and closing remarks by the Chair

85
 11:45 - 13:15 Moscow Hall

OP 25 Disparities and diversity in diabetes epidemiology

Chair: S. Wild, UK
Thursday, 30 September

145 Marked and widening and socio-economic inequalities in

prevalence of type 2 diabetes in Scotland
S.H. Wild, J. Wang, Scottish Diabetes Research Network epidemiology
group, UK

146 Prevalence and characteristics associated with antidepressant and

antipsychotic prescribing prior to diagnosis of type 2 diabetes in
Scotland
C.R. Greene, S.H. Wild, H. Wu, C.A. Jackson, UK

147 Selection pressures on the ACE2 gene in a Scottish and South

Indian type 2 diabetes population
C. Nangia, S. Srinivasan, V. Radha, V. Mohan, C.N. Palmer, UK, India

148 Sex, race, and ethnicity representativeness in cardiovascular

outcomes trials in type 2 diabetes: a meta-epidemiological study
I. Avgerinos, T. Karagiannis, A. Liakos, P. Kakotrichi, A. Tsapas, E. Bekiari,
Greece, UK

149 GWAS reveals a novel locus associated with kidney function in

people of Middle-Eastern decent
S.A. Mohamed, J. Tares, P.W. Franks, L. Bennet, Sweden

150 People with type 1 diabetes of African-Caribbean ethnicity are at

increased risk of sight-threatening retinopathy
A. Mangelis, S. Ayis, A. Nirmalakumaran, J. Collins, L. Webster, S.M.
Thomas, S. Mann, J. Karalliedde, UK

86
11:45 - 13:15 Paris Hall

OP 26 Beta cells: sensing, signalling and secreting

Chair: M. Solimena, Germany

Thursday, 30 September
151 Gamma aminobutyric acid-induced calcium signalling in the
primary cilium of islet beta cells
G. Sanchez, C. Incedal, J. Prada, T. Dandekar, O. Idevall-Hagren, Sweden,
Germany

152 Involvement of extracellular ATP signalling in the diabetogenic

response of pancreatic beta cells
T. Brun, D. Duhamel, L. Oberhauser, C. Jiménez-Sánchez, C. Bartley, V.
Lavallard, P. Maechler, Switzerland

153 A dual GLP-1/GIP agonist may encompass the beneficial effects of

both incretins on pancreatic beta cell function in the absence of beta-
arrestin2
N. Zaïmia, S. Costes, S. Dalle, G. Bertrand, M.A. Ravier, France

154 Feeding inhibits the catabolic activity of glutamate dehydrogenase

in mouse pancreatic beta cells as revealed by in situ assessment of
enzyme activity
Y. Zhou, P. Maechler, Switzerland

155 Alterations in the expression of proteins involved in nuclear-

cytoplasmic shuttling of cargo in pancreatic beta cells under the
duress of chronic hyperglycaemia
A. Kowluru, S. Elebra, V. Thamilselvan, A. Harajli, USA

156 What regulates insulin granule mobility in the submembrane

space? Role of cAMP and adenine nucleotides
B. Gaus, I. Rustenbeck, Germany

87
 11:45 - 13:15 London Hall

OP 27 Prediction tools for outcomes in diabetes

Chair: D. Gordin, Finland

Thursday, 30 September

157 Prediction models for future complications in type 1 diabetes

N. Al-Sari, Denmark

158 Validation of the classification for type 2 diabetes into five

subgroups: a report from the ORIGIN trial
M. Pigeyre, S. Hess, M.F. Gomez, O. Asplund, L. Groop, G. Pare, H.
Gerstein, Canada, Germany, Sweden

159 Machine learning approaches for prediction of nocturnal

hypoglycaemia in patients with type 1 diabetes in a hospital setting
V.B. Berikov, R.M. Kozinetz, J.F. Semenova, V.V. Klimontov, Russian
Federation

160 Non-invasive prenatal diagnosis of fetal genotype in pregnant

women with GCK-MODY: the impact of precision medicine on antenatal
care
A.E. Hughes, J.A. Houghton, A.J. Chakera, G. Spyer, M.H. Shepherd, S.E.
Flanagan, A.T. Hattersley, UK

161 Validation of fear of hypoglycaemia screener: results from the T1D

Exchange Registry
J. Liu, J.-L. Poon, J. Bispham, M. Perez-Nieves, A. Hughes, K. Chapman, B.
Mitchell, F. Snoek, L. Fisher, USA, Netherlands

162 Mental illness, ethnicity and civil status are associated with non-
attendance in diabetic retinopathy screening among people with type 2
diabetes
G.B. Petersen, S. Byberg, M.V. Fangel, D. Vistisen, L.E. Joensen, H. Vorum,
J.K. Kristensen, Denmark

88
11:45 - 13:15 Madrid Hall

OP 28 Pathogenic mechanisms of complications

Chair: D. Van Raalte, Netherlands

Thursday, 30 September
163 The gut microbiome composition is altered in long-standing type 1
diabetes and associated with disease-related complications
J.I. Van Heck, R. Gacesa, R. Stienstra, R.K. Weersma, L.A. Joosten, C.J.
Tack, Netherlands

164 No association between haptoglobin genotype and cerebral small-

vessel disease in type 1 diabetes
M.I. Eriksson, A. Syreeni, E.H. Dahlström, N. Sandholm, C. Forsblom, D.
Gordin, T. Tatlisumak, J. Putaala, P.-H. Groop, J. Martola, L.M. Thorn, on
behalf of the FinnDiane Study Group, Finland, Sweden

165 Nox5 in circulating peripheral blood mononuclear cells: a potential

biomarker in unstable diabetic vascular and renal disease
T.J. Block, K.C. Sourris, W.A. Khan, P. Kantharidis, J.C. Jha, M.E. Cooper, J.
Shaw, K. Jandeleit-Dahm, Australia, Germany

166 Dicarbonyl stress alters mitochondrial protein homeostasis in

endothelial cells
R. Bulkescher, S. Herzig, J. Szendrödi, P.P. Nawroth, J. Zemva, Germany

167 Insulin resistance associates with arterial stiffness in type 1

diabetes: a novel component of double diabetes
G. Llaurado, A. Cano, L. Albert, I. Mazarico, A. Romero, O. Giménez-Palop,
S. Fernández-Veledo, J. Vendrell, J.-M. González-Clemente, Spain

168 Wnt regulation and collagen gene expression in the bone of type 2
diabetes elderly women
G. Leanza, F. Tramontana, F. Cannata, A. Piccoli, V. Viola, M. Faraj, R.
Strollo, P. Pozzilli, N. Napoli, Italy

89
 11:45 - 13:15 Barcelona Hall

OP 29 Understanding muscle and liver metabolism

Chair: M. Roden, Germany

Thursday, 30 September

169 Assessing the association between metabolic flexibility measured

upon insulin stimulation and during incremental submaximal exercise
M. Bergman, R.F. Mancilla, Y.M. Bruls, P. Schrauwen, V.B. Schrauwen-
Hinderling, M.K. Hesselink, Netherlands

170 TSC22D4 interacts with Akt to regulate insulin sensitivity

B. Ekim Ustunel, S. Demir, G. Wolff, A. Wieder, J. Szendrödi, S. Herzig,
Germany

171 C2-ceramide recycling inhibits insulin signalling in muscle cells

C.L. Bandet, S. Tan-Chen, A. Blachnio-Zabielska, J.-P. Pais-de-Barros, P.
Ferré, F. Foufelle, H. Le Stunff, E. Hajduch, France, Poland

172 The impact of different lipogenic diets on indirect pathway

contributions to hepatic glycogen synthesis
A. Reis-Costa, G.D. Belew, L.C. Tavares, M.J. Meneses, J.G. Jones,
Portugal

173 Transcriptional repression of the iron exporter ferroportin via the

PI3K-AKT-Foxo1 signalling pathway may explain liver iron overload in
patients with type 2 diabetes
R. Qiu, N. Volk, O. Marques, S. Altamura, M.U. Muckenthaler, Germany

174 Ciprofibrate decreases net hepatic glucose uptake and tends to

decrease net myocardial glucose uptake in prediabetic male volunteers
V. De Wit-Verheggen, F. Vanweert, J. Raiko, G. Schaart, A. Gemmink, E.B.
Nascimento, M.K. Hesselink, J.E. Wildberger, R. Wierts, D. Montaigne, B.
Staels, E. Phielix, P. Schrauwen, V.B. Schrauwen-Hinderling, T. Van de
Weijer, Netherlands, Finland, France

90
11:45 - 13:15 Saint Petersburg Hall

OP 30 GLP-1 receptor agonism: putative mechanisms of benefit

Chair: R. IJzerman, Netherlands

Thursday, 30 September
175 Combination very low dose sulphonylurea and DPP4 inhibitor have
a potent glucose lowering effect through augmentation of beta cell
function without increase in hypoglycaemia
R.L. Cordiner, A. Mari, K.F. Bedair, E.R. Pearson, UK, Italy

176 Emotional eating is associated with reduced sensitivity to the

central effects of GLP-1 receptor agonist treatment
C.C. Van Ruiten, J. Ten Kulve, L. Van Bloemendaal, M. Nieuwdorp, D.
Veltman, R.G. IJzerman, Netherlands

177 Liraglutide decreases postprandial fibroblast growth factor 19 and

glucagon-like peptide 2, and increases postprandial cholecystokinin in
individuals with obesity
A. Brønden, H.H. Nerild, C.C. Nexøe-Larsen, P.H. Hellmann, M. Baekdal,
I.M. Gether, M.P. Gillum, B. Hartmann, L.B. Knudsen, L.V. Jacobsen, J.F.
Rehfeld, J.J. Holst, T. Vilsbøll, D.P. Sonne, F.K. Knop, Denmark

178 Short-term treatment with liraglutide does not improve cardiac

diastolic function in patients with type 2 diabetes: a randomised
double-blind placebo-controlled trial
A.S. Bojer, M.H. Soerensen, J. Bjerre, P. Gæde, N. Vejlstrup, P.L. Madsen,
Denmark

179 Glucose-dependent insulinotropic polypeptide (GIP) contributes to

sitagliptin-mediated improvement of beta cell function in patients with
type 2 diabetes
S. Stensen, L.S. Gasbjerg, M.M. Rosenkilde, B. Hartmann, T. Vilsbøll, J.J.
Holst, M.B. Christensen, F.K. Knop, Denmark

180 Semaglutide reduces hsCRP levels across different treatment

settings: post hoc analyses of SUSTAIN and PIONEER trials
O. Mosenzon, M. Capehorn, A. De Remigis, S. Rasmussen, P. Weimers, J.
Rosenstock, Israel, UK, Denmark, USA

91
 11:45 - 13:15 Short Oral Discussion Event E Page

SO 05 Therapeutic advances 130

SO 11 In vivo and ex vivo beta cell function in diabetes 136

SO 17 Novel aspects of beta cell and insulin secretion 142

Thursday, 30 September

SO 23 Fatty matters 148

SO 29 Novel glucose-lowering agents 155

SO 35 More on insulins 163

SO 41 Closed loop systems 169

SO 47 Autonomic neuropathy 175

SO 53 New insights from animal models of complications 181

SO 59 Vascular complications: mechanisms and risk factors 187

92
13:30 - 15:00 Short Oral Discussion Event F Page

SO 06 Genes and genomic engineering 131

SO 12 Sugar Moms 137

SO 18 It must be my hormones 143

Thursday, 30 September
SO 24 Glucose-lowering drugs and the liver 149

SO 30 The advantage of dual agonists 157

SO 36 Determinants and consequences of hypoglycaemia 164

SO 42 Other aspects of managing blood glucose levels 170

SO 48 Peripheral neuropathy - predictors of disease 176

and prognosis

SO 54 Pathogenic mechanisms of complications 182

SO 60 Hepatic fibrosis: from screening to treatment 188

93
 13:30 - 15:00 Moscow Hall

OP 31 Modelling diabetes long term complications

Chair: G. Medina-Gomez, Spain

Thursday, 30 September

181 Mir-34a mediates progression of liver injury from NAFLD to fibrosis

in diabetes associated liver fibrosis
Q. Su, UK

182 An siRNA strategy to silence apolipoprotein CIII in the fight against

the metabolic syndrome
P. Recio-López, P.-O. Berggren, L. Juntti-Berggren, I. Valladolid-Acebes,
Sweden

183 Loss of Hsp70 leads to increased albuminuria in a STZ-induced

diabetic mouse model
J. Zemva, R. Bulkescher, T. Poth, I. Hausser, C. Rodemer, A. Erhardt, J.G.
Okun, S. Herzig, J. Szendrödi, P. Nawroth, Germany

184 Involvement of gut-hormones in regulating female reproductive

function in obese and incretin receptor knockout animal models
D. Khan, O.O. Ojo, A. Sridhar, P.R. Flatt, R.C. Moffett, UK

185 Adiporon improves endurance capacity and decreases ectopic

lipid deposition in middle-aged obese mice
C. Selvais, Belgium

186 Analysis of the hypothalamic transcriptome controlling counter-

regulatory responses to hypoglycaemia
J. Castillo-Armengol, A. Rodriguez Sanchez-Archidona, C. Fledelius, B.
Thorens, Denmark, Switzerland

94
13:30 - 15:00 Paris Hall

OP 32 Benefits of GLP-1: from traditional to non-traditional

complications

Chair: F. Giorgino, Italy

Thursday, 30 September
187 Liraglutide may induce impaired diastolic heart function by
activation of sympathetic tonus: A group effect of this class of drugs?
S.B. Haugaard, P. Kumaraturai, C. Anholm, O.W. Nielsen, A. Sajadieh,
Denmark

188 Liraglutide reduces cardiac adipose tissue in type 2 diabetes:

results from the LiraFlame randomised controlled trial
T. Hansen, I. Rasmussen, E. Zobel, R. Ripa, B. Von Scholten, V. Curovic, A.
Kjaer, P. Rossing, Denmark

189 Positive impact of liraglutide on pulmonary function in patients

with type 2 diabetes: data from the randomised cross-over LIRALUNG
study
C. López-Cano, A. Ciudin, E. Sánchez, F. Tinahones, A. Soto, S. Pellitero, F.
Barbé, M. Dalmases, M. García-Ramírez, A. Gaeta, R. Martí, C. Hernández,
R. Simó, A. Lecube, Spain

190 Effect of subcutaneous semaglutide on features of the metabolic

syndrome in patients with non-alcoholic steatohepatitis
L.L. Gluud, I. Bakulin, S. Ladelund, P.N. Newsome, A. Rendon, A.-S. Sejling,
M.E. Tushuizen, K. Cusi, Denmark, Russian Federation, UK, Netherlands,
USA

191 Multi-target engagement effect of a novel long-acting

Glucagon/GIP/GLP-1 triple agonist (HM15211) in animal model of NASH
J. Choi, J. Lee, J. Kim, H. Kwon, E. Park, J. Lee, D. Kim, Y. Kim, I. Choi,
Korea, Republic of

192 In patients with fatty liver, higher fasting GLP-1 levels are
associated with increased insulin resistance and reduced beta
hydroxybutirate
G. Mocciaro, F. Carli, M. Gaggini, C. Barbieri, B. Patricio, C. Rosso, A.
Armandi, E. Lembo, E. Bugianesi, G. Mingrone, A. Gastaldelli, Italy

95
 13:30 - 15:00 London Hall

OP 33 Diabetic foot problems: from prediction to treatment

Chair: A.J.M. Boulton, UK

Thursday, 30 September

193 Metabolomic risk predictors of diabetic foot ulcers

J. Hedegaard Andersen, T. Suvitaival, K. Trošt, S. Theilade, I. Mattila, A.
Rasmussen, M. Frimodt-Møller, P. Rossing, C. Legido-Quigley, T.S.
Ahluwalia, Denmark

194 IDR-1018 peptide improves wound healing in vitro and when

topically applied to skin wounds in a model of type 1 diabetes
M. Petkovic, M.V. Mouritzen, N. Molchanova, K. Qvist, P. Nyeng, E.C. Leal,
E. Carvalho, L.T. Dalgaard, H. Jenssen, Denmark, Portugal

195 Protein tyrosine phosphatase 1B inhibition promotes diabetic

wound healing via activation of the antioxidant enzyme heme
oxygenase 1
E.C. Leal, A. Figueiredo, D. Santos, M. Delibegovic, E. Carvalho, Portugal, UK

196 A M1/M2-macrophages-regulating new drug for diabetic foot ulcers

with poor-controlled HbA1c risk factor in an International Phase 3 study
M.-L. Kuo, S.-C. Chang, Taiwan

197 Long-term outcomes of autologous cell therapy, angioplasty and

conservative therapy in patients with chronic limb-threatening
ischaemia and diabetes
M. Dubsky, J. Husakova, R. Bem, V. Fejfarova, R. Jarosikova, A. Jirkovska,
V. Woskova, Czech Republic

198 Diabetes is not associated with major amputation after open

vascular surgery for chronic limb-threatening ischaemia: a nationwide
propensity score analysis
E. Lilja, A. Gottsäter, M. Miftaraj, J. Ekelund, B. Eliasson, A.-M. Svensson, M.
Zarrouk, S. Acosta, Sweden

96
13:30 - 15:00 Madrid Hall

OP 34 SGLT2 inhibition: putative mechanisms of benefit

Chair: B. Zinman, Canada

Thursday, 30 September
199 The SGLT2 inhibitor ertugliflozin causes a switch of cardiac
substrate utilisation leading to reduced cardiac mTOR-signalling,
unfolded protein response and apoptosis
P.A. Mann, J. Möllmann, B.M. Klinkhammer, P. Droste, B. Peter, N. Marx, M.
Lehrke, Germany

200 Empagliflozin induced white adipocyte browning and modulated

mitochondrial dynamics in KK Cg-Ay/J mice and mouse adipocytes
L. Chen, L. Xu, X. Liu, T. Li, X. Li, M. Xue, B. Sun, China

201 SGLT2 inhibition improves beta cell function and glucose

tolerance, but does not affect glucose or FFA uptake in skeletal muscle
J.H. Voigt, K.M. Lauritsen, S.B. Pedersen, T.K. Hansen, N. Møller, N.
Jessen, L.C. Gormsen, M.C. Laurenti, C.D. Man, A. Vella, E. Søndergaard,
Denmark, USA, Italy

202 Urinary proteomics and the effect of dapagliflozin treatment in

persons with type 2 diabetes and diabetic kidney disease: a
randomised crossover trial
T.K. Rönkkö, M.K. Eickhoff, H. Mischak, P. Rossing, F. Persson, T.S.
Ahluwalia, Denmark, Germany

203 Effect of SGLT2 inhibition on ketone bodies in patients with stable

chronic heart failure
R. Pietschner, J. Kolwelter, A. Bosch, D. Kannenkeril, C. Ott, M. Schiffer, S.
Achenbach, R.E. Schmieder, Germany

204 Effects of SGLT2 inhibition on lipid storage and lipolysis in adipose

tissue in type 2 diabetes
K.M. Lauritsen, J.H. Voigt, S.B. Pedersen, T.K. Hansen, N. Møller, N.
Jessen, L.C. Gormsen, E. Søndergaard, Denmark

97
 13:30 - 15:00 Barcelona Hall

OP 35 Omics and more for type 2 diabetes and complications

Chair: D. Vistisen, Denmark

Thursday, 30 September

205 CpG sites associated with insulin resistance and related novel
variants suggest a possible mechanism linking insulin resistance and
cardiometabolic traits
N. Fragoso-Bargas, S. Lee-Ødegård, J.O. Opsahl, L. Sletner, A.K. Jenum,
L.C. Groop, E. Qvigstad, G.-H. Moen, K.I. Birkeland, R.B. Prasad, C.
Sommer, Norway, Sweden, Australia

206 Novel biomarkers for glycaemic deterioration in type 2 diabetes: an

IMI RHAPSODY study
R.C. Slieker, L.A. Donnelly, L. Lopez-Noriega, G.N. Giordano, M. Åkerlund,
IMI-RHAPSODY, I. Pavo, V. Lyssenko, C. Legido Quigley, L. Groop, M.
Ibberson, J.W. Beulens, L.M. 't Hart, E.R. Pearson, G.A. Rutter, Netherlands,
UK, Sweden, Austria, Norway, Denmark, Switzerland

207 Mirror effects of rare OPRD1 variants on the aetiology of type 2

diabetes and obesity
S. Meulebrouck, G. Quéniat, M. Baron, M. Canouil, M. Derhourhi, B. Balkau,
G. Charpentier, S. Franc, M. Marre, R. Roussel, R. Scharfmann, P. Froguel,
A. Bonnefond, France

208 Multi-phenotype association analysis reveals shared biological

pathways between type 2 diabetes and depression
J.G. Maina, Z. Balkhiyarova, M. Kaakinen, A. Nouwen, I. Prokopenko,
France, UK

209 Serum magnesium is inversely associated with heart failure, atrial

fibrillation and microvascular complications in type 2 diabetes
L.J. Oost, A.A. Van der Heijden, E.A. Vermeulen, C. Bos, P.J. Elders, R.C.
Slieker, S. Kurstjens, M. Van Berkel, J.G. Hoenderop, C.J. Tack, J.W.
Beulens, J.H. De Baaij, Netherlands

210 Genome-wide meta-analysis and omics integration identifies novel

genes for diabetic kidney disease
N. Sandholm, J.B. Cole, V. Nair, X. Sheng, H. Liu, N. VanZuydam, E.
Ahlqvist, D. Fermin, M. Kretzler, K. Susztak, J.N. Hirschhorn, J.C. Florez, P.-
H. Groop, GENIE consortium, Finland, USA, Sweden

98
13:30 - 15:00 Saint Petersburg Hall

OP 36 Optimising insulin therapy

Chair: T. Vilsbøll, Denmark

Thursday, 30 September
211 Impact of the fasting plasma glucose titration target on the success
of basal insulin titration in insulin-naive patients with type 2 diabetes: a
systematic analysis
J. Wolters, D. Wollenhaupt, M. Abd El Aziz, M.A. Nauck, Germany

212 Advancing therapy in basal insulin users with type 2 diabetes:

better clinical outcomes with iGlarLixi vs premix BIAsp 30 in the
SoliMix trial
C. Trescoli, J. Rosenstock, R. Emral, L. Sauque-Reyna, V. Mohan, S. Al Sifri,
N. Lalic, A. Alvarez, P. Picard, N. Demil, M. Bonnemaire, R.J. McCrimmon,
Spain, USA, Turkey, Mexico, India, Saudi Arabia, Serbia, Argentina, France,
UK

213 Real-world persistence, adherence, healthcare resource utilisation,

and costs in people with type 2 diabetes switching from basal insulin
(BI) to 2nd- vs 1st-generation BI
E. Wright, J. Gill, S. Huse, X. Li, T. Reid, F. Zhou, USA

214 Glycaemic improvement in 3,436 people with type 1 diabetes using the
Omnipod DASH® Insulin Management System over first 90 days of use
G. Aleppo, D. J. DeSalvo, F. Lauand, L. M. Huyett, A. Chang, T. Vienneau, T.
T. Ly, USA, France

215 Pharmacodynamics, pharmacokinetics, safety, and tolerability of

INS068 vs insulin degludec in type 1 diabetes at steady state: a phase I,
randomised, double-blind, cross-over-trial
M. Hernandez, B. Franey, J. Wang, Y. Li, B. Zhang, M. Hompesch, USA,
China

216 Glycaemic control with once weekly basal insulin Fc in persons

with type 2 diabetes using continuous glucose monitoring in a phase 2
study
C. Kazda, J. Chien, Q. Zhang, E. Chigutsa, W. Landschulz, P. Wullenweber,
A. Haupt, J. Frias, USA

99
 MINKOWSKI PRIZE

The prize will be given in relation to research

which has been carried out by a person normally
residing in Europe.
Thursday, 30 September

It is awarded for distinction, manifested by

publications which contribute to the advancement
of knowledge in the field of diabetes mellitus.

The prize commemorates Oskar Minkowski

(1858-1931) who successfully performed the
extirpation of the pancreas in dogs in 1889 and
noticed that they developed diabetes.

MINKOWSKI LECTURERS

1966 Aarhus P.J. PELTONEN-PALOTIE, UK 1994 Düsseldorf T. MANDRUP POULSEN, DK

1967 Stockholm E.R. FROESCH, CH 1995 Stockholm J. TODD, UK
1968 Louvain L.A. CARLSON, SE 1996 Vienna P. RORSMAN, DK
1969 Montpellier B. HELLMAN, SE 1997 Helsinki P. FROGUEL, FR
1970 Warsaw B. JEANRENAUD, CH 1998 Barcelona J.H. AUWERX, FR
1971 Southampton C.N. HALES, UK 1999 Brussels R. SCHARFMANN, FR
1972 Madrid W.J. MALAISSE, BE 2000 Jerusalem H. EDLUND, SE
1973 Brussels L. ORCI, CH 2001 Glasgow J.R. ZIERATH, SE
1974 Jerusalem E. CERASI, SE 2002 Budapest B.O. ROEP, NL
1975 Munich P. FREYCHET, FR 2003 Paris M. STUMVOLL, DE
1976 Helsinki K.D. HEPP, DE 2004 Munich G.A. RUTTER, UK
1977 Geneva J. WAHREN, SE 2005 Athens P. ROSSING, DK
1978 Zagreb J. NERUP, DK 2006 Copenhagen M. RODEN, AT
1979 Vienna S.J.H. ASHCROFT, UK 2007 Amsterdam M. STOFFEL, CH
1980 Athens I.-B. TALJEDAL, SE 2008 Rome J.C. BRÜNING, DE
1981 Amsterdam P. DE MEYTS, BE 2009 Vienna G. PERSEGHIN, IT
1982 Budapest G.F. BOTTAZZO, UK 2010 Stockholm F. GRIBBLE, UK
1983 Oslo S.L. HOWELL, UK 2011 Lisbon N. SATTAR, UK
1984 London A. LERNMARK, DK 2012 Berlin T.M. FRAYLING, UK
1985 Madrid E. VAN OBBERGHEN, FR 2013 Barcelona M. CNOP, BE
1986 Rome D. PIPELEERS, BE 2014 Vienna A.L. GLOYN, UK
1987 Leipzig J.-L. CARPENTIER, CH 2015 Stockholm M. BLÜHER, DE
1988 Paris J.C. HUTTON, UK 2016 Munich P. SCHRAUWEN, NL
1989 Lisbon H.U. HÄRING, DE 2017 Lisbon E.R. PEARSON, UK
1990 Copenhagen P. A. HALBAN, CH 2018 Berlin F. BÄCKHED, SE
1991 Dublin C. BOITARD, FR 2019 Barcelona F.K. KNOP, DK
1992 Prague E. VAN SCHAFTINGEN, BE 2020 Virtual G.P. FADINI, IT
1993 Istanbul H. YKI-JÄRVINEN, FI

100
15:15 INDUCTION OF HONORARY MEMBERS Moscow Hall

S. Del Prato, President EASD and EFSD

followed by

56TH MINKOWSKI LECTURE

Thursday, 30 September
Chair: S. Del Prato, President EASD and EFSD

Speaker: A. Bonnefond, France

Title: Hunt for rare variants of pretty little things in the

genetics of diabetes

Amélie Bonnefond is Director of Research (Inserm) at

the INSERM/CNRS 1283/8199 unit, (Lille Pasteur
Institute and University of Lille).

She heads a team tackling “Metabolic functional

(epi)genomics and their abnormalities in type 2
diabetes and related disorders”. She is also the
current scientific director of the PIA-funded EquipEx
LIGAN-PM platform dedicated to the use of next-
generation sequencing in precision medecine. She is
a visiting professor at Imperial College London where
she teaches in several Master courses.

She was laureate of the 2012 Rising Star award from European Association
for the Study of Diabetes (EASD), the 2018 Auguste Loubatières award
from the French-speaking Association for Diabetes (SFD), and a European
Research Council Starting Grant.

101
 16:15
Moscow Hall

Michael Berger Debate: Who suffers more: Are women with diabetes at
higher cardiovascular risk?
Thursday, 30 September

Chair: A. Kautzky-Willer, Austria

C.N. Bairey-Merz, USA:

Yes

N. Sattar, UK:
No

Paris Hall

The future of incretin-based treatments

Chair: M.A. Nauck, Germany

F.K. Knop, Denmark:

Activating multiple receptors

T.R. Pieber; Austria:

Established items in new packaging

P.N. Newsome, UK:

Is the liver a target of GLP-1?

London Hall

Will human-first approaches finally get to the root cause of diabetic

vascular disease?

Chair: A. Avogaro, Italy

L. Bjerre Knudsen, Denmark:

Mechanistic studies on GLP-1 analogues in atherosclerosis

K.E. Bornfeldt, USA:

Apolipoprotein C3 and its mechanisms in diabetic vascular disease

102
16:15
Madrid Hall

Devices support diabetes treatment

Chair: R. Weitgasser, Austria

Thursday, 30 September
G. Freckmann, Germany:
Glucose sensors on the rise: new technologies?

L. Gonder-Frederick, USA:
Psychological challenges raised by diabetes technology

Barcelona Hall

Small vessels, big problems: cerebral small-vessel disease - a potential

microvascular complication of diabetes

Chair: L.M. Thorn, Finland

H.S. Markus, UK:

General aspects of cerebral small-vessel disease and link to type 2
diabetes

E. van Duinkerken, Netherlands:

Clinical picture of cerebral small-vessel disease in adults with type 1
diabetes

Saint Petersburg Hall

Harnessing intracellular pathways for therapy

Chair: B. Cannon, Sweden

G.I. Shulman, USA:

Uncouplers in fatty liver therapy

A. Zeigerer, Germany:
Intracellular transport in systemic energy homeostasis and diabetes

103
 16:15
Rome Hall

INNODIA - Translational approaches to disease modifying therapy of

type 1 diabetes: an innovative approach towards understanding and
arresting type 1 diabetes
Thursday, 30 September

Chair: C. Mathieu, Belgium; M. Peakman, USA

C. Mathieu, Belgium:
Introduction

S. Brunak, Denmark:
Multiomics analysis for biomarker discovery in type 1 diabetes: the
First 100 newly diagnosed in INNODIA

T. Danne, Germany:
INNODIA pathways to clinical intervention in type 1 diabetes

Discussion

104
16:15
Athens Hall

EMPEROR Preserved Study

Chair: F. Zannad, France

Thursday, 30 September
J. Butler, USA:
EMPEROR-Preserved: context, design and population

S.D. Anker, Germany:

EMPEROR-Preserved: main results

G. Filippatos, Greece:
New data from EMPEROR-Preserved: patient population, efficacy
endpoints and safety of empagliflozin in patients with and without
diabetes

M. Packer, USA:
Pooled-Analysis of EMPEROR-Reduced and EMPEROR-Preserved
trials: key results

A. Norhammar, Sweden:
Commentary

Group Discussion

105
 10:00
Moscow Hall

Retinopathy and artificial intelligence

Chair: H. Colhoun, UK

S.R. Aravind, India:

Friday, 1 October

Diabetic retinopathy screening, a model for AI

A. Storkey, UK:
Deep learning approaches to retinal images for prediction of outcomes
in diabetes

Paris Hall

Current guidelines on diabetes management

Chair: P. Fioretto, Italy

C. Wanner, Germany:
Current EASD/ADA and KDIGO guidelines for treating type 2 diabetes
with CKD

H.J. Lambers Heerspink, Netherlands:

New data on SGLT2 inhibitors and mineralocorticoid receptor
antagonism in type 2 diabetes with CKD

London Hall

Importance of insulin clearance in the regulation of glucose

metabolism

Chair: Amalia Gastaldelli, Italy

S. Najjar, USA:
Hepatic insulin clearance: mechanisms

B. Mittendorfer, USA:
Insulin clearance in diabetes and obesity

106
10:00
Madrid Hall

Debate: Preventing diabetic complications – 100 years on from insulin:

Which of the newer classes will prevail?

Chair: R.K. Semple, UK

Friday, 1 October
M.A. Nauck, Germany:
100 years later, it’s GLP-1 receptor agonists

J.P.H. Wilding, UK:

100 years later, it’s SGLT2 inhibitors

Barcelona Hall

In-hospital management of hyperglycaemia: still a Cinderella of

diabetes management?

Chair: T. Tankova, Bulgaria

G. van den Berghe, Belgium:

Treatment of hyperglycaemia in ICU: tight or not too tight?

J. Mader, Austria:
Treatment of hyperglycaemia in general ward: glucose targets and
best approaches

Saint Petersburg Hall

COVID-19 infection in people with diabetes: a risky combination

Chair: T. Fall, Sweden

S. Schlesinger, Germany:
Diabetes and risk of COVID-19 progression and mortality –
epidemiological perspective

K. Khunti, UK:
Care of people with diabetes post COVID-19 in primary care

107
 10:00
Rome Hall

EASD-Lancet Symposium: Treatment of obesity: the future of diabetes

treatment?

Chair: J. Bagenal, UK; M.J. Davies, UK

Friday, 1 October

H. Yki-Järvinen, Finland:
Back to the basics: Why are obesity and diabetes related?

P. Sumithran, Australia:
Harnessing weight loss interventions for diabetes treatment: How
successful have we been?

I. Lingvay, USA:
Back to the future: Is a weight-centric goal for diabetes treatment
feasible?

B. Van der Schueren, Belgium:

Type 1 diabetes and obesity: a two-way road filled with potholes

All speakers:
Bring it on! Q&A

108
11:15
Rome Hall

Finerenone: a new approach to kidney protection in patients with type

2 diabetes

Chair: A. Solini, Italy

Friday, 1 October
R.A. DeFronzo, USA:
New directions in kidney care in diabetes: targeting mineralocorticoid
receptor overactivation with finerenone

G.L. Bakris, USA:

FIDELIO-DKD: cardiorenal outcomes in people with high-risk CKD and
type 2 diabetes

L.M. Ruilope, Spain:

FIGARO-DKD: cardiorenal outcomes across the broad spectrum of
CKD and type 2 diabetes

J.B. McGill, USA:

Navigating the data for key subgroup

A.L. Birkenfeld, Germany:

Maintaining the course: safety considerations for optimising patient
outcomes

R. Agarwal, USA:
Setting the route for CKD and type 2 diabetes care: clinical
consequences of the FIDELIO-DKD and FIGARO-DKD data

P.-H. Groop, Finland:

Commentary followed by Q&A

109
 11:15 - 12:15 Moscow Hall

OP 37 Cytokine storm in type 1 diabetes: from signalling to interventions

Chair: L. Marroqui Esclapez, Spain

217 Specific alterations in the STAT1/STAT6 axis may contribute to beta

cell loss in type 1 diabetes
Friday, 1 October

K. Afi Leslie, S.J. Richardson, N.G. Morgan, M.A. Russell, UK

218 Type III interferons are expressed in human pancreas at type 1

diabetes onset and induce immunostimulatory and antiviral activities in
human beta cells
E.E. Ringqvist, S. Tuomela, M. Mazur, K. Burdsall, A. Parajuli, H. Sork, L.
Krogvold, K. Dahl-Jørgensen, C. Matthews, I. Gerling, M. Flodström-
Tullberg, Sweden, Norway, USA

219 Using the HALO image analysis platform to study pancreas

pathology and insulitis in young people with recent-onset type 1 diabetes
R.C. Wyatt, P. Leete, M. Padilla, M. Yang, M. Bogdani, G. Deutsch, C.
Flaxman, M. Atkinson, I. Kusmartseva, N.G. Morgan, S.J. Richardson, UK,
USA

220 Ag019 ActoBiotics as monotherapy or in association with

teplizumab in recent-onset type 1 diabetes was safe and demonstrated
encouraging metabolic and immunological effects
C. Mathieu, S. Blomme, S. Caluwaerts, L. Haazen, L. Steidler, K. Van
Huynegem, J. Vermeiren, K. Cerosaletti, A. Wiedeman, S.A. Long, E. Serti,
AG019-T1D-101 Trial Investigators, P. Rottiers, G.T. Nepom, K.C. Herold,
Belgium, USA

110
11:15 - 12:15 Paris Hall

OP 38 Novel agents

Chair: M. Muskiet, Netherlands

221 The novel GIP, GLP-1, and glucagon triple receptor agonist LY3437943
exhibits robust efficacy in preclinical models of obesity and diabetes

Friday, 1 October
T. Coskun, J.S. Moyers, W. Roell, L. O'Farrell, A. Regmi, A.D. Showalter,
K.W. Sloop, D.B. Wainscott, F.S. Willard, J. Ficorilli, O. Cabrera, S. Urva, F.
Norouziyan Cooper, J. Alsina-Fernandez, H. Qu, USA

222 Novel GIP/GLP-1/glucagon receptor agonist LY3437943: a first in

human dose study in healthy subjects
C.T. Benson, C. Loghin, Y. Du, M.K. Thomas, T. Coskun, S. Urva, Z.
Milicevic, USA

223 Safety and pharmacokinetic study of CPL207280, a novel GPR40

receptor agonist, after a multiple-dose in healthy volunteers
K. Bazydlo-Guzenda, K. Jarus-Dziedzic, A. Gierczak-Pachulska, K. Bus-
Kwasnik, P.J. Rudzki, M. Wieczorek, Poland

224 DA-1241 a novel GPR119 agonist: Safety, tolerability,

pharmacokinetics, and pharmacodynamics: Part 2 of multiple
ascending dose study in type 2 diabetes patients
M. Hompesch, B. Franey, M. Grimm, D. Lee, J. Jeong, M.-K. Kim, USA,
Korea, Republic of

111
 11:15 - 12:15 London Hall

OP 39 Glucagon metabolism in humans

Chair: J.J. Holst, Denmark

225 Different patterns of glucose- and glucagon-stimulated insulin

secretion in new diabetes subphenotypes
Friday, 1 October

K. Prystupa, K. Kantartzis, M. Heni, L. Fritsche, O.-P. Zaharia, I. Yurchenko,

K. Bodis, S. Trenkamp, V. Burkart, J. Szendrődi, N. Stefan, A.L. Birkenfeld,
A. Fritsche, M. Roden, R. Wagner, Germany

226 Increased glucagon sensitivity in totally pancreatectomised patients

I. Rix, A. Lund, L.F. Garvey, K. Owen, C. Hansen, G. Van Hall, J.J. Holst, T.
Vilsbøll, F.K. Knop, Denmark

227 Splanchnic and leg glucagon metabolism in healthy adults

A. Basu, R. Ruchi, Y. Yadav, A. Weaver, L. Wilkins, M. Schiavon, C. Cobelli,
C. Dalla Man, A. Pandey, K. Johnson, S. Renuse, R. Basu, USA, Italy

228 A 2-year follow-up of RYGB surgery in obesity and type 2 diabetes:

enhanced responses of multiple hormones to oral glucose but not i.v.
arginine challenge
G. Fanni, P. Katsogiannos, M.J. Pereira, J.W. Eriksson, Sweden

112
11:15 - 12:15 Madrid Hall

OP 40 Protecting the kidney in diabetes

Chair: N. Sandholm, Finland

229 Protective impact and potential mechanisms of Elabela on DKD via

ß-arrestins

Friday, 1 October
M. Shi, D. Tan, Y. Chen, W. Gu, H. Zhang, China

230 Chop-ASO ameliorates glomerular and tubular damage on top of

ace-inhibition in diabetic nephropathy
R. Klar, K. Shahzad, S. Fatima, M. Al-Dabet, I. Gadi, H. Khawaja, A.
ElWakiel, P.P. Nawroth, P.R. Mertens, S. Michel, F. Jaschinski, B. Isermann,
Germany, Jordan

231 SGLT2 inhibition prevents acute kidney injury by inhibiting glucose

transport and mTORC1 activity in proximal tubule cells
A. Kogot-Levin, L. Hinden, Y. Riahi, I. Abramovich, E. Gottlieb, A. Rothner, L.
Kadosh, T. Vaisid, J. Roitelman, E. Cerasi, J. Tam, O. Mosenzon, G.
Leibowitz, Israel

232 Acute effects of dapagliflozin on renal oxygenation and perfusion

in type 1 diabetes with albuminuria: a randomised, double-blind,
placebo-controlled crossover trial
J.C. Laursen, N. Søndergaard Heinrich, J.M. De Melo, B. Haddock, I.K.
Rasmussen, F. Safavimanesh, C. Stevns Hansen, J. Størling, H.B. Wiberg
Larsson, P.-H. Groop, M. Frimodt-Møller, U.B. Andersen, P. Rossing,
Denmark, Finland

113
 11:15 - 12:15 Barcelona Hall

OP 41 Building the evidence base for new devices

Chair: F.W. Gibb, UK

233 Cambridge hybrid closed-loop in very young children with type 1

diabetes: a multi-national 4-month randomised trial
Friday, 1 October

J. Fuchs, J.M. Allen, C.K. Boughton, M.E. Wilinska, A. Thankamony, C. De

Beaufort, E. Froehlich-Reiterer, T.M. Kapellen, B. Rami-Merhar, S.E. Hofer,
F.M. Campbell, J. Sibayan, L. Bocchino, R. Hovorka, KidsAP Consortium,
UK, Luxembourg, Belgium, Austria, Germany, USA

234 Cambridge hybrid closed-loop in children and adolescents with

type 1 diabetes: a multicentre 6-month randomised trial
C.K. Boughton, L. Kanapka, R. Hovorka, DAN05 Consortium, UK, USA

235 Effect of intermittent-scanning CGM to glycaemic control including

hypoglycaemia and quality of life of patients with type 1 diabetes
(ISCHIA study)
T. Murata, N. Sakane, A. Kuroda, J. Miura, Y. Hirota, K. Kato, M. Toyoda, R.
Kouyama, K. Kouyama, A. Shimada, S. Kawashima, Y. Matoba, K.
Nishimura, K. Hosoda, The ISCHIA study group, Japan

236 Evaluation of accuracy and safety of the next generation 180-day

long-term implantable Eversense CGM system: the PROMISE Study
S. Garg, D. Liljenquist, B. Bode, M. Christiansen, T. Bailey, R. Brazg, D.
Denham, A.R. Chang, H. Akturk, A. Dehennis, K.S. Tweden, F.R. Kaufman,
USA

114
11:15 - 12:15 Saint Petersburg Hall

OP 42 Cardiovascular disease: predictors and outcomes

Chair: C.J. Tack, Netherlands

237 Respective predictive value of glycation gap and silent myocardial

ischaemia for cardio-vascular events in asymptomatic patients with

Friday, 1 October
type 2 diabetes
P. Valensi, M. Nguyen, I. Banu, S. Chiheb, E. Cosson, France

238 Validation study for coronary heart disease (CHD) among diabetes
patients based on automatic retinal image analysis (ARIA) method
D.R. Owens, J. Lee, Y. Qu, Y. Zhou, L. Ding, S. Liu, W. Yuan, M. Chen, J.
Zhang, J.M. Rafferty, R.L. Thomas, B. Zee, UK, China

239 Cardiovascular and renal diseases in type 1 compared with type 2

diabetes: a nationwide observational study
D. Angoulvant, G. Fauchier, C. Semaan, A. Bisson, J. Herbert, P. Ducluzeau,
L. Fauchier, France

240 A longitudinal study on the incidence of cardiovascular events in a

population of Northern Italy
E. Bianco, M. Dei Cas, M. Bignotto, C. Morano, C. Rigoldi, G. Trevisi, C.
Berra, P. Zermiani, M. Zuin, R. Paroni, F. Folli, P. Battezzati, Italy

115
 12:30 - 13:30 Moscow Hall

OP 43 Genes, epigenes and telomeres in type 1 diabetes

Chair: R. Oram, UK

241 Birth weight, BMI in adulthood and latent autoimmune diabetes in

adults: a Mendelian randomisation study
Friday, 1 October

Y. Wei, Y. Zhan, J.E. Löfvenborg, T. Tuomi, S. Carlsson, Sweden, Finland

242 The influence of HLA haplotype, number of injections and

administration route on the effect of GAD-specific immunotherapy in
type 1 diabetes
U. Hannelius, C. Beam, J. Ludvigsson, Sweden, USA

243 Epigenome-wide association study identifies differentially

methylated DNA sites for diabetic kidney disease in type 1 diabetes
E.H. Dahlstrom, L.J. Smyth, A. Syreeni, J. Killner, G.J. McKay, N. Sandholm,
C. Forsblom, A. Maxwell, A. McKnight, P.-H. Groop, Finland, UK

244 Telomeres do not always shorten over time in people with type 1
diabetes: a FinnDiane substudy
A. Syreeni, L. Carroll, S. Mutter, A.S. Januszewski, C. Forsblom, M. Lehto,
P.-H. Groop, A.J. Jenkins, Finland, Australia

116
12:30 - 13:30 Paris Hall

OP 44 Diabetes around the clock!

Chair: C. Dibner, Switzerland

245 The influence of residual beta cell function upon free-living

postprandial and nocturnal glycaemic control in individuals with

Friday, 1 October
type 1 diabetes
A.C. Shaw, G.S. Taylor, T.J. McDonald, R.A. Oram, J.A. Shaw, D.J. West,
UK

246 Diurnal rhythms in the human skeletal muscle metabolome are

altered in insulin resistant individuals
J.-F. Harmsen, M. Van Weeghel, J. Wefers, J. Hoeks, R.H. Houtkooper, P.
Schrauwen, Netherlands

247 Diurnal pattern of meal tolerance and insulin sensitivity in type 2

diabetes
Y. Yadav, D. Romeres, C. Cobelli, R. Carter, A. Basu, C. Dalla Man, R. Basu,
USA, Italy

248 The effect of melatonin on incretin hormones: results from

experimental and randomised clinical studies
E. Stistrup Lauritzen, J. Støy, C. Bæch-Laursen, N. Grarup, T. Hansen, N.
Jessen, N. Møller, B. Hartmann, J. Holst, U. Kampmann, Denmark

117
 12:30 - 13:30 London Hall

OP 45 What surgery can do for you

Chair: K. Virtanen, Finland

249 Sleeve gastrectomy suppresses hepatic glucose production and

increases hepatic insulin clearance independent of weight loss
Friday, 1 October

D. Ben-Zvi, A. AlKurd, B. Moalem, A. Permyakova, H. Israeli, A. Bardugo, L.

Hefetz, M. Bergel, A. Haran, S. Azar, J. Tam, R. Grinbaum, R. Ben-Haroush
Schyr, Israel

250 Beta cell mass in type 2 diabetes before and after gastric bypass
surgery, measured as pancreatic uptake of radiolabeled exendin in human
L.N. Deden, M. Boss, E.J. Hazebroek, F.J. Berends, M. Gotthardt,
Netherlands

251 Identification of myokines potentially involved in the improvement

of glucose homeostasis induced by bariatric surgery
L. Orioli, J. Derop, M. Canouil, P. Lause, M. De Barsy, A. Loumaye, Y.
Deswysen, B. Navez, A. Bonnefond, J.-P. Thissen, Belgium, France

252 Bariatric surgery, type 2 diabetes remission and proteomic

changes Z. Iqbal, H. Fachim, M. Gibson, I. Baricevic-Jones, A. Campbell, B.
Geary, R. Donn, A. Syed, A. Whetton, H. Soran, A. Heald, UK

118
12:30 - 13:30 Madrid Hall

OP 46 (Path)ways to develop human beta cells

Chair: M. Rovira, Spain

253 Generation of stem cell derived islets with adult-like

cytoarchitecture and function in vitro

Friday, 1 October
V. Lithovius, H. Montaser, T. Barsby, D. Balboa, J. Saarimäki-Vire, H.
Vihinen, E. Jokitalo, H. Ibrahim, V. Chandra, T. Otonkoski, Finland

254 Mapping glucose metabolism and function in human pluripotent

stem cell derived islets
T. Barsby, D. Balboa, V. Lithovius, E. Vähäkangas, H. Montaser, A.
Nieminen, J. Kvist, J. Ustinov, J. Saarimäki-Vire, T. Otonkoski, Finland, Spain

255 Single cell transcriptomic profiling of the developing human

pancreas reveals unique features of maturing islet cells
O. Olaniru, U. Kadolsky, S. Persaud, UK

256 tRNA derived small RNAs regulate the maturation of neonatal beta cell
B. Bayazit, C. Jacovetti, C. Cosentino, J. Sobel, K. Wu, F. Brozzi, A.
Rodriguez-Trejo, L. Stoll, C. Guay, R. Regazzi, Switzerland

119
 12:30 - 13:30 Barcelona Hall

OP 47 Hypoglycaemia consequences at system level

Chair: S.A. Amiel, UK

257 Associations of hypoglycaemia and glycaemic variability with

cardiac arrhythmias using a long-term monitoring approach in insulin-
Friday, 1 October

treated patients with type 2 diabetes

A. Andersen, J.I. Bagger, S.K. Sørensen, M.P. Baldassarre, U. Pedersen-
Bjergaard, J.L. Forman, G. Gislason, T.B. Lindhardt, F.K. Knop, T. Vilsbøll,
Denmark, Italy

258 The impact of acute fluctuations in plasma glucose on

echocardiographic derived measures of systolic function in patients
with type 1 diabetes
C.R. Andreasen, A. Andersen, P.G. Haqelqvist, K. Abelin, J.V. Lauritsen, P.G.
Jørgensen, S. Engberg, J. Faber, J.J. Holst, U. Pedersen-Bjergaard, F.K.
Knop, T. Vilsbøll, Denmark

259 Investigating the blood flow responses of different thalamic nuclei

to hypoglycaemia in intact and impaired awareness of hypoglycaemia
P. Jacob, S.A. Amiel, M. Nwokolo, F. Zelaya, O. O'Daly, P. Choudhary, UK

260 Differential symptoms and hormonal counter-regulation during

hypoglycaemia in people with type 1 diabetes and post bariatric
hypoglycaemia
V. Lehmann, A. Tripyla, T. Zueger, D. Herzig, N. Styger, C. Albrecht, J. Meier,
L. Bally, C. Stettler, Switzerland

120
Diabetologia
Journal of the European Association for the Study of Diabetes (EASD)

utting-edge articles on all aspects of /FX

diabetes, from basic science through *NQBDU
'BDUPS


translational work to clinical research

Themed issues on timely topics published annually

Web: diabetologia-journal.org Twi琀er: @DiabetologiaJnl

121
 13:45
Moscow Hall

Management of type 1 diabetes: ADA-EASD Consensus Report 2021

Chair: R.I.G. Holt, UK; A. Peters, USA

R.I.G. Holt, UK:

Friday, 1 October

Introduction and methods, goals and targets

J.H. DeVries, Netherlands:
Diagnosis of type 1 diabetes
R. Weinstock, USA:
Schedule of care
A. Hess-Fischl, USA:
Diabetes self-management education and lifestyle considerations
I.B. Hirsch, USA:
Monitoring
S. Kirkman, USA:
Insulin therapy
E.M. Renard, France:
Hypoglycaemia
F.J. Snoek, Netherlands:
Psychosocial care
K. Nørgaard, Denmark:
DKA
B. Ludwig, Germany:
Pancreas and islet cell transplantation
J. Pettus, USA:
Adjunctive therapy
T. Klupa, Poland:
Special populations
J.S. Skyler, USA:
Emergent and future perspectives
A. Peters, USA:
Key knowledge gaps, question and discussion period

122
13:45
Paris Hall

Going to bed with diabetes

Chair: P. Schrauwen, Netherlands

R. Basu, USA:

Friday, 1 October
Nocturnal hepatic glucose metabolism in type 2 diabetes

S.M. Schmid, Germany:

Importance of sleep and circadian rhythm for energy metabolism

R.N. Bergman, USA:

Nocturnal FFA metabolism and insulin sensitivity

London Hall

What do the cells talk about and how? Extracellular vesicles:

biomarker, diagnostic tool or therapeutic vehicle

Chair: G. Gruden, Italy

E. Marbán, USA:
Introduction to the world of exosomes / The clinicians guide to
exosomes

M. Puhka, Finland:
Urinary extracellular vesicles as a biomarker and a diagnostic tool in
diabetic kidney disease

J.P.G. Sluijter, Netherlands:

Extracellular vesicles as a therapeutic tool in cardiovascular disease

123
 13:45
Madrid Hall

My cells are getting old! Ageing in diabetes

Chair: M. Cnop, Belgium

D.A. Sinclair, USA:

Friday, 1 October

The biology of longevity and ageing

D Avrahami, Israel:
Pancreatic endocrine cell maturation state in health and disease

J. Hoeks, Netherlands:
Metabolism, insulin sensitivity and physical fitness of human skeletal
muscle in ageing

Barcelona Hall

Turning stem cells into beta cells

Chair: V. Sordi, Italy

H. Lickert, Germany:
From stem cells to beta cells

G.G. Nair, USA:

Functional maturation of human iPSC-derived beta cells

T. Otonkoski, Finland:
Applications of human islet-like organoids in research and in the clinic

124
13:45
Saint Petersburg Hall

Major results from the Glycaemia Reduction Approaches in Diabetes: a

Comparative Effectiveness (GRADE) Study

Chair: S.E. Kahn, USA

Friday, 1 October
D.M. Nathan, USA:
Background, rationale, design, conduct, adherence

J.B. Buse, USA:

Major results: Metabolic, microvascular and cardiovascular with
subgroup analyses

M.A. Tiktin, USA:

Side-effects / Adverse events / QOL

N. Younes, USA:
Heterogeneity of treatment effects including baseline factors
associated with success

D.R. Matthews, UK:

Discussant

Rome Hall

A novel approach to problematic hypoglycaemia: the HARPdoc RCT

Chair: S.R. Heller, UK

H. Rogers, UK:
The background to HARPdoc

N. De Zoysa, UK:
An overview of the intervention

S.A. Amiel, UK:

The HARPdoc RCT

R.A. Ajjan, UK:

Commentary

Panel discussion with questions from the audience

125
 16:15
Saint Petersburg Hall

EASD General Assembly

For EASD Members only

Friday, 1 October

126
Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 01 Diabetes epidemiology at scale: registries and large databases

Chair: T. Fall, Sweden

261 Disease heterogeneity of adult diabetes patients based on routine

Short Oral Discussions

clinical parameters at diagnosis: results from the German/Austrian
DPV registry
S.R. Tittel, B. Mayer, A. Fritsche, J. Seufert, M. Laimer, S. Zimny, S.M.
Schmid, M. Hummel, P. Bramlage, R.W. Holl, Germany, Switzerland

262 Epidemiology of diabetes in Kazakhstan: data from unified

nationwide electronic healthcare system 2014 - 2019
D. Galiyeva, A. Gusmanov, Y. Sakko, A. Issanov, K. Atageldiyeva, K.
Kadyrzhanuly, A. Sarria-Santamera, A. Nurpeissova, A. Gaipov, Kazakhstan

263 Identifying and delineating the Dutch type 2 diabetes population

using an all-payer claims database: characteristics, healthcare
utilisation, and expenditures
R.J. Geurten, A.M. Elissen, H.J. Bilo, J.N. Struijs, C. Van Tilburg, D. Ruwaard,
Netherlands

264 Association between weight change and incidence of

cardiovascular disease events and mortality among adults with type 2
diabetes: a systematic review and meta-analysis
J. Strelitz, E.R. Lawlor, Y. Wu, A. Estlin, G. Nandakumar, A.L. Ahern, S.J.
Griffin, UK

265 Mortality rates associated with diabetes are now increasing

compared to general population: outcomes from a general practice
level analysis in England
M. Whyte, M. Stedman, A. Heald, UK

266 The impact of the timing of pregnancies after bariatric surgery on

children’s health: a retrospective, registry analysis
M. Krebs, E. Mörth, B. Reichardt, T. Stamm, B. Itariu, J. Harreiter, M.
Hufgard-Leitner, P. Fellinger, J. Eichelter, G. Prager, A. Kautzky-Willer, P.
Wolf, H. Beiglböck, Austria, Norway

127
 267 Childhood bereavement and risk of type 1 diabetes: a Swedish
population-based register study
M.-L. Wernroth, B. Kennedy, K. Fall, B. Svennblad, C. Almqvist, T. Fall, Sweden

268 Total costs of care in patients with type 2 diabetes and

cardiovascular disease: a comparative cohort study (OFFSET)
M. Evans, A. Shankar Chandramouli, M. Faurby, K. Sommer Matthiessen, P.
Short Oral Discussions

Bredahl Mogensen, S. Verma, UK, India, Denmark, Canada

Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 02 Diabetes across generations

Chair: R.B. Prasad, Sweden

269 Paternal ketogenic diet in mice programmes offspring fasting

metabolism and physical activity
J. Magrill, M. Stolovich-Rain, E. Ben Cnaan, S. Baraghithy, B. Glaser, Y. Tam,
Y. Dor, Israel

270 Hyperglycaemic memory: role of epigenetic signature in the

transmission of gestational diabetes-associated inflammatory and pro-
oxidant phenotype
N. Di Pietrantonio, M. Shumliakivska, R. Suades, D. Mandatori, P. Di Tomo,
G. Formoso, M.P. Baldassarre, F. Cosentino, A. Pandolfi, Italy, Sweden

271 Imprinted genes in beta cell function

G. Hatem, O. Asplund, T. Singh, I. Artner, R.B. Prasad, Sweden

272 Methylomic trajectories in the human pancreas: from fetal

development to adulthood
A. MacCalman, E. De Franco, A.R. Jeffries, J. Burrage, E.M. Walker, A.
Franklin, N.D. Owens, A.T. Hattersley, J. Mill, UK

273 Increased risk of fetal abdominal obesity (FAO) in old and/or obese
pregnant women with normal glucose tolerance
Y. Kim, W. Kim, S. Park, Korea, Republic of, USA

128
274 Both gestational diabetes exposure and maternal methylome
interaction impacts offspring epigenetic signature
A. Khamis, M. Canouil, E. Keikkala, S. Hummel, A. Bonnefond, F. Delahaye,
M. Vääräsmäki, M.-R. Jarvelin, S. Sebert, E. Kajantie, P. Froguel, T. Andrew,
France, Finland, Germany, UK

275 New clinical score to predict glucose intolerance at postpartum

Short Oral Discussions

reclassification in women with gestational diabetes
C. Cidade-Rodrigues, F.M. Cunha, C. Chaves, F. Castro, C. Pereira, S.
Paredes, M. Vieira, A. Melo, O. Figueiredo, A. Morgado, M. Martinho, M.
Almeida, M. Almeida, Portugal

276 Postpartum screening of women with gestational diabetes in

specialised diabetes practices in the period from 2015 - 2017: data from
12,991 women from the GestDiab registry
U. Linnenkamp, G.G. Greiner, B. Haastert, H. Adamczewski, M. Kaltheuner,
D. Weber, A. Icks, Germany

277 A lifestyle intervention to prevent deterioration of glycaemic status

among women with previous gestational diabetes: the LIVING trial
N. Tandon, D. Kapoor, J.K. Lakshmi, A. Bhattacharya, L. Billot, A. Patel, India,
Australia

Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 03 Diet, lifestyle and behaviour

Chair: F. Rutters, Netherlands

278 Vitamin C intake and the risk of islet autoimmunity and type 1
diabetes: The Environmental Determinants of Diabetes in the Young
(TEDDY) Study
M. Mattila, S. Niinistö, L.K. Mramba, X. Liu, U. Uusitalo, C. Andrén Aronsson,
S. Hummel, H. Parikh, J.M. Norris, S.M. Virtanen, for the TEDDY Study
Group, Finland, USA, Sweden, Germany

279 A high-protein and -unsaturated fatty acid diet increases fasting

and postprandial insulin sensitivity independently of weight loss: 6-
months results of the NutriAct Trial
L. Pletsch-Borba, C. Wernicke, K. Apostolopoulou, N. Meyer, D. Spira, A.
Pohrt, C. Gerbracht, A.F. Pfeiffer, J. Spranger, K. Mai, Germany

129
 280 Habitual intake of dietary advanced glycation endproducts is not
associated with generalised microvascular function: the Maastricht study
A. Linkens, A. Houben, B. Kroon, M. Schram, T. Berendschot, C. Webers, M.
Van Greevenbroek, R. Henry, B. De Galan, C. Stehouwer, S. Eussen, C.
Schalkwijk, Netherlands

281 Oral glucose tolerance test results are altered by the size of the
Short Oral Discussions

last meal before the test

W. Nakanga, R. Andrews, A. Jones, B. Shields, P. Hughes, A. Karabarinde,
A. Hattersley, M. Nyirenda, UK, Uganda

282 Tobacco use and interaction with genotypes of human leucocyte

antigen in the risk of latent autoimmune diabetes in adults: results
from two population-based studies
J. Edstorp, E. Ahlqvist, L. Alfredsson, V. Grill, L. Groop, B. Rasouli, E.P.
Sørgjerd, T. Tuomi, B.O. Åsvold, S. Carlsson, Sweden, Norway, Finland

283 Clustering of risk behaviors and associations between risk

behaviors and cardio-metabolic risk factors in adult individuals with
type 1 diabetes
A.J. Ahola, H. Tikkanen-Dolenc, C. Forsblom, V. Harjutsalo, P.-H. Groop, on
behalf of the FinnDiane Study Group, Finland

284 Occupational and domestic physical activity and the risk of

diabetes in adults: results from a long-term follow-up cohort
L. He, J. Wang, N. Yang, L. Xu, J. Huang, W. Li, F. Ping, Y. Li, H. Zhang, China

285 Association between social jetlag and change in glycaemic control

in people with type 2 diabetes. The Hoorn diabetes care system cohort
E.J. Bouman, J.W. Beulens, S. Remmelzwaal, L. Groeneveld, N.R. Den
Braver, A.A. Van der Heijden, P.J. Elders, F. Rutters, Netherlands

130
Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 04 Prediction models and precision medicine

Chair: R. Slieker, Netherlands

286 Phenotypic and genetic determinants of glycaemic deterioration

Short Oral Discussions

among Asian Indian type 2 diabetes population
A. Thakarakkattil Narayanan Nair, L.A. Donnelly, A.Y. Dawed, S. Gan, R.M.
Anjana, C.N. Palmer, V. Mohan, E.R. Pearson, UK, India

287 Recursive partitioning analysis of the glomerular filtration rate

optima: the 10-year-health examinees study
Y. Nakasone, H. Koike, K. Yamashita, T. Aizawa, Japan

288 A serum resistin and multi-cytokine inflammatory pathway is

associated with and helps predict all-cause mortality in type 2 diabetes:
a step toward precision medicine
M. Scarale, A. Antonucci, M. Cardellini, M. Copetti, L. Salvemini, R.
Menghini, V. Casagrande, G. Ferrazza, O. Lamacchia, S. De Cosmo, R. Di
Paola, M. Federici, V. Trischitta, C. Menzaghi, Italy

289 Estimation and validation of machine-learning-based retinal image

analysis for detection of the risk of undiagnosed diabetes
R.L. Thomas, J. Lee, P. Chee, Y. Zhou, M. Lai, J.M. Rafferty, D.R. Owens, B.
Zee, UK, China

290 A clinical-genetic score for predicting type 2 diabetes remission

after bariatric surgery: the OBEGEN project
A. Lecube, A. Ciudin, E. Fidilio, L. Gutiérrez-Carrasquilla, A. Caixàs, N.
Vilarrasa, A. Simó, R. Vilallonga, M. De la Fuente, A. Luna, E. Sánchez, M.
Bueno, C. Hernández, E. Salas, R. Simó, Spain

291 Targetome redirection by adenosine-to-inosine editing of miRNAs

could unravel the complexity of diabetic complications
A. Abukiwan, S. Kopf, R. Thiele, J. Szendrödi, P. Nawroth, T. Fleming,
Germany

131
 292 Predicting the onset of APECED diabetes
P.M. Paldánius, O. Mäkitie, S. Laakso, Finland

293 Phenotypic and genetic heterogeneity in a Thai glucokinase MODY

family reveals the complexity of young-onset diabetes
Y. Thewjitcharon, E. Wanothayaroj, S. Krittiyawong, S. Nakasatien, T.F. Tsoi,
C.K. Lim, J.C. Chan, T. Himathongkam, Thailand, China
Short Oral Discussions

Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 05 Therapeutic advances

Chair: R. Ma, Hong Kong

294 Cholecalciferol therapy effect on glucose metabolism in patients

with prediabetes
A.T. Andreeva, A.O. Ustyuzhanina, A.A. Bystrova, T.L. Karonova, Russian
Federation

295 Five years of treatment with liraglutide improves glucose tolerance

in women with prior gestational diabetes, but effects are lost after
wash-out
E.S. Andersen, S. Foghsgaard, L. Vedtofte, M.H. Pedersen, J.L. Forman,
E.R. Mathiesen, J.A. Svare, J.J. Holst, T.D. Clausen, P. Damm, F.K. Knop, T.
Vilsbøll, Denmark

296 Treatment patterns for first- and second-line management of type 2

diabetes in the Middle East and North Africa region: insights from
DISCOVER
K. Al-Rubeaan, A. Echtay, F. Bayram, R. Malek, A. Kok, A. Bennakhi, K.
Hafidh, E. Roushdy, V. Rajadhyaksha, M. Alsayed, Saudi Arabia, Lebanon,
Turkey, Algeria, South Africa, Kuwait, United Arab Emirates, Egypt, UK

297 The association between hormone therapy and sarcopenia in

postmenopausal women: the Korea National Health and Nutrition
Examination Survey, 2008-2011
S. Kim, E. Jeon, J.-H. Lee, H.-S. Shon, Korea, Republic of

132
298 A multivalent vaccine does not accelerate the onset of diabetes in
NOD mice
V.M. Stone, M. Butrym, M.M. Hankaniemi, A.-B. Sioofy-Khojine, V.P.
Hytönen, H. Hyöty, M. Flodström-Tullberg, Sweden, Finland

299 Risk factors for severe hypoglycaemia in adults with insulin-

treated type 2 diabetes

Short Oral Discussions

B.M. Frier, C.J. Child, M. Gorritz, J.K. Multani, C.B. McGuiness, R.L. Wade,
H. Kan, J. Settles, UK, USA

300 Changes in HbA1c, BMI and rates of severe hypoglycaemia in 4,113

adults with type 1 or type 2 diabetes using continuous glucose
monitoring systems
S. Lanzinger, F. Best, T. Bergmann, M. Laimer, B. Lipovsky, T. Danne, S.
Zimny, P. Bramlage, R.W. Holl, Germany, Switzerland, Austria

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 06 Genes and genomic engineering

Chair: O. Hansson, Sweden

301 A case-cohort of genome-wide association analysis of type 2

diabetes in Qataris: an insight from 1.000 Qataromics cohort of biobank
A.A.-S. Akil, I. Ahmed, S.S. Padma Jeya, K.A. Fakhro, Qatar

302 Whole genome- and whole exome sequencing analyses provide

novel rare genetic variants for coronary artery disease and stroke in
type 1 diabetes
A.A. Antikainen, J. Haukka, L. Thorn, S. Hägg-Holmberg, J. Putaala, A.
Ylinen, C. Forsblom, V. Harjutsalo, N. Sandholm, P.-H. Groop, on behalf of
the FinnDiane Study Group, Finland

303 Epigenetic mechanisms of hyperglycaemic macrophage programming

E. Badillo, K. Moganti, M.M. Dieuwertje, V. Ryabov, H. Klüter, M. Harmsen, J.
Kzhyshkowska, Germany, Netherlands

304 Beta cell miR-125b controls glucose homeostasis by targeting

lysosomal and mitochondrial genes
A. Martinez-Sanchez, R. Cheung, G. Pizza, D. Rolando, P. Chabosseau, A.
Tomas, A. Salowska, T. Burgoyne, I. Leclerc, G.A. Rutter, UK

133
 305 WFS1 gene engineering reverts ER stress related to autophagy
dysfunctions in an iPSC-derived beta cell model of Wolfram syndrome
S. Torchio, R. Chimienti, G. Rossi, F. Manenti, M.T. Lombardo, S. Pellegrini,
V. Sordi, F. Meschi, T. Raouf, G. Frontino, V. Broccoli, L. Piemonti, Italy

306 CRISPR editing of the PPARGC1A Gly482ser (rs8192678)

polymorphism in human white adipose cells shows differential effects
Short Oral Discussions

on mitochondrial function and adipogenesis

M. Huang, M. Claussnitzer, A. Saadat, H. Mulder, S. Kalamajski, P.W.
Franks, Sweden, USA

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 07 Risk factors and consequences of poor glycaemic control

Chair: T. Stulnig, Austria

307 Clinical characteristics of COVID-19 patients in a regional

population with diabetes: the ACCREDIT study
D. Llanera, R. Wilmington, H. Shoo, P. Lisboa, I. Jarman, S. Wong, J. Nizza,
D. Sharma, D. Kalathil, S. Rajeev, R. Yadav, Z. Qureshi, R. Narayanan, N.
Furlong, S. Nair, UK

308 Impact of COVID-19 lockdown on glycaemic control in patients with

type 1 diabetes
S. Stichling, C. Eberle, Germany

309 Impact of COVID-19 lockdown on metabolic control and access to

healthcare in patients with diabetes from a tertiary care centre: the
CONFI-DIAB study
L. Ludwig, N. Scheyer, T. Remen, B. Guerci, France

310 Diabetes prevalence is rising among young residents in Malmö,

Sweden M. Annersten Gershater, M. Rämgård, S. Zdravkovic, C. Nagorny
Holmberg, M. Grahn, M. Andersson, Sweden

311 Insulin secretion with increasing age: a comparison between

Middle Eastern immigrants and native Swedes
N. Fadhel Dhaher, N. Shaat, L. Bennet, Sweden

134
312 Fetuin-a and risk of diabetes-related vascular, including
microvascular, complications
A. Birukov, E. Polemiti, S. Jäger, N. Stefan, M.B. Schulze, Germany

313 Risk of type 2 diabetes in polycystic ovary syndrome is associated

with obesity: a meta-analysis of observational studies
P. Anagnostis, R.D. Paparodis, J.K. Bosdou, C. Bothou, D. Macut, D.G.

Short Oral Discussions

Goulis, S. Livadas, Greece, USA, Switzerland, Serbia

314 Prevalence of and factors associated with undiagnosed stage 3

chronic kidney disease in patient with type 2 diabetes: a report from
REVEAL-CKD
E. Wittbrodt, P. Kushner, S. Salvatore, S. Kumar, H. Chen, K. Järbrink, J.
Garcia Sanchez, A. Abdul Sultan, N. Tangri, USA, Sweden, UK, Canada

Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 08 Preservation versus destruction of beta cell mass

Chair: J.-M. Servitja, Spain

315 A fatty acid modified apelin-13 analogue demonstrates benefits on

pancreatic islet cell morphology and beta cell preservation in diabetic
mouse models
F.P. O'Harte, N. Tandy, C.R. Moffett, P.R. Flatt, N. Irwin, UK

316 High-fat diet-induced upregulation of chemokine Ccl4 in mouse

visceral adipose tissue: potential crosstalk with beta cells
T. Ashik, P. Atanes, V. Lee, S.J. Persaud, UK

317 Proteomic profiling of glucose regulated ACC1 phospho-sites in

pancreatic beta cells
R. Bany Bakar, S. Liberatori, A. Veprik, N. N.Tebeka, V. A. Morfin, B. E.
Kemp, S. Mohammed, J. Cantley, UK, Australia

318 The role of TSC2 acetylation and its subcellular localisation in

mitochondrial turnover of pancreatic beta cells
P. Marqués, J. Burillo, C. González, B. Jiménez, G. García, C. Guillén, M.
Benito, Spain

135
 319 Regulation of autophagy activity by PERK attenuation contributes
to insulin synthesis with an Atg7-dependent manner
S. Moon, M. Kim, J. Lim, M. Kim, K. Park, H. Jung, Korea, Republic of

320 Exposure to bisphenol-A induces pancreatic beta cell apoptosis

R.S. Dos Santos, L. Marroqui, R. Medina-Gali, A. Nadal, Spain
Short Oral Discussions

321 Novel islet staging defined by progression of beta cell destruction

B. Ehall, L. Herbsthofer, C. Karacay, C. Harer, P. Kotzbeck, B. Prietl, T.R.
Pieber, Austria

Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 09 The ins and outs of insulin secretion

Chair: S.J. Ullrich, Germany

322 Loss of maturity in overworked beta cells of normoglycaemic mice

N. Téllez, K. Rivera, C. Fernández, S. Masó, E. Montanya, Spain

323 Novel miR-29 mitochondrial-associated gene pathways predicted

to regulate beta cell insulin secretion
E. Cowan, J. Sun, J.K. Ofori, C. Luan, E. Zhang, C. Ling, H. Mulder, L.
Eliasson, Sweden

324 An integrated microfluidic sensing system platform for dissecting

insulin secretion and extracellular Ca2+dynamics of pancreatic islets
W. Huang, J. Zhao, L.M. Nicholas, A. Shallan, C. Priest, C.K. Rayner, H.
Ebendorff-Heidepriem, T. Wu, Australia, Egypt

325 The potential role of metal-dependent protein phosphatase, PPM1E

in pancreatic B cell function
S. Gheibi, L.R. Cataldo, A. Hamilton, M. Fex, H. Mulder, Sweden

136
326 Mouse strain- and Ffar1-independent changes of islet
transcriptome induced by overnight culture transcriptome induced by
overnight culture
S. Ullrich, E. Lorza-Gil, G. Kaiser, S. Sabrautzki, G.K. Przemeck, A.L.
Birkenfeld, M. Hrabě de Angelis, H.-U. Häring, F. Gerst, Germany

327 Therapeutically relevant concentrations of atypical antipsychotic

Short Oral Discussions

drugs, aripiprazole and clozapine, promote beta cell mass expansion
K.W. Toczyska, G. Day, N. Guccio, H. Rosa, B. Liu, S.J. Persaud, UK

Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 10 Beta cells to the grave in type 1 diabetes

Chair: I. Santin, Spain

328 Proinflammatory cytokines have a toxic effect on human stem cell-

derived beta cells
R. Dettmer, I. Niwolik, I. Mehmeti, E. Gurgul-Convey, O. Naujok, Germany

329 Identification of new therapeutic targets for the treatment of type 1

diabetes based on the survival strategies of pancreatic alpha cells
L. Marroqui, A.A. Perez-Serna, R. Medina-Gali, R.S. Dos Santos, Spain

330 Desensitisation of STAT mediated-signalling during chronic

exposure of EndoC-βH1 cells to type I and type II interferons
S. Dhayal, M. Baity, K. Afi Leslie, P. Akhbari, S.J. Richardson, M.A. Russell,
N.G. Morgan, UK

331 Sphingosine-1 phosphate lyase overexpression prevents cytokine-

mediated beta cell cellular structure damage and lipidome changes
E. Gurgul Convey, Y. Tang, S. Coldewey, M. Gräler, A. Jörns, Germany

332 PTPN2 regulates the interferon signalling in pancreatic beta cells

and its expression correlates with therapy outcome in autoimmune
diabetes
V. Vandenbempt, B. Elvira, J. Martinez, J. Negueruela, H. Ibrahim, M. Winder,
B. Vekeriotaite, S. Pal, F. Rossello, P. Lybaert, T. Otonkoski, C. Gysemans,
W. Wu, E. Gurzov, Belgium, Netherlands, Finland, Australia

137
 333 The role of NIK in beta cell-mediated type 1 diabetes
P. Xiao, T. Takiishi, N.M. Violato, G. Licata, F. Dotta, G. Sebastiani, E.N.
Gurzov, E. Dejardin, A.K. Cardozo, Belgium, Italy

334 The parasite-derived peptide, FhHDM-1, promotes beta cell

function and survival via PI3K/Akt signalling to prevent type 1 diabetes
I. Camaya, M. Robinson, J. Santos, J.P. Dalton, B. O'Brien, S. Donnelly,
Short Oral Discussions

Australia, UK, Ireland

Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 11 In vivo and ex vivo beta cell function in diabetes

Chair: I. Rustenbeck, Germany

335 Beta cell loss in treatment-naive patients with type 2 diabetes based
on disease duration and HbA1c levels: results from 15 clinical trials
M. Blüher, A. Malhotra, G. Bader, Germany, India, Switzerland

336 Beta cell activity modulates treatment response in treatment-naive

patients: exploratory analysis from the VERIFY study
D.R. Matthews, P.M. Paldánius, G. Bader, S. Del Prato, UK, Finland,
Switzerland, Italy

337 Human beta cell dedifferentiation might be induced by

noradrenergic stimulus
F. Cinti, F. Fantuzzi, A. Carfì, T. Mezza, C. Cefalo, S. Moffa, F. Impronta, G.
Di Giuseppe, U. Capece, A. Giaccari, M. Cnop, Italy, Belgium

338 In vivo and in vitro effect of vertical sleeve gastrectomy upon

glucose-insulin homeostasis and beta cell function and survival
G.M. Soares, S.L. Balbo, G.A. Bronczek, C. Marmentini, L. Zangerolamo,
L.A. Velloso, E.M. Carneiro, Brazil

339 Extracorporeal islet-based continuous glucose monitoring sensor

in rodents
E. Puginier, F. Poulletier de Gannes, A. Pirog, J. Gaitan, A. Hurtier, Y. Bornat,
C. Cruciani-Guglielmacci, C. Magnan, B. Catargi, M. Raoux, S. Renaud, J.
Lang, France

138
340 Islet microcapsules with core-shell structure from Microfluidic
electrospray for diabetes treatment
X. Liu, J. Li, J. Sun, L. Li, China

341 Weight gain following pancreas transplantation in type 1 diabetes is

associated with a worse glycaemic profile: a retrospective cohort study
A. Amor, A. Casas, A. Pané, S. Ruiz, E. Montagud-Marrahi, A. Molina-

Short Oral Discussions

Andújar, M. Ruiz, R. Mayordomo, M. Musquera, J. Ferrer-Fàbrega, C.
Fondevila, F. Diekmann, P. Ventura-Aguiar, E. Esmatjes, Spain

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 12 Sugar Moms

Chair: A. Kautzky-Willer, Austria

342 Diagnosing gestational diabetes: COVID-19 criteria vs oral glucose

tolerance test
D. Hirani, T. Ladha, M. Tan, L. Sykes, B. Jones, A. Dornhorst, C. Yu, R. Agha-
Jaffar, S. Robinson, UK

343 Diabetes management delivery and pregnancy outcomes in women

with gestational diabetes during the first wave of the 2020 COVID-19
pandemic
M. Wilk, P. Surowiec, B. Matejko, A. Wróbel, J. Zięba-Parkitny, K. Cyganek,
H. Huras, M. Małecki, Poland

344 Comparison of clinical and metabolic characteristics, and

pregnancy outcomes in women with gestational diabetes depending on
the time of diagnosis
M. Zurawska-Klis, K. Czarnik, K. Cypryk, Poland

345 The use of flash glucose monitoring is as effective and safe as self
monitoring blood glucose in a cohort of pregnant women with type 1
diabetes using multiple doses of insulin
N. Seguí, V. Perea, D. Tundidor, D. Roca, M. Vidal, J. Bellart, M. Giménez, I.
Conget, I. Vinagre, Spain

139
 346 Risk for ketonaemia in type 1 diabetes pregnancies with sensor-
augmented pump therapy with predictive low glucose suspend
compared to low glucose suspend: a crossover RCT
K. Benhalima, F. Van Nes, P. Gillard, C. Mathieu, Belgium

347 Analysis of insulin requirement during pregnancy in patients with

type 1 diabetes treated with a personal insulin pump
Short Oral Discussions

M. Kosinski, M. Zurawska-Klis, K. Cypryk, Poland

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 13 From pregnant women and mice

Chair: E.R. Mathiesen, Denmark

348 Maternal overweight and obesity is associated with impaired

glucose homeostasis and fetal overgrowth in the absence of
gestational diabetes
G. Kotzaeridi, C. Salamon, D. Eppel, T. Linder, I. Rosicky, K. Weisshaupt, W.
Henrich, A. Tura, C.S. Göbl, Austria, Germany, Italy

349 Impact of prepregnancy overweight and obesity on treatment

modality and pregnancy outcome in women with gestational diabetes
T. Linder, A. Eder, I. Rosicky, D. Eppel, K. Redling, F. Geissler, E.A. Huhn, I.
Hoesli, C.S. Goebl, Austria, Switzerland

350 Reliance on lipid and protein energy sources is associated with

materno-fetal complications in type 1 diabetes pregnancy: a CONCEPTT
trial substudy
Z.A. Stewart, C.L. Meek, J. Yamamoto, S. Furse, D.S. Feig, A. Koulman, H.R.
Murphy, UK, Canada

351 Enhanced hepatic insulin resistance may counteract metabolic

adaption processes during gestation
M. Liebmann, K. Grupe, S. Scherneck, Germany

140
352 Serum Elabela is associated with inflammatory abnormalities in
gestational diabetes
Y. Chen, M. Shi, J. Song, D. Tan, Y. Xu, H. Zhang, X. Zhang, China

353 Improvement of insulin and glucagon secretion profiles by

estradiol and serotonin in prediabetic mice during gestation
M. Asuaje Pfeifer, M. Liebmann, K. Grupe, S. Scherneck, Germany

Short Oral Discussions

Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 14 Exercise effects beyond blood glucose

Chair: J. Hoeks, Netherlands

354 Glycaemic excursions during a standardised bout of

hypoglycaemia-inducing physical activity and subsequent
hypoglycaemia treatment in adult type 1 diabetes patients
J. Broz, M. Campbell, J. Urbanová, M. Nunes, D. Rahelic, D. Janíčková
Žďárská, A. Taniwall, M. Brabec, V. Berka, J. Michalec, J. Polák, Czech
Republic, UK, Croatia

355 Effect of 14-week high-intensity interval training on blood lactate

concentrations in type 2 diabetes patients
T. Zhao, W. Yao, X. Wang, C. Chen, J. Lu, Q. Lu, J. Cao, J. Tian, M.
Schumann, S. Cheng, S. Le, China, Germany, Finland

356 Regular exercise training improves femoral bone marrow

metabolism in monozygotic twin pairs discordant for body weight
R. Ojala, J. Hentilä, M.S. Lietzén, M.A. Heiskanen, S.M. Honkala, R.
Lautamäki, E. Löyttyniemi, T. Malm, L. Lahti, J.O. Rinne, K.H. Pietiläinen, J.
Kaprio, K.K. Ivaska, J.C. Hannukainen, Finland

357 Different fueling strategies during racing and training in

professional cyclists with type 1 diabetes
J.P. Pitt, R.M. Bracken, S. Scott, F.Y. Fontana, O.M. McCarthy, UK,
Switzerland, Italy

141
 358 The effects of regular excercise training on colon glucose uptake
in monozygotic twins discordant for BMI
M.S. Lietzén, R. Ojala, J. Hentilä, M.A. Heiskanen, S.M. Honkala, R.
Lautamäki, E. Löyttyniemi, T. Malm, L. Lahti, J.O. Rinne, K.H. Pietiläinen, J.
Kaprio, P. Iozzo, J.C. Hannukainen, Finland, Italy

359 The level of muscle and intestinal damage biomarkers after an

Short Oral Discussions

exercise with a predominance of eccentric contractions in male

patients with type 1 diabetes
B. Matejko, &. Tota, M. Morawska, S. Mrozińska, T. Klupa, M. Małecki,
Poland

360 Assessment of factors influencing changes in blood lactate levels

in children and adolescents with type 1 diabetes during a football
tournament (GoalDiab Study)
J. Flotynska, A. Gawrecki, A. Araszkiewicz, M. Parchimowicz, M. Michalski,
O. Różańska, M. Stopczyńska-Szymecka, M. Kamiński, A. Cieluch, G.
Biegański, A. Michalak, K. Domaszewska, D. Zozulińska-Ziółkiewicz, Poland

Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 15 Novel methods to study metabolism in diabetes

Chair: P. Nuutila, Finland

361 Applying a microphysiological 3D human liver-islet microtissue

platform to study drug-drug interaction
L. Hoelting, I. Karakoc, C. Rufer, W. Moritz, B. Yesildag, O. Frey, Switzerland

362 Real-time metabolomics of glucose response in pancreatic islet

cells resolved using infrared microspectroscopic imaging
A. Tarasov, M. Draper, A. Poonprasartporn, G. Cinque, A. Ka-Lung Chan, UK

363 Single-cell optogenetics and cell-tracking reveal a functional

hierarchy connecting leader and follower beta cells in vivo
L. Delgadillo Silva, M. Akhtar, E. Taşöz, N. Ninov, Germany

364 Estimated glucose disposal rate, non-alcoholic fatty liver disease

and micro- and macrovascular complications in type 1 diabetes:
Towards a new predictor?
J. Mertens, L. Vonghia, E. Dirinck, S. Francque, C. De Block, Belgium

142
365 Development and evaluation of a glucagon sensitivity test
S.A. Kjeldsen, N.J. Jensen, M.S. Nilsson, J.D. Nybing, F.H. Linden, E. Høgh-
Schmidt, M.P. Boesen, S. Madsbad, H.V. Vilstrup, E.B. Rashu, L.L. Gluud,
S.B. Haugaard, J.J. Holst, J. Rungby, N.J. Wewer Albrechtsen, Denmark

366 In-vivo determination of NAD metabolites in skeletal muscle, using

phosphorus magnetic resonance spectroscopy

Short Oral Discussions

Y.M. Bruls, J. Mevenkamp, R.A. De Graaf, J.E. Wildberger, M.K. Hesselink, P.
Schrauwen, L. Lindeboom, V.B. Schrauwen-Hinderling, Netherlands, USA

Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 16 The many faces of insulin sensitivity

Chair: A. Krook, Sweden

367 The extracellular vesicles from myotubes improved insulin-

stimulated glucose uptake in adipocytes by regulating AMPK pathway
and Glut4 expression
T. Saito, H. Saito-Aoki, T. Shimizu, Y. Shimoda, A. Osaki, E. Yamada, S.
Okada, M. Yamada, Japan

368 Insulin resistance and type 2 diabetes studied using a new

combination of microphysiological systems and mathematical modelling
G. Cedersund, B. Casas, S. Bauer, K. Kanebratt, C. Wennberg Huldt, L.
Magnusson, C. Ämmälä, U. Marx, T.B. Andersson, P. Gennemark, L. Vilén,
Sweden, Germany

369 Deletion of the mammalian Indy homologue (Slc13a5) improves

hepatic insulin sensitivity through vagal nerve signalling
A. Kurzbach, M. Schell, D.M. Willmes, N. El-Agroudy, S.R. Bornstein, A.
Kleinridders, A.L. Birkenfeld, Germany

370 Insulin sensitivity and beta cell function in IGT and treatment-naive
patients with type 2 diabetes of different ethnicities: a pooled analysis
from clinical studies
S. Del Prato, D.R. Matthews, G. Bader, P.M. Paldánius, Italy, UK,
Switzerland, Finland

143
 371 Metabolic effects on aortic valves in static and pulsatile 3D
cultivation environments
J.I. Selig, J. Boulgaropoulos, N. Niazy, D.M. Ouwens, K. Preuß, R.
Westenfeld, A. Lichtenberg, P. Akhyari, M. Barth, Germany

372 Cardiac insulin resistance does not predict mortality or morbidity

in ischaemic heart failure
Short Oral Discussions

T.V. Luong, M.G. Pedersen, A.L. Ebbehøj, E. Søndergaard, L.C. Gormsen,

Denmark

373 The association of insulin resistance with early predictors of

cardiovascular, renal and neurologic complications in patients with
type 1 diabetes
A. Barmpagianni, G. Karamanakos, C. Kapelios, M. Bonou, J. Barbetseas, S.
Liatis, Greece

374 Human skeletal muscle THY1+fibro-adipogenic progenitors are

associated with muscle degeneration in type 2 diabetic patients
J. Farup, J. Just, F. De Paoli, L. Lin, J.B. Jensen, T. Billeskov, C. Cömert, A.B.
Møller, L. Madaro, U. Kampmann, S.B. Pedersen, P. Bross, P.L. Puri, N.
Jessen, Denmark, Italy, USA

Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 17 Novel aspects of beta cell and insulin secretion

Chair: M. Cnop, Belgium

375 Proinsulin insulin in situ localisation defects are associated to UPR

response and loss of beta cell phenotype in islets of type 2 diabetic
and glucose intolerant living donors
N. Brusco, G. Licata, G.E. Grieco, D. Fignani, L. Nigi, E. Aiello, F. Cinti, G.P.
Sorice, S. Moffa, C.M. Cefalo, A. Mari, A. Giaccari, T. Mezza, G. Sebastiani,
F. Dotta, Italy

376 Pancreatic and gut hormone responses to mixed meal test

differentiate pancreatic cancer associated diabetes from type 2
diabetes
J. Bao, Y. Zhang, C. Sun, L. Li, China, USA

144
377 The nutrient sensor mTORC1 regulates insulin secretion by
modulating beta cell autophagy
T. Israeli, Y. Riahi, P. Garzon, R. Yeroslaviz-Stolper, L. Kadosh, S. Tornovsky-
Babeay, B. Tirosh, E. Cerasi, E. Bernal-Mizrachi, G. Leibowitz, Israel, USA

378 EPDR1, a novel human batokine regulating glucose-stimulated

insulin secretion in beta cells

Short Oral Discussions

L.R. Cataldo, L. Argemi, D. Geng, S. Gheibi, P. Spégel, R.B. Prasad, M. Fex,
H. Mulder, T. Moritz, Sweden, Denmark

379 The Nova1-Bim axis in pancreatic beta cells does not alter glucose
homeostasis in obesity and multiple low-dose streptozotocin-induced
diabetes
M.K. Brahma, P. Xiao, M. Popa, V. Vandenbempt, J. Negueruela, A.K.
Cardozo, E.N. Gurzov, Belgium

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 18 It must be my hormones

Chair: M.A. Nauck, Germany

380 Evaluation of the 26RFa/GPR103 peptidergic system in a mouse

model of insulinopenia
M.-A. Le Solliec, J. Maucotel, A. Arabo, M. Picot, S. Takhlidjt, A. Benani, E.
Nedelec, A. Nordqvist, Y. Anouar, N. Chartrel, G. Prévost, France, Sweden

381 Urolithin B protects pancreatic beta cells against IAPP

proteotoxicity: a potential strategy for dietary interventions in diabetes
A.F. Raimundo, S. Ferreira, J. Brito, M. Silva, C.N. Dos Santos, R. Menezes,
Portugal

382 Postprandial dynamics of proglucagon cleavage products and their

relation to metabolic health
R. Wagner, S. Eckstein, L. Fritsche, K. Prystupa, H.-U. Häring, A.L.
Birkenfeld, A. Peter, A. Fritsche, M. Heni, Germany

383 Effects of irisin on human pancreatic islets from type 2 diabetic

subjects
N. Marrano, A. Natalicchio, G. Biondi, A. Borrelli, A. Cignarelli, A. Signorile, L.
Vincenti, L.G. Lupo, S. Perrini, L. Laviola, F. Giorgino, Italy

145
 384 Association between bone biomarkers Osteoactivin and
Osteoprotegerin with plasma levels of irisin and meteorin-like protein
in people with type 2 diabetes and obesity
P. Cherian, I. Al Khairi, M. Jamal, S. Al-Sabah, H. Ali, C. Dsouza, E. Al
Shawaf, W. Al-Ali, G. Al-khaledi, F. Al-Mulla, M. Abu-Farha, J. Abubaker,
Kuwait
Short Oral Discussions

385 Post prandial glucagon metabolism in humans with and without

type 1 diabetes
R. Ruchi, M. Schiavon, Y. Yadav, A. Weaver, K. Johnson, S. Renuse, A.
Pandey, C. Cobelli, C. Dalla Man, R. Basu, A. Basu, USA, Italy

386 Tmem117 in vasopressin neurons is a novel regulator of

counterregulatory response to hypoglycaemia
S. Gaspari, G. Labouèbe, A. Picard, B. Thorens, Switzerland

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 19 Gastro-entero pancreatic factors

Chair: F.K. Knop, Denmark

387 Importance of endogenous GLP-1 and GIP for postprandial glucose

tolerance after Roux-en-Y gastric bypass and sleeve gastrectomy surgery
M. Hindsø, N. Hedbäck, A. Møller, M.S. Svane, C. Martinussen, N.B.
Jørgensen, C. Dirksen, L.S. Gasbjerg, V.B. Kristiansen, B. Hartmann, M.M.
Rosenkilde, J.J. Holst, S. Madsbad, K.N. Bojsen-Møller, Denmark

388 Characterisation of biological activity and antidiabetic efficacy of a

novel neurotensin/xenin fusion peptide in high fat fed mice
N. Irwin, R. Perry, P.R. Flatt, V.A. Gault, UK

389 Circulating dopamine is regulated by gut nutritional signals and

acts in the adipose tissue to sensitise for GLP-1 action
P. Matafome, G. Tavares, D. Rosendo-Silva, F. Simões, H. Eickhoff, D.
Marques, R. Seiça, S. Conde, Portugal

146
390 Pro-neurotensin levels and the prediction of cardiovascular risk in
individuals with type 1 diabetes: a longitudinal study with 10 year follow-up
I. Barchetta, F.A. Cimini, L. Bertoccini, V. Ceccarelli, M.G. Baroni, O.
Melander, M.G. Cavallo, Italy, Sweden

391 The feature of the gut microbiota in patients with newly diagnosed
type 2 diabetes

Short Oral Discussions

K.G. Lobanova, T.Y. Demidova, Russian Federation

392 Altered hormonal milieu in pancreatic islets and intestine

accompany alterations of metabolism in high-fat fed Wistar rats
A. Sridhar, D. Khan, P.R. Flatt, R.C. Moffett, UK

Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 20 Carbohydrate and protein metabolism

Chair: C.G. Schalkwijk, Netherlands

393 The postprandial methylglyoxal formation during an oral glucose

tolerance test is derived from exogenous glucose
X. Zhang, J. Scheijen, G. Duchateau, M. Alssema, C. Stehouwer, K.
Wouters, C. Schalkwijk, Netherlands

394 Glucose suicide mechanisms induced by methylglyoxal

B. Stratmann, Y. Mattern, T. Silva de Carvalho, D. Tschoepe, Germany

395 Anti-hyperglycaemic effect of alpha-cyclodextrin after oral glucose

loading via GLP-1 dependent- and independent-pathways
E. Lee, R. Hatano, X. Zhang, J. Miyamoto, I. Kimura, T. Miki, Japan

396 Mechanisms of improvement in glucose tolerance and insulin

sensitivity after complex carbohydrate meal in type 2 diabetes
D. Romeres, Y. Yadav, A. Asfa, C. Lane, R. Ruchi, C. Cobelli, C. Dalla Man,
A. Basu, R. Basu, Italy, USA

397 Metabolite secretome profiling of human pancreatic islets and

rodent beta cells under glucolipotoxicity reveals key mitochondrial
metabolism rerouting
J. Perrier, G. Rautureau, J. Rieusset, A.-M. Madec, M.-A. Berger, C. Thivolet,
B. Panthu, France

147
 398 Proteome dynamics of extracellular vesicles in plasma following an
acute bout of exercise
L. Peijs, N.Z. Jespersen, S. Heywood, B.K. Pedersen, A.S. Deshmukh, Denmark

399 Amino acid- and keto acid-induced changes of the ATP/ADP ratio in
alpha cells in comparison with beta cells
D. Brüning, M. Morsi, E. Früh, I. Rustenbeck, Germany, Egypt
Short Oral Discussions

400 Gender specific alterations in glucose homeostasis driven by

glyoxalase 1: New road towards type 2 diabetes?
M. Campos, J. Morgenstern, T. Poth, N. Volk, J. Szendrödi, P. Nawroth, T.
Fleming, Germany

Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 21 Metabolic control during and after pregnancy

Chair: M. Maresh, UK

401 Effects of vitamin D3 supplementation in obese pregnant women

on maternal and fetal lipid metabolism
J. Harreiter, L. Mendoza, G. Desoye, D. Simmons, M.N. Van Poppel, D.
Bancher-Todesca, R. Corcoy, A. Kautzky-Willer, Austria, Spain, Australia

402 Improvements in diabetes related outcomes for women attending

peripheral centres: the ATLANTIC DIP experience
C. Newman, A.M. Egan, L.A. Carmody, G. Gaffney, B.B. Kirwan, A. Liew,
C.M. McHugh, F. Dunne, Ireland, USA

403 Prediabetic values of OGTT results and HbA1c postpartum as

predictors of later development of diabetes in 101 Danish women with
previous gestational diabetes
M.H. Christensen, T.P. Lundberg, I.S. Smietana, C.A. Vinter, J. Aalders, L.S.
Snogdal, D. Glintborg, K. Højlund, M.S. Andersen, D.M. Jensen, Denmark

404 Is HbA1c associated with materno-fetal complications in type 1

pregnancies?
M. Lemaitre, C. Ternynck, J. Bourry, F. Baudoux, D. Subtil, A. Vambergue,
France

148
405 Duration of breast-feeding associates with anti-atherogenic lipid
profile in women
D. Löffler, K. Kantartzis, J. Machann, J. Hummel, A.L. Birkenfeld, A. Peter, A.
Fritsche, L. Fritsche, Germany

406 Postpartum oral glucose tolerance test in women with prior

gestational diabetes: Does breastfeeding affects the results?

Short Oral Discussions

G. Monroy, C. Fernández, T. Caballé, L. Altimira, G. Sáenz de Navarrete, R.
Corcoy, Spain

Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 22 News from the drug pipeline

Chair: M. Rohm, Germany

407 Liraglutide decreases plasma PCSK9 in patients with type 2

diabetes not treated with statins
B. Vergès, J. Hassid, A. Rouland, B. Bouillet, S. Baillot-Rudoni, J.-M. Petit, L.
Duvillard, France

408 Effects of simvastatin on human subcutaneous adipose tissue

metabolism
A. Sarsenbayeva, B. Nandi Jui, P. Barbosa, F. Ahmed, G. Fanni, R. Kristófi,
J.W. Eriksson, M.J. Pereira, Sweden, Portugal

409 Exogenous secretin decreases ad libitum food intake and exhibits

a biphasic effect on supraclavicular brown adipose tissue activity in
healthy men
M.J. Bentzen, S.M. Heimbürger, B. Hartmann, J.J. Holst, M.B. Christensen,
F.K. Knop, Denmark

410 Targeting G protein-coupled receptor 110 for the treatment of

obesity and its related metabolic diseases
Z. Huang, L. Xu, R. Yang, X. Yan, S. He, A. Xu, Hong Kong

411 Exendin-4 treatment improves adipose tissue microcirculation in

obese rats through AMPK -eNOS pathways
L. Han, C. Zhou, X. Zhu, H. Tan, H. Fan, H. Wang, L. Zhong, J. Huang, F.
Yan, X. Wen, China

149
 412 Potential effect of a novel combination of GLP-1RA (efpeglenatide)
and long-acting glucagon analogue (HM15136) in animal models of
metabolic disorder
S. Lee, J. Lee, J. Kim, J. Choi, E. Park, D. Kim, S. Bae, S. Lee, I. Choi, Korea,
Republic of

413 Chronic effects of an antifibrotic agent pirfenidone on insulin

Short Oral Discussions

sensitivity and cardiac function in high-fat diet induced insulin-

resistant mice
V. Musale, C.K. Hennayake, C.E. Murdoch, L. Kang, UK

Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 23 Fatty matters

Chair: F. Karpe, UK

414 A microRNA cluster controls fat cell differentiation and adipose

tissue expansion by regulating SNCG
F.J. Ortega, R. Rodríguez-Barrueco, J. Latorre, L. Devis-Jáuregui, A. Lluch, N.
Bonifaci, F.J. Llobet, M. Olivan, L. Coll-Iglesias, J.M. Moreno-Navarrete, A.
Castells-Nobau, J.M. Fernández-Real, J.M. Silva, D. Llobet-Navas, Spain, USA

415 Increased contribution of fructose to de novo synthesis of

saturated over unsaturated fatty acids in mice fed high-sugar and high
fat-high sugar diets
J. Jones, G.D. Belew, L. Tavares, M.J. Meneses, M. Macedo, Portugal

416 Purinergic receptor P2X7: a new target for the degradation of lipid
droplets by lipophagy
Z. Dong, L. Zhang, China

417 Ectopic lipid deposition upregulates SGLT2 and GLUT1 in renal

tubules
T. Li, T. Wu, Z. Sun, China, Australia

418 Regulatory loop of IR signalling is critical for adipocyte dynamics

and mitochondrial homeostasis
M. Sakaguchi, S. Okagawa, Y. Okubo, K. Fukuda, M. Igata, T. Kondo, E.
Araki, Japan

150
419 Neonatal overfeeding permanently programs hypertrophic
adiposity: potential implications of adipose tissue turnover
I. Palacios-Marin, M. Parra-Vargas, J. Fos-Domènech, F. Ribas-Aulinas, M.
Ramon-Krauel, D. Serra, C. Lerin, L. Herrero, J.C. Jimenez-Chillaron, Spain

420 Insulin-stimulated brain glucose uptake correlates negatively with

peripheral insulin sensitivity already in the early phase of metabolic

Short Oral Discussions

dysregulation
L. Pekkarinen, T. Kantonen, T. Karjalainen, M. Bucci, E. Rebelos, P. Dadson,
A. Latva-Rasku, K. Kalliokoski, K. Laitinen, N. Houttu, A. Kirjavainen, T.
Rönnemaa, L. Nummenmaa, P. Nuutila, Finland

421 Divergent effects of estradiol and its receptors on human

adipocyte glucose uptake: impact of menopausal status
F. Ahmed, P.G. Kamble, S. Hetty, G. Fanni, M. Vranic, A. Sarsenbayeva, A.
Dakhel, R. Kristofi, M.J. Pereira, J.W. Eriksson, Sweden

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 24 Glucose-lowering drugs and the liver

Chair: A. Holleboom, Netherlands

422 The glucose-lowering effect of the bile acid sequestrant sevelamer

in patients with type 2 diabetes is not mediated by glucagon-like
peptide 1
H.H. Nerild, A. Brønden, A.E. Haddouchi, J.J. Holst, D.P. Sonne, T. Vilsbøll,
F.K. Knop, Denmark

423 Metformin lowers portal pressure in patients with cirrhosis and

portal hypertension: a randomised clinical trial
N. Rittig, N.K. Aagaard, G.E. Villadsen, T.D. Sandahl, N. Jessen, H.
Grønbæk, J. George, Denmark, Australia

424 Sodium-glucose linked transporter 2 inhibitors (SGLT2s) and

alanine aminotransferase levels (ALT) in the Associated of British
Clinical Diabetologists (ABCD) audits
I. Gallen, T.S. Crabtree, A. Gallagher, K. Dhatariya, A. Bickerton, J. Elliott, G.
Rayman, R.E. Ryder, UK

151
 425 Long-term effects of ertugliflozin (ERTU) on liver enzymes and
indices in patients with type 2 diabetes: analyses from VERTIS CV
K.D. Corbin, S. Dagogo-Jack, C.P. Cannon, B. Charbonnel, D.Z. Cherney, F.
Cosentino, D.K. McGuire, W.J. Shih, R. Frederich, J. Liu, A. Pong, N.B.
Cater, R.E. Pratley, USA, France, Canada, Sweden

426 Effect of tirzepatide versus insulin degludec on liver fat content

Short Oral Discussions

and abdominal adipose tissue in patients with type 2 diabetes

(SURPASS-3 MRI)
A. Gastaldelli, K. Cusi, L. Fernández Landó, R. Bray, B. Brouwers, Á.
Rodríguez, Italy, USA

427 Hepatic impairment has no impact on the clinical pharmacokinetics

of tirzepatide
C. Loghin, T. Quinlan, J. Landry, X. Ma, J.A. Martin, S. Urva, USA

428 Blueberry juice counteracts metabolic dysregulation in a rat model

of prediabetes by targeting hepatic mitochondrial bioenergetics and
metabolic pathways
S. Nunes, S.D. Viana, I. Preguiça, A. Alves, J.S. Teodoro, I. Jarak, R.A.
Carvalho, A.P. Rolo, C.M. Palmeira, M.M. Pintado, F. Reis, Portugal

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 25 Interaction of digestive system and glucose metabolism

Chair: B. Eliasson, Sweden

429 Effects of SGLT2-inhibition on postprandial insulin exposure in

patients with postbariatric hypoglycaemia: a modelling analysis
D. Herzig, M. Schiavon, M. Hepprich, M.Y. Donath, L. Bally, C. Dalla Man,
Switzerland, Italy

430 SGLT2 contributes to glucoregulatory improvements following

vertical sleeve gastrectomy in mice
E. Akalestou, L. Lopez-Noriega, M. Hu, I. Leclerc, G.A. Rutter, UK

152
431 Robust metabolic benefits of a novel orally administered polymeric
duodenal exclusion therapy in animal models of type 2 diabetes: an
alternative treatment for type 2 diabetes
A. Nimgaonkar, T. Jozefiak, K. Colbert, T. Carlson, J. Petersen, M. Vieira, S.
Kulkarni, P.J. Pasricha, J. Vora, S. Polomoscanik, USA

432 Orally administered lactate elevates glucagon like peptide-1 and

Short Oral Discussions

slows gastric emptying in young men
M.G. Pedersen, E. Søndergaard, C.B. Nielsen, M. Johannsen, L. Gormsen,
N. Møller, N. Jessen, N. Rittig, Denmark

433 Three weeks of time restricted eating improves fasting glucose in

type 2 diabetes patients but does neither increase nocturnal fat
oxidation nor insulin sensitivity
C. Andriessen, C. Fealy, A. Veelen, N. Connell, E. Kornips, K. Roumans, J.
Hoeks, P. Schrauwen, Netherlands, Ireland

434 Remission of type 2 diabetes following a short-term intervention

with insulin glargine and metformin/sitagliptin: results of the REMIT-
sita randomised controlled trial
H. Gerstein, S. Hall, I. Hramiak, R.J. Sigal, R. Goldenberg, N. Gupta, R.
Rabasa-Lhoret, M. Braga, V. Woo, F. Sultan, R. Otto, A. Smith, D. Sherifali,
Y.Y. Liu, N. McInnes, Canada

435 Incidence and prevalence of gastrointestinal tolerability in once

weekly dulaglutide (3 and 4.5 mg): a posthoc analysis
J. Van, J.P. Frias, E. Bonora, S. Raha, H. Jung, D. Cox, M. Konig, J.
Peleshok, USA, Italy

436 Remission of type 2 diabetes following intensive treatment with

insulin glargine/lixisenatide, metformin and lifestyle approaches:
results of the REMIT-iGlarLixi trial
N. McInnes, S. Hall, H. Lochnan, S. Harris, Z. Punthakee, R.J. Sigal, I.
Hramiak, M. Azharuddin, J. Liutkus, J.-F. Yale, F. Sultan, A. Smith, D.
Sherifali, Y.Y. Liu, H. Gerstein, Canada

153
 Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 26 Cardiorenal consequences of SGLT2 inhibition

Chair: N. Sattar, UK

437 The effect of two different sodium-glucose co-transporter 2

Short Oral Discussions

(SGLT2) inhibitors on decreasing serum uric acid level in patients with

type 2 diabetes
M.I. Szabo, L. Marton, Á. Szőcs, Á. Farkas, Romania

438 Glycaemic efficacy and safety of ertugliflozin in patients with type

2 diabetes and stage 3 chronic kidney disease: an analysis from
VERTIS CV
S. Dagogo-Jack, R.E. Pratley, D.Z. Cherney, B. Charbonnel, D.K. McGuire,
F. Cosentino, W.J. Shih, J. Liu, R. Frederich, J.P. Mancuso, A. Raji, I. Gantz,
USA, Canada, France, Sweden

439 Cardiorenal outcomes with ertugliflozin by baseline glucose-

lowering agent: an analysis from VERTIS CV
B. Charbonnel, S. Dagogo-Jack, C.P. Cannon, D.Z. Cherney, F. Cosentino,
D.K. McGuire, W.J. Shih, J. Liu, A. Pong, I. Gantz, R. Frederich, J.P.
Mancuso, R.E. Pratley, France, USA, Canada, Sweden

440 Effects of canagliflozin on hospitalisation for heart failure by baseline

eGFR: pooled analysis from the CANVAS Program and CREDENCE
M. Kosiborod, J. Gogate, J. Seufert, K.W. Mahaffey, USA, Australia, Germany

441 Effects of canagliflozin on major adverse cardiovascular events by

baseline albuminuria: integrated analyses from the CANVAS Program
and CREDENCE trial
D.C. Wheeler, M.R. Weir, J. Gogate, V. Perkovic, K.W. Mahaffey, UK,
Australia, USA

442 The effect of SGLT-2 inhibitors on mortality and heart failure in

randomised trials versus observational studies
J. Krogh, C. Hjorthøj, S.L. Kristensen, C. Selmer, S.B. Haugaard, Denmark

443 Sodium Glucose Co-Transporter 2 Inhibitors do not increase the risk of

hyperkalemia in type 2 diabetes: a systematic review and meta-analysis
C. Charlwood, J. Chudasama, A. Darling, H. Logan Ellis, M. Whyte, UK
V.J. Horváth, A.G. Tabák, Hungary, UK

154
Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 27 Glucose-lowering agents: Real World Evidence

Chair: K. Eeg-Olofsson, Sweden

444 Healthcare resource utilisation after empagliflozin initiation in

Short Oral Discussions

Europe: real-world evidence from the EMPRISE study
L. Niskanen, M.H. Kyaw, A. Deruaz-Luyet, A. Ustyugova, K. Karlsdotter, M.
Tuovinen, P. Casajust, E. Toresson Grip, E. Söreskog, T. Nyström, EMPRISE
group, Finland, USA, Germany, Sweden, Spain

445 Effectiveness and safety of empagliflozin in routine care in Europe

and East Asia: results from the empagliflozin comparative effectiveness
and safety (EMPRISE) study
A. Karasik, S. Lanzinger, E. Chia-Hui Tan, D. Yabe, D. Jung Kim, W. H-H
Sheu, C. Melzer-Cohen, R.W. Holl, K. Ha, T. Nyström, L. Niskanen, M.
Linnemann Jensen, M.H. Kyaw, J. Núñez, EMPRISE EU and East Asia Study
Group, Israel, Germany, Taiwan, Japan, Korea, Republic of, Sweden,
Finland, Denmark, USA, Spain

446 Real-world use of once-weekly semaglutide in diverse patient

populations with type 2 diabetes: pooled analysis of four SURE studies
J.-F. Yale, A.-M. Catarig, S.-B. Catrina, U. Erhan, T. Sathyapalan, B. Schultes,
M. Tariq, S.T. Knudsen, Canada, Denmark, Sweden, UK, Switzerland, India

447 Patients reaching treatment targets with once-weekly semaglutide

in real-world practice: pooled analysis of four SURE studies
G. Rudofsky, U. Bodholdt, A.-M. Catarig, N. Rajamand Ekberg, U. Erhan, J.F.
Liutkus, M. Tariq, P. Holmes, Switzerland, Denmark, Sweden, Canada, India, UK

448 Trends in initiation of GLP-1 RA in patients with type 2 diabetes

during 2014 - 2019: a US database study
J. Broe Honoré, M.N. Kosiborod, V.R. Aroda, L.L. Husemoen, A.B. Jensen,
K.S. Matthiessen, I. Lingvay, Denmark, USA

449 Greater adherence and persistence with dulaglutide compared to

injectable semaglutide at 6- and 12- months follow-up in U.S. real-
world data
R. Mody, J. Manjelievskaia, M. Yu, E.H. Marchlewicz, R. Malik, N.M.
Zimmerman, D.E. Irwin, USA

155
 450 Mobile health application as a real-world data resource: self-
recorded weight reduction with once-weekly semaglutide
U. Bodholdt, S. Birot, A.-M. Catarig, U. Erhan, F.K. Knop, Denmark

451 Efficacy and safety of alogliptin versus acarbose in Chinese type 2

diabetes individuals with cardiovascular risk or coronary heart
disease: a randomised prospective study
Short Oral Discussions

B. Gao, W. Gao, H. Wan, F. Xu, R. Zhou, X. Zhang, H. Yin, Q. Ji, China

Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 28 GLP-1 receptor agonists and weight loss

Chair: J.P.H. Wilding, UK

452 Once-weekly semaglutide 2.4 mg improved glucose metabolism

and prediabetes in adults with overweight or obesity in the STEP 1 trial
L. Perreault, M. Davies, J.P. Frias, P.N. Laursen, I. Lingvay, S. Machineni, A.
Varbo, J.P. Wilding, S.O. Wallenstein, C.W. Le Roux, USA, UK, Denmark,
Ireland

453 Effect of semaglutide 2.4 mg on achievement of weight loss and

HbA1c <7%, without hypoglycaemia, in adults with overweight/obesity
and type 2 diabetes in STEP 2
R. Goldenberg, L. Færch, D. Horn, A. Jain, O.K. Jeppesen, K. Khunti, A.
Pakseresht, L. Perreault, A. Tahrani, A. Viljoen, S. Jacob, Canada, Denmark,
USA, UK, Germany

454 Effect of once weekly dulaglutide 3.0 and 4.5 mg in patients

with different baseline renal function: post hoc analysis from the
AWARD-11 trial
L.-E. García-Pérez, J.M. Maldonado, K.T. Ranta, S. Raha, USA

455 Influence of baseline characteristics on weight loss with

semaglutide 2.4 mg in adults with overweight/obesity and type 2
diabetes (STEP 2)
C.W. Le Roux, L. Færch, T. Holst-Hansen, A. Koroleva, R.F. Kushner, S. Lim,
I. Lingvay, O. Mosenzon, T.A. Wadden, W.T. Garvey, Ireland, Denmark, USA,
Korea, Republic of, Israel

156
456 Higher doses of dulaglutide induce weight loss in patients
with type 2 diabetes regardless of baseline BMI: post hoc analysis
of AWARD-11
E. Bonora, J.P. Frias, R. Malik, A. Kwan, S. Raha, A. Bethel, D. Cox, Italy,
USA

457 The use of semaglutide alongside other diabetes medications: real-

Short Oral Discussions

world results from the Association of British Clinical Diabetologists
(ABCD) audit programme
T.S. Crabtree, K. Adamson, H. Reid, D. Barnes, S. Sivappriyan, A. Bickerton,
I.W. Gallen, R.E. Ryder, UK

458 Body weight loss with oral semaglutide is predominantly mediated

by effects other than gastrointestinal adverse events
J.J. Meier, R.M. Agesen, L. Bardtrum, A.Y. Cheng, S. Deenadayalan, E.
Montanya, R.E. Pratley, Germany, Denmark, Canada, Spain, USA

459 Benefits of insulin glargine/lixisenatide fixed-ratio combination for

patients inadequately controlled on premixed insulin and oral agents
I. Risovic, M. Bojic, D. Djekic, Bosnia and Herzegovina

Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 29 Novel glucose-lowering agents

Chair: W. Rathmann, Germany

460 Dual GLP-1 and glucagon receptor agonism with cotadutide

significantly increases insulin secretion in overweight and obese
adults with type 2 diabetes
R. Golubic, J. Kennet, V. Parker, D. Robertson, D. Luo, L. Hansen, L.
Jermutus, P. Ambery, A. Park, M. Evans, UK, USA, Sweden

461 A novel, stable mutation of FGF1 separates the glucose lowering

effect from its proliferative properties through interaction with the
insulin receptor
M. Janiszewski, E. Drzazga, P. Buda, K. Bazydlo-Guzenda, B. Miedziak, A.
Sowinska, O. Abramczyk, J. Hucz-Kalitowska, M. Teska-Kaminska, M.
Wieczorek, J. Pieczykolan, Poland

157
 462 VEGF-a/ang-2 neutralisation causes sustained prevention of
subretinal macrophage infiltration in a mouse model of spontaneous
choroidal neovascularisation
J. Canonica, S. Uhles, R. Foxton, N. Colé, M. Lazendic, M. Garcia Garrido,
P. Westenskow, Switzerland

463 Novel GLP-1 analogue, GZR18: a preclinical evaluation in type 2

Short Oral Discussions

diabetes models
Y. Wang, M. Zhang, Y. Zhang, F. Xue, Y. Deng, Y. Qian, C. Cui, B. Wei, W.
Chen, Z. Gan, USA, China

464 Oz101, an oligofructose prebiotic, may ameliorate beta cell

deterioration associated with long-term sulphonylurea therapy in type
2 diabetes patients: a pilot study
M.A. Noor, K.H. Kim†, W.L. Free, J. Henson, P. Shamanna, S. Ajdari, C.R. Kahn,
T.R. Hirst, A.H. Barnett, S.K. Paul, N.N. Gorgani, Australia, India, USA, UK

465 Beneficial antidiabetic actions of a novel V1a and V1b receptor

specific AVP analogue in high fat fed mice
C.R. Moffett, S. Mohan, N. Irwin, P.R. Flatt, UK

466 DA-1241 a novel GPR119 agonist: Data on safety, tolerability and

pharmacokinetics (PK), from part 1 of a phase 1b multiple ascending
dose (MAD) study in healthy volunteers (HV)
B. Franey, M. Grimm, D. Lee, J. Jeong, M.-K. Kim, M. Hompesch, USA,
Korea, Republic of

467 A novel, long-acting dual agonist for GIPR/GLP-1R, HISHS-2001,

demonstrates effects on HbA1c and weight loss in the db/db mouse
model of type 2 diabetes
R. Thennati, V. Burade, A. Garcia-Ocana, R.E. Pratley, G.A. Rutter, T. Vilsbøll,
B. Thorens, India, USA, UK, Denmark, Switzerland

468 Effect of probenecid and cyclosporin on the pharmacokinetics of

SNAC in healthy subjects
T.K. Thorning, A. Breitschaft, T.B. Jensen, K. Kallenbach, T.A. Bækdal,
Denmark, Germany

469 Effects of anti-diabetes therapies on irisin secretion in type 2

diabetes patients
A. Natalicchio, N. Marrano, G. Biondi, G. Le Grazie, A. Montedoro, L. Di Gioia,
F. Guarini, A. Borrelli, A. Cignarelli, S. Perrini, L. Laviola, F. Giorgino, Italy

158
Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 30 The advantage of dual agonists

Chair: D. Mathiesen, Denmark

470 Effect of tirzepatide versus insulin degludec on glycaemic control

Short Oral Discussions

captured with continuous glucose monitoring in patients with type 2
diabetes (SURPASS-3 CGM)
T. Battelino, R. Bergenstal, A. Rodríguez, L. Fernández Landó, R. Bray, Z.
Tong, K. Brown, Slovenia, USA

471 Patient-reported outcomes in patients with type 2 diabetes treated

with tirzepatide or placebo as an add-on to basal insulin (SURPASS-5)
M. Yu, K. Boye, R. Huh, H. Patel, A. Rodriguez, Canada, USA

472 Efficacy and safety of tirzepatide, a dual GIP/GLP-1 receptor

agonist, compared to insulin degludec in patients with type 2 diabetes
(SURPASS-3)
B. Ludvik, F. Giorgino, E. Jódar, J.P. Frias, L. Fernández Landó, K. Brown, R.
Bray, Á. Rodríguez, Austria, Italy, Spain, USA

473 Weekly dual GIP/GLP-1 receptor agonist tirzepatide monotherapy

improved markers of islet cell function and insulin sensitivity in people
with type 2 diabetes (SURPASS-1)
C.J. Lee, V.T. Thieu, H. Mao, M.K. Thomas, USA

474 Efficacy and safety of once weekly tirzepatide, a dual GIP/GLP-1

receptor agonist versus placebo as monotherapy in people with type 2
diabetes (SURPASS-1)
J. Rosenstock, C. Wysham, J.P. Frias, S. Kaneko, C.J. Lee, L. Fernández
Landó, H. Mao, X. Cui, V.T. Thieu, USA, Japan

475 Patient-reported outcomes in patients with type 2 diabetes treated

with tirzepatide or placebo (SURPASS-1)
K. Boye, M. Yu, C.J. Lee, H. Mao, X. Cui, L. Fernández Landó, V. Thieu, USA

476 Efficacy, safety and tolerability of cotadutide as an add-on therapy

in overweight subjects with type 2 diabetes treated with dapagliflozin
and metformin
A. Flor, M. Petrone, J. Sanchez, T. Petrohoy, L. Jermutus, L. Hansen, P.
Ambery, USA, UK, Sweden

159
 Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 31 Clinical aspects of semaglutide

Chair: T. Vilsbøll, Denmark

477 Semaglutide 2.4 mg improves patient-reported outcome measures

Short Oral Discussions

of physical functioning in adults with overweight or obesity and type 2

diabetes in the STEP 2 trial
S. Wharton, H.H. Meincke, R.F. Kushner, T.K. Oral, S.D. Pedersen, D.M. Rubino,
D.H. Ryan, N. Zeuthen, R.L. Kolotkin, Canada, Denmark, USA, Norway

478 Semaglutide 2.4 mg improves health-related quality of life in adults

with overweight or obesity and type 2 diabetes in the STEP 2 trial
D.M. Rubino, L. Færch, H.H. Meincke, R.F. Kushner, S.D. Pedersen, D.H.
Ryan, S. Wharton, N. Zeuthen, R.L. Kolotkin, USA, Denmark, Canada, Norway

479 Treatment with once-weekly semaglutide 2.4 mg improves

cardiometabolic risk factors in adults with overweight or obesity and
type 2 diabetes: STEP 2 post-hoc analysis
J.E. Deanfield, M. Davies, W.T. Garvey, O.K. Jeppesen, U. Khalid, M. Kosiborod,
R.F. Kushner, P.N. Laursen, D.M. Rubino, S. Verma, UK, USA, Denmark

480 Time spent in glycaemic control after initiating treatment with

oral semaglutide vs empagliflozin: an exploratory analysis of the
PIONEER 2 trial
F.K. Knop, B. Cariou, E. Christiansen, A.L. Davies, E. Montanya, M.T.
Abildlund, J. Rosenstock, Denmark, France, Spain, USA

481 Reduced glycaemic variability with once-weekly semaglutide vs

active comparators in post hoc analysis of the SUSTAIN programme
E. Jodar, V.R. Aroda, Y. Kose, M. Kaltoft, A.L. Søndergaard, R. Pratley, Spain,
USA, Denmark

482 Derived time in glycaemic range with once-weekly semaglutide

vs active comparator: post hoc analysis from the SUSTAIN clinical
trial programme
V.R. Aroda, C. De Block, M. Kaltoft, J. Lawson, A.L. Søndergaard, A. Philis-
Tsimikas, USA, Germany, Denmark

160
483 Effect of once-weekly semaglutide on insulin use in subjects with
type 2 diabetes: a post hoc analysis of SUSTAIN 6
J. Seufert, C. Desouza, A.R. Kirk, J. Lawson, I. Lingvay, A.L. Søndergaard,
S.C. Bain, Germany, USA, Denmark, UK

484 Achievement of near-normal HbA1c with early initiation of oral

semaglutide: an exploratory subgroup analysis of PIONEER 1

Short Oral Discussions

E.C. Morales-Villegas, V.R. Aroda, L. Bardtrum, E. Christiansen, K.
Kallenbach, J. Rosenstock, M. Davies, Mexico, USA, Denmark, UK

485 Incorporating treatment pauses, dosing flexibility and education to

support GLP-1RA therapy persistence: data from PIONEER 6
S. Bain, R. Bauer, A.L. Davies, E.B. Kreiner, P. Lin, R. Pratley, V.R. Aroda,
UK, Denmark, Canada, USA

486 Neutrophil-to-lymphocyte ratio predicts cardiovascular events

in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6
and PIONEER 6
S. Verma, M. Husain, C.M. Madsen, L.A. Leiter, S. Rajan, T. Vilsbøll, S.
Rasmussen, P. Libby, Canada, Denmark, USA

Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 32 Different aspects of SGLT2 inhibitors

Chair: C.-G. Östenson, Sweden

487 Empagliflozin reduces inflammation and alters bioenergetic

metabolism in proinflammatory human macrophages: Clues to
mechanisms of vascular protection?
V. Spigoni, G. Cinquegrani, F. Fantuzzi, A. D'Antuono, S. Lorusso, N.
Iannozzi, A. Dei Cas, R.C. Bonadonna, Italy

488 Conceptual health economic modelling study of treatment

sequencing for SGLT2is
G. Chen, V. Foos, R.L. Martin, R. Hoff, R. Boyce, P. Carter, P. McEwan, UK

489 Empagliflozin reduced the total burden of events leading to or

prolonging hospitalisation in EMPA-REG OUTCOME
S.E. Inzucchi, C. Wanner, D. Fitchett, B. Zinman, S.D. Anker, M. Mattheus,
O. Vedin, S. Hantel, S.S. Lund, USA, Germany, Canada, Sweden

161
 490 Angiotensin profiles in patients with type 2 diabetes and
combination therapy of empagliflozin and linagliptin versus metformin
and insulin glargine
A. Bosch, M. Poglitsch, D. Kannenkeril, C. Ott, K. Striepe, R.E. Schmieder,
Germany, Austria

491 Efficacy and safety of sotagliflozin in patients with type 2 diabetes:

Short Oral Discussions

meta-analysis of randomised controlled trials

P. Kakotrichi, I. Avgerinos, T. Karagiannis, T. Michailidis, A. Liakos, A. Tsapas,
E. Bekiari, Greece, UK

492 Glycaemic variability of oral semaglutide vs empagliflozin: a post-

hoc analysis of PIONEER 2
E. Montanya, M.T. Abildlund, E.B. Kreiner, O. Mosenzon, S. Rosenlund, T.
Vilsbøll, Spain, Denmark, Israel

493 Anaplerotic therapy counters ketosis induced by empagliflozin in

diabetic sheep
H. Dvir, J. Asiku, M. Kalyesubula, A. Rosov, M. Ross, G. Van Bommel, Israel

Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 33 Non-insulin treatment in type 1 and type 2 diabetes

Chair: D.L. Russell-Jones, UK

494 Six-day sc GIP infusion increases plasma NEFA without altering

the adipose tissue transcriptome, GIPR levels or plasma markers of
inflammation in patients with type 1 diabetes
S.M. Heimbürger, B. Hoe, C.N. Nielsen, B. Hartmann, J.J. Holst, F. Dela, J.
Overgaard, J. Størling, T. Vilsbøll, T.F. Dejgaard, C. Pyke, M.B. Christensen,
F.K. Knop, Denmark

495 Effects of liraglutide in type 1 diabetes by baseline

anthropometrics in ADJUNCT ONE and TWO
T. Dejgaard, L. Bardtrum, E. Christiansen, F. Flindt Kreiner, S. Madsbad, M.
Von Herrath, B.J. Von Scholten, C. Mathieu, Denmark, Belgium

162
496 Multicenter, open-label, two-arm, pilot trial for safe reduction of
basal insulin dose combined with SGLT2 inhibitor in type 1 diabetes:
RISING-STAR trial
M. Hamaguchi, M. Yamazaki, T. Tanaka, M. Ishii, H. Okada, K. Mitsuhashi, N.
Kitagawa, G. Hasegawa, M. Fukui, Japan

497 Real-world efficacy and safety of SGLT2 inhibitors in type 1

Short Oral Discussions

diabetes: a two-center cohort retrospective study
F. Van Nes, A. Palanca, F. Ampudia-Blasco, F. Pardo, J. Real, C. Mathieu,
Belgium, Spain

498 A pre-exercise low-carbohydrate-high-protein meal stabilises plasma

glucose during and after exercise in persons with type 1 diabetes
K.B. Kristensen, A.G. Ranjan, R.M. Bracken, K. Nørgaard, S. Schmidt,
Denmark, UK

499 A pragmatic low carbohydrate diet intervention changes neither

carbohydrate consumption nor glycaemia appreciably in adolescents
and young adults with type 1 diabetes
S.H. Duffus, K.C. Coate, S.S. Jaser, K.D. Niswender, J.M. Gregory, USA

500 Exploring a suitable marker of residual beta cell function

associated with glycaemic response to dulaglutide in patients with
type 2 diabetes
M. Hasebe, S. Yoshiji, Y. Iwasaki, S. Kimura, Y. Seno, Y. Keidai, T. Haraguchi,
K. Iwasaki, Y. Wada, S. Honjo, J. Fujikawa, A. Hamasaki, Japan

501 Fixed-ratio combination of insulin glargine plus lixisenatide

(iGlarLixi) improves beta cell function in people with type 2 diabetes
E. Ferrannini, A. Boss, T. Dex, S. Servera, A. Mari, Italy, USA

163
 Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 34 News from new insulins

Chair: K. Nørgaard, Denmark

502 Cellular internalisation and localisation of once weekly basal

Short Oral Discussions

insulin Fc
J. Moyers, C.B. Volk, C. Zhang, USA

503 Ultra Rapid Lispro (URLi) accelerates insulin lispro absorption and
insulin action vs lispro in healthy Chinese subjects
Y. Yu, H. Tao, J. Leohr, E. LaBell, D. Coutant, H. Liu, C. Qian, China, USA

504 Faster recovery from hyperglycaemia with ultra rapid lispro vs

lispro in patients with type 1 diabetes on continuous subcutaneous
insulin infusion
J. Leohr, M.A. Dellva, E. LaBell, J. Arrubla, L. Plum-Mörschel, E. Zijlstra, T.
Fukuda, T. Hardy, USA, Germany

505 Achieving HbA1c <7% in insulin naive people with type 2 diabetes
on insulin glargine 300 U/mL in interventional vs observational
European studies: REALI pooled database
P. Gourdy, D. Mauricio, N. Freemantle, M. Bonnemaire, G. Bigot, C.
Mauquoi, D. Müller-Wieland, R. Bonadonna, France, Spain, UK, Belgium,
Germany, Italy

506 Real-world effectiveness and safety of insulin glargine 300 U/mL in

insulin-naive people with type 2 diabetes and renal impairment: a
subgroup analysis of the ATOS study
A. Tirosh, N. Khan, H. Vargas-Uricoechea, M.A. Mabunay, M. Coudert, V.
Pilorget, G. Galstyan, Israel, United Arab Emirates, Colombia, Singapore,
France, Russian Federation

507 Assessing infusion site reactions with ultra rapid lispro in

continuous subcutaneous insulin infusion
D. Ignaut, J. Cho, J. Elpers, F. Chigutsa, C. Piras de Oliveira, USA

164
508 CGM-based parameters for once-weekly insulin icodec vs once-
daily insulin glargine U100 in insulin-naive patients with type 2 diabetes
I. Lingvay, R. Beck Bang, L. Liu, J. Mader, J. Pettus, L. Wagner, C. Mathieu,
USA, Denmark, Austria, Belgium

509 CGM-based measurements for once-weekly insulin icodec vs once-

daily insulin glargine U100 in insulin-treated patients with type 2

Short Oral Discussions

diabetes: a post hoc analysis
H.S. Bajaj, R. Beck Bang, A. Gowda, L. Liu, P. Senior, R. Bergenstal,
Canada, Denmark, USA

Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 35 More on insulins

Chair: J.-B. Gallwitz, Germany

510 Proposed biosimilar insulin aspart (GL-ASP) shows

pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to
US-licenced and EU-authorised insulin aspart
L. Plum-Mörschel, E. Uhrmacher, E. Zijlstra, J. Lu, M. Wilson, M. Barton, T.
Heise, Germany, USA

511 Proposed biosimilar insulin glargine (GL-GLA) shows

pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to
US-licenced and EU-authorised insulin glargine
T. Heise, L. Plum-Mörschel, G. Andersen, J. Lu, M. Wilson, E. Zijlstra,
Germany, USA

512 Star.ro - real world data on effectiveness and safety of iglarlixi in

people with type 2 diabetes uncontrolled on oral antidiabetic drugs ±
basal insulin treatment
C. Guja, C. Bala, A. Cerghizan, B. Mihai, M. Moise, Romania

513 Phase 3 confirmatory study comparing efficacy and safety of

proposed biosimilar and reference insulin aspart, combined with
metformin, in patients with diabetes
J. Yao, D. Wang, X. Guo, China

165
 514 Proposed biosimilar insulin lispro (GL-LIS) shows pharmacokinetic
(PK) and pharmacodynamic (PD) bioequivalence versus US-licenced
and EU-authorised insulin lispro
E. Zijlstra, T. Heise, M. Ermer, J. Lu, M. Wilson, L. Plum-Mörschel, Germany, USA

515 Efficacy and safety of iGlarLixi vs insulin glargine 100 U/ml in

Chinese people with type 2 diabetes (T2D) inadequately controlled on
Short Oral Discussions

basal insulin (BI): LixiLan-L-China trial

X. Guo, J. Zhang, X. Dong, Y. Lu, W. Pang, S. Gu, L. Ping, G. Nian, E.
Niemoeller, E. Souhami, China, USA, Germany, France

516 Effect of insulin degludec vs insulin glargine U100 on occurrence

of nocturnal hypoglycaemia assessed by plasma glucose profiles in
people with type 1 diabetes: HypoDeg trial
J.M. Brøsen, R.M. Agesen, P.L. Kristensen, A.C. Alibegovic, H.U. Andersen,
H. Beck- Nielsen, P. Gustenhoff, C. Hedetoft, T. Jensen, C.B. Juhl, S.S.
Lerche, K. Nørgaard, H.-H. Parving, L. Tarnow, U. Pedersen-Bjergaard,
Denmark

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 36 Determinants and consequences of hypoglycaemia

Chair: M. Evans, UK

517 Prolonged effect of hypoglycaemia on circulating immune cell

composition in people with type 1 diabetes
C.E. Verhulst, T.W. Fabricius, R. Stienstra, C.J. Tack, U. Pedersen-Bjergaard,
B.E. De Galan, Netherlands, Denmark

518 Development and validation of a risk prediction model for

hypoglycaemia in inpatients with type 2 diabetes during intensive
insulin therapy
X. Hu, S. Lin, Y. Zhang, W. Xu, L. Gao, China

519 Is obstructive sleep apnoea and/or nocturnal hypoglycaemia

associated with arrhythmia in type 1 diabetes?
M.M. Henriksen, H.U. Andersen, B. Thorsteinsson, U. Pedersen-Bjergaard,
Denmark

166
520 Physical activity and type 1 diabetes - habits, management and
obstacles
R.F. Johansen, P.L. Kristensen, S. Caunt, E. Søndergaard, S. Heller, S.
Molsted, Denmark, UK

521 Hypoglycaemia increases the left ventricular ejection fraction in

people with diabetes and healthy controls

Short Oral Discussions

T. Wilbek Fabricius, C.E. Verhulst, M. Wienberg, A.L. Duijnhouwer, P.L.
Kristensen, B.E. De Galan, U. Pedersen-Bjergaard, Denmark, Netherlands

522 Momentary assessment of type 1 diabetes patient's experiences in

glucose variability and mood in real life (MERITS): first findings
M. De Wit, K. Van den Berg, E. Serné, D. Van Raalte, F.J. Snoek,
Netherlands

523 The glycaemic status determines the direction of the relationship

between the red cell distribution width and HbA1c
D. Tsilingiris, K. Makrilakis, B. Aikaterini, M. Dalamaga, A. Tentolouris, O.
Kosta, I. Eleftheriadou, S. Liatis, Greece

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 37 New approaches to health care delivery

Chair: R. Holl, Germany

524 Impact of diabetes group visits on patient clinical outcomes:

results from a cluster randomised intervention trial among U.S.
Midwestern health centres
A.A. Baig, E.M. Staab, S. Siddiqui, M. Zhu, W. Wan, A. Campbell, C.
Schaefer, M.T. Quinn, USA

525 Person-centered approach for elderly in chronic disease management

H.E. Hart, A.G. Somers, I. Looijmans- van den Akker, L. Rozendaal, M.
Hollander, B. Baar, R.C. Vos, Netherlands

526 The pattern of testing for glycosylated haemoglobin (HbA1c) in

people with diabetes is linked to the long term trajectory of blood
glucose control
A.A. Fryer, D. Holland, C.J. Duff, A. Heald, UK

167
 527 Effectiveness of diabetes education tailored to psychiatric nurses
on quality of diabetes care and psycho-social outcomes in people with
diabetes and severe mental illness
L. Knudsen, D.L. Hansen, L.E. Joensen, L.J. Diaz, K.K. Clemmesen, M.E.
Joergensen, G.S. Andersen, Denmark

528 A core outcome set for the treatment of pregnant women with
Short Oral Discussions

pregestational diabetes
O. Kgosidialwa, F. Dunne, INSPIRED Research Group, Ireland

529 Effect of traditional versus communication technology-based

health educational intervention focusing on diabetes in Bangladesh: a
randomised controlled trial
B. Banu, M. Hossain Khan, L. Ali, R. Sauerborn, A. Souares, Germany,
Bangladesh

530 Virtual versus in-person pump and CGM training experiences

among adults with diabetes in Europe
E.R. Ye, E. Asamoa, C. Florissi, J. Tait, R. Gowen, C. Pang, R. Wood, USA

Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 38 Psychological aspects of diabetes care

Chair: B. Kulzer, Germany

531 A qualitative evidence synthesis exploring the determinants of self-

management in adults with severe mental illness
C. Carswell, J.V. Brown, A. Balogun-Katung, J. Taylor, P.A. Coventry, C.
Kitchen, I. Kellar, S. Bellass, J. Wright, S. Alderson, J. Lister, R.I. Holt, D.
Shiers, N. Siddiqi, DIAMONDS Research Team, UK

532 Prevalence of needle phobia and anxiety among younger subjects

with diabetes who are uncontrolled on multiple oral glucose lowering
drugs and influence counselling
A. Baidya, India

168
533 Cognitive decrements and ventricular volume increase are related
to white matter lesion presence in type 1 diabetes without peripheral
microangiopathy
C.G. Pariz, E. Van Duinkerken, D.G. Corrêa, F.J. Snoek, A.C. Moll, M. Klein,
F. Barkhof, R.G. IJzerman, Brazil, Netherlands, UK

534 Effects of bariatric surgery on quality of life, body image and sex

Short Oral Discussions

life in obese women
L. Di Gioia, S. Perrini, A. Braun, I. Caruso, F. Giordano, F. Guarini, G. Le
Grazie, E. Rossi, A. Barbone, A. Cignarelli, A. Natalicchio, L. Laviola, A.
Bertolino, F. Giorgino, Italy

535 Motivational interviewing and self-care in type 1 diabetes: a

randomised controlled clinical trial
J.C. Betancort Acosta, D. Alvarado Martel, M. Boronat, M.D. Alberiche
Ruano, M.A. Algara González, Y. Ramallo Fariña, A.M. Wägner, Spain

536 High diabetes-related distress is associated with cerebral

functional and structural alterations in middle-aged patients with
type 1 diabetes
L.M. Loureiro, E.V. Duinkerken, M. Klein, F. Barkhof, R. IJzerman, F.J.
Snoek, Brazil, Netherlands, UK

Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 39 Apps, devices and tools and their impact on diabetes care

Chair: A. Jeyam, UK

537 Are the benefits of FreeStyle Libre evident across a range of

indications for its use? A UK Diabetes centre experience
P. Thadani, A. Musharraf, O. Awala, S. Chan, K. Swinhoe, S. Sankar, H.
Randeva, N. Gholap, UK

538 Assessing the SPUR adherence diagnostic framework

K. Dolgin, M.-E. Laporte, L. Nabec, H. Mosnier Pudar, G. Reach, L.
Kombargi, France

169
 539 Initiating the digital diabetes questionnaire as a clinical tool in
routine diabetes care: patients' and professionals' perspectives
captured in focus group discussions
M. Svedbo Engström, U.-B. Johansson, E. Linder, J. Leksell, K. Eeg-
Olofsson, Sweden

540 Effect of WhatsApp messaging based intervention on insulin

Short Oral Discussions

adherence and treatment effectiveness in diabetic patients in central India

S. Saboo, B. Saboo, India

541 Long-term HbA1c outcomes with and without intermittent CGM use
in adults with type 2 diabetes participating in the Onduo Program
J.E. Layne, R.M. Bergenstal, N.A. Barleen, R.F. Dixon, H. Zisser, USA

542 Development of a new device for screening for peripheral diabetic

neuropathy
D. Coppini, J. Dave, V. Dubey, UK, Malta

Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 40 CGM

Chair: J. Soupal, Czech Republic

543 High treatment satisfaction and less severe hypoglycaemia after

24-month use of intermittently scanned continuous glucose monitoring
S. Charleer, C. De Block, L. Van Huffel, E. Dirinck, F. Nobels, C. Mathieu, P.
Gillard, Belgium

544 Safety and performance evaluation of a novel continuous glucose

monitoring system: Lumee Glucose
C. Nguyen, N.Q. Tran, P.T. Ma, H.T. Nguyen, S. Gamsey, C. Lepak, S.
Cereceres, K. Rebrin, USA, Viet Nam

545 Performance evaluation of the Glunovo® continuous blood glucose

monitoring system in Chinese participants with diabetes
R. Meng, D. Zhu, China

170
546 Accuracy comparison of the WaveForm cascade CGM system at
different body sites over 15 days
M. Rebec, A.-M. Liberati-Pso, R. Dutt-Ballerstadt, USA, Croatia

547 Understanding why we do not have consensus for coefficient of

variation with CGM
J.E. Perlman, T.A. Gooley, J. Meyers, I.B. Hirsch, USA

Short Oral Discussions

548 GMI might over estimate quality of glycaemic control in diabetes
patients
P. Fellinger, K. Rodewald, M. Ferch, A. Kautzky-Willer, Y. Winhofer, Austria

549 The impact of glycaemic variability on the relationship between

hypoglycaemia and HbA1c
S.L. Ellis, R.B. McQueen, M. Perez-Nieves, G.T. Alonso, R. Juneja, K.
Hannah, L. Fan, E.R. Hankosky, V.N. Shah, Y. Yan, USA

Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 41 Closed loop systems

Chair: P.-Y. Benhamou, France

550 Real-world data from 1,988 people with type 1 diabetes on the
Omnipod DASH® Insulin Management System with continuous glucose
monitoring and cloud-based data management
W. Keuthage, I.B. Hirsch, R.S. Weinstock, I. Hadjiyianni, L.M. Huyett, J.
Jantz, S. Lowen, A. Chang, T. Vienneau, T.T. Ly, Germany, USA

551 Daily meal size variation does not affect glycaemic control in adult
type 1 diabetes patients equipped with hybrid closed loop DBLG1 system
P. Gimenez, S. Lachal, Y. Tourki, S. Franc, C. Amadou, A. Penfornis, G.
Charpentier, P.-Y. Benhamou, France

552 A novel method for unannounced meal detection and control

S. Lachal, Y. Tourki, E. Huneker, M. Doron, E. Villeneuve, France

553 Glycaemic outcomes and patient satisfaction after 3 months of use

of an advanced hybrid closed-loop system use
P.I. Beato-Víbora, F. Gallego-Gamero, A. Ambrojo-López, E. Gil-Poch, I.
Martín-Romo, F.J. Arroyo-Díez, Spain

171
 554 Insulin pump interoperability of Diabeloop DBLG1 system
A. Adenis, S. Pou, H. Romero-Ugalde, S. Madrolle, Y. Tourki, S. Franc, G.
Charpentier, P. Benhamou, E. Huneker, France

555 Improvement of outcomes in type 1 diabetic patients with HCL

system compared to SAP and PLGS system
P.S. Morpurgo, M.E. Lunati, A. Rossi, I. Cogliati, A. Gandolfi, A.M. Bolla, L.
Short Oral Discussions

Plebani, G. Volpi, S. Argenti, P. Fiorina, Italy

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 42 Other aspects of managing blood glucose levels

Chair: A. Maran, Italy

556 Indirect treatment comparison of ready-to-use glucagon rescue

treatments for severe hypoglycaemia: nasal glucagon versus liquid
stable glucagon
Y. Yan, C.J. Child, K. Syring, Q. Wang, R. Threlkeld, USA

557 Integrated safety analysis of dasiglucagon for the treatment of

severe hypoglycaemia
S. Heller, T. Battelino, T. Bailey, R. Tehranchi, L. Klaff, T. Pieber, U.
Hovelmann, L. Plum-Morschel, A.E. Melgaard, R. Aronson, L. DiMeglio, T.
Danne, UK, Slovenia, USA, Denmark, Austria, Germany, Canada

558 The next-generation glucagon analogue dasiglucagon consistently

achieves rapid recovery from hypoglycaemia across subgroups
T. Danne, T. Bailey, R. Tehranchi, L.J. Klaff, T. Pieber, U. Hovelmann, L. Plum-
Morschel, A.E. Melgaard, R. Aronson, L.A. DiMeglio, T. Battelino, Germany,
USA, Denmark, Austria, Canada, Slovenia

559 Glycaemic tracking of HbA1c in patients with type 1 diabetes has a

strong modifiable component reliant on intensive diabetes support
L.M. Quinn, K. Nirantharakumar, P. Narendran, UK

172
560 Variability of carbohydrate estimation skills in adults with type 1
diabetes
R. Visentin, M. Stoll, M. Bloechlinger, K. Fuchs, D. Herzig, L. Bally, C. Dalla
Man, Italy, Switzerland

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

Short Oral Discussions

SO 43 Insulin pumps

Chair: R. Hovorka, UK

561 Glycaemic management over 6 months with the Omnipod® 5

automated insulin delivery system
A.L. Carlson, A.B. Criego, T.T. Ly, Omnipod 5 Research Group, USA

562 Biomedical and patient reported outcomes from the PRO solo
multi-national, multi-centre clinical trial
K. Barnard-Kelly, N. Oliver, F. Thienel, E. Franek, T. Kuensting, N.
Dagenbach, T. Etter, J.K. Mader, UK, Germany, Poland, Austria

563 Glycaemic profiles and treatment patterns: real-world data of 2,536

people with type 2 diabetes using the Omnipod® Insulin Management
Systems and cloud-based data management
T. Kader, I.B. Hirsch, R.S. Weinstock, I. Hadjiyianni, L.M. Huyett, J. Jantz, S.
Lowen, A. Chang, T. Vienneau, T. Ly, USA

564 Safety evaluation of the Omnipod® 5 automated insulin delivery

system over three months of use in adults and children with type 1
diabetes
G.P. Forlenza, S.A. Brown, T.T. Ly, Omnipod 5 Research Group, USA

565 Six months pump treatment improves cardiovascular and

endothelial function compared to MDI in patients with type 1 diabetes,
independently of HbA1c
A. Kountouri, I. Ikonomidis, J. Thymis, E. Korakas, K. Katogiannis, V. Prentza,
K. Balampanis, L. Pliouta, F. Kousathana, G. Kostelli, D. Benas, A.
Barmpagianni, G. Dimitriadis, S. Liatis, V. Lambadiari, Greece

173
 Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 44 Glycaemic management in special settings and populations

Chair: C.D.T. Byrne, UK

566 Continuous glucose monitoring with multiple daily insulin

Short Oral Discussions

injections improves perinatal outcomes in women with type 1 diabetes

K. Anderlova, H. Krejčí, M. Mráz, M. Haluzík, M. Kršek, A. Pařízek, P.
Šimják, Czech Republic

567 The effect of liver transplantation on total daily doses of insulin

requirement
O. Awala, A. Coulden, C. Antza, N. Shah, A. Nahar, L. Kandaswamy, A.
Phillips, Z. Khan, S. Upadhyaya, A. Asif, F. Babwah, S. Mostafa, W. Hanif, UK

568 Duodenal jejunal bypass liner (DJBL) for treatment of type 2

diabetes and obesity: risks and benefits among 926 patients in the
worldwide EndoBarrier (EB) registry
R.E. Ryder, P. Sen Gupta, R. Stengel, K. Mitchell, R. Drummond, H.
Frydenberg, L. Munro, S. Fishman, R. Cohen, C. De Jonge, J. Greve, M.
Benes, J. Aberle, K. Laubner, J. Seufert, UK, Germany, Australia, Israel,
Brazil, Netherlands, Czech Republic

569 Exogenous insulin therapy failed to improve insulin sensitivity and

beta cell function in non-diabetic cystic fibrosis assessed with the oral
minimal model method
M. Schiavon, G.M. Toffolo, C. Cobelli, K.S. Nair, A. Moran, Italy, USA

174
Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 45 Seeing the full picture of diabetic retinopathy

Chair: T. Peto, UK

570 Impact of ethnicity and glycaemic control on developing sight

Short Oral Discussions

threatening retinopathy in people with type 2 diabetes
A. Nirmalakumaran, A. Mangelis, S. Thomas, S. Mann, J. Karalliedde, J.
Collins, S. Ayis, L. Webster, UK

571 HbA1c variability is associated with microvascular complications in

patients with type 1 diabetes: results of the 25-year observation
programme
L. Bolotskaya, Y. Golubkina, Russian Federation

572 Urinary proteome and diabetic retinopathy in the Direct-Protect 1

and 2 trials
V. Rotbain Curovic, P. Magalhães, T. He, T.W. Hansen, H. Mischak, P.
Rossing, Denmark, Germany

573 Study to evaluate relationship between the various components of

serum lipids with retinal hard exudate formation, CSME and the
occurrence and increasing severity of DR
A. Das, P. Prusty, S. Guha, A. Bhagat, India

574 Fenofibrate in the prevention and treatment of diabetic retinopathy:

systematic review
M. Malowicka, M. Szalanska, E. Lukomska, A. Jakubowska, D. Wilkowski,
Poland

575 Modified and conventional contact trans-scleral

cyclophotocoagulation for diabetic neovascular glaucoma
management
E.A. Mahmoud, S. Fenton, J. Lee, Ireland

175
 Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 46 Diabetic foot: from cost to COVID

Chair: N. Papanas, Greece

576 Impact of immunosuppressive drugs on the metabolic activity and

Short Oral Discussions

functional properties of stem cells isolated from the bone marrow of

diabetic patients
J. Husakova, B. Echalar, R. Bem, R. Jarosikova, V. Fejfarova, A. Jirkovska, J.
Kossl, V. Holan, M. Dubsky, Czech Republic

577 Cost-effectiveness and cost-utility of foot temperature monitoring for

preventing diabetic foot ulcer recurrence: a randomised controlled trial
J.J. Van Netten, M.G. Dijkgraaf, W.B. Aan de Stegge, S.A. Bus, Netherlands

578 The impact of the COVID-19 pandemic on the presentation rate and
severity of diabetic foot ulcers in Belgium
A.-S. Vanherwegen, P. Lauwers, K. Doggen, F. Nobels, E. Dirinck, IQED-
Foot COVID-19 Working Group, Belgium

579 Diabetic foot ulcers: Should a radiological diagnosis of osteitis be

treated as osteomyelitis?
K. Bishop, L. Pankaj, D. Hikmat, C. Ooi, UK

580 Enhancement of growth factor expression in chronic diabetic

wounds by cold atmospheric plasma: data from the randomised,
placebo-controlled, prospective KPWTRIAL
J. Hiller, B. Stratmann, T.C. Costea, D. Tschoepe, Germany

581 Poor adherence to medication and high HbA1c level predict risk of
amputation in patients with diabetes
M. Kaneko, K. Fujihara, M.Y. Harada, M. Kitazawa, Y. Yaguchi, M. Yamamoto,
S. Kodama, H. Sone, Japan

582 Evaluation of mortality rate in patients amputated by diabetic foot

in a third-level hospital
I. Hernández, A. Ortiz-Zúñiga, A. Pons Bartroli, J. Samaniego, J. Royo
Serrando, R. Busquets Net, N. Fernández, R. Simó, C. Hernández, Spain

176
Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 47 Autonomic neuropathy

Chair: C. Hansen, Denmark

583 Does the diagnostic value of the questionnaire for autonomic

Short Oral Discussions

symptoms COMPASS 31 differ between type 1 and type 2 diabetes?
I. D'Ippolito, M. Menduni, C. D'Amato, C. Greco, M. Leoni, D. Lauro, V.
Spallone, Italy

584 Carotid baroreceptor magnetic stimulation abrupt blood pressure

elevation buffering, implication to treat unstable hypertension in diabetes
J. Gmitrov, Slovakia, Japan

585 Lowering of blood pressure and pulse rate by switching from DPP-4
inhibitor to luseogliflozin in patients with type 2 diabetes and hypertension
R. Hashimoto-Kameda, K. Cho, H. Nomoto, A. Nakamura, K. Omori, S.
Nagai, S. Edagawa, S. Kawata, J. Takeuchi, H. Kameda, Y. Kurihara, T.
Atsumi,, H. Miyoshi, Japan

586 Association between cardiac autonomic neuropathy, arterial

stiffness and diastolic dysfunction in patients with type 2 diabetes
V. Serhiyenko, A. Serhiyenko, V. Segin, L. Serhiyenko, Ukraine

587 Cardiac autonomic function is associated with coronary artery

calcification in type 2 diabetes
S. Sivalingam, E.H. Zobel, C.S. Hansen, R.S. Ripa, B.J. Scholten, V.R.
Curovic, A. Kjaer, T.W. Hansen, P. Rossing, Denmark

588 Low grade inflammation does not attenuate the association

between glycated haemoglobin and parasympathetic tonus in people
with type 2 diabetes and pre-diabetes
R. Hadad, S.F. Akobe, P. Weber, P. Kumarathurai, A. Sajadieh, S.B.
Haugaard, Denmark

177
 589 Five-year change in body composition is related to heart rate but
not related to autonomic dysfunction in The Whitehall II study
C. Hansen, G.S. Andersen, M. Malik, D.R. Witte, E.J. Brunner, A.G. Tabák,
M. Kivimäki, D. Vistisen, Denmark, UK

590 Gall bladder ejection fraction as a marker of autonomic neuropathy

in type 2 diabetes
Short Oral Discussions

N. Dora, A. Shankar, M. Alam, N. Anubhav, India

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 48 Peripheral neuropathy - predictors of disease and prognosis

Chair: F. Picconi, Italy

591 Phase angle as indicator for sarcopenia and diabetic

polyneuropathy: a cross-sectional observational study in patients
with type 2 diabetes
L. Schimpfle, C. Mooshage, Z. Kender, D. Tsilingiris, F.T. Kurz, J. Szendroedi,
J.M. Jende, P. Nawroth, M. Bendszus, S. Kopf, Germany

592 Histamine-induced axon flair response in people with diabetic

peripheral neuropathy
J. Roeikjer, S.S. Croosu, T.M. Hansen, J.B. Froekjaer, L. Arendt-Nielsen, C.D.
Mørch, N. Ejskjaer, Denmark

593 Altered resting state connectivity in people with diabetic peripheral

neuropathy and correlation with functional status
K. Venkataraman, A.Z. Mohamed, F. Nasrallah, Singapore, Australia

594 Relationship between circulating sestrin2 level and diabetic

peripheral neuropathy in type 2 diabetic patients
X. Sun, F. Han, E. Mao, C. Kan, N. Hou, China

595 Effect of obesity on the associations of 25-hydroxyvitamin D with

prevalent and incident distal sensorimotor polyneuropathy
H. Maalmi, C. Herder, C. Huth, W. Rathmann, G.J. Bönhof, M. Heier, W.
Koenig, M. Roden, A. Peters, D. Ziegler, B. Thorand, Germany

178
596 Diabetic painful neuropathy treatment response with deep learning
classification
K. Teh, S. Tesfaye, D. Selvarajah, UK

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

Short Oral Discussions

SO 49 Neuropathy: from mechanisms to memory

Chair: S. Tesfaye, UK

597 Brain network disruptions in type 1 diabetes with and without

diabetic peripheral neuropathy
S.S. Croosu, J. Røikjer, C.D. Mørch, N. Ejskjaer, J.B. Frøkjær, T.M. Hansen,
Denmark

598 Machine learning techniques for the analysis of tactile sensitivity in

type 1 diabetes
F. Picconi, A. Moscatelli, A. Pepe, C. Ryan, S. Ciotti, B. Russo, M. Menduni,
F. Lacquaniti, S. Frontoni, Italy

599 Mechanism of insulin-induced proliferation and myelin formation in

Schwann cells
N. Nakamura, T. Saiki, M. Miyabe, M. Ito, T. Minato, K. Sango, T. Matsubara,
K. Naruse, Japan

600 Working memory is affected in type 1 diabetes and neuropathy

contributes to the cognitive deterioration
M. Gjela, S.S. Croosu, J. Røikjer, T.M. Hansen, C.D. Mørch, J.B. Frøkjær, N.
Ejskjaer, Denmark

601 A novel, multimodal magnetic resonance imaging and a machine

learning approach to classifying sensory phenotypes in painful DPN
D. Selvarajah, K. Teh, I. Wilkinson, F. Heiberg-Gibbons, M. Awadh, A. Kelsall,
G. Sloan, S. Tesfaye, UK

602 A 5 years follow up observational study of type 1 diabetes patients

not attending secondary care clinics
Q. Siah, A. Sharma, A. Howell, C. Dayan, M. Alhadj Ali, UK

179
 Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 50 Nephropathy interventions: from blueberries to SGLT2

Chair: A. Solini, Italy

603 Blueberry effects on kidney and perirenal adipose tissue in a rat

Short Oral Discussions

model of high fat diet-induced prediabetic nephropathy

S.D. Viana, P. Vieira, S. Nunes, A. Alves, I. Preguiça, P. Gomes, F. Reis, Portugal

604 Ss-DS-ONJ treatment abrogates the inflammatory events

underlying during diabetic nephropathy: the use of adult kidney
explants from BB rat as an ex vivo model
A.I. Arroba, L. Gomez-Jaramillo, F. Cano-Cano, E.M. Sanchez-Fernandez,
C. Ortiz Mellet, J.M. Garcia-Fernandez, M. Aguilar-Diosdado, Spain

605 Intermittent fasting has short-term effects on albuminuria, AGE

formation and acylcarnitines in patients with type 2 diabetes
A. Sulaj, S. Kopf, T. Fleming, A. Teleman, J. Okun, J. Szendroedi, S. Herzig, P.
Nawroth, Germany

606 Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for

type 1 diabetes and the benefit on cardiovascular and renal disease
evaluated by Steno risk engines
E. Buur Stougaard, D. Vistisen, F. Persson, P. Rossing, Denmark

607 Liraglutide plus SGLT2 inhibitors might be synergistically

beneficial to reduce progression to end stage renal disease in rapidly
progressive diabetes kidney disease
K. Kashima, H. Shimizu, M. Yamada, Japan

Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 51 Burdens and bones in CKD and diabetes

Chair: S. Hadjadj, France

608 Study of non diabetic kidney disease in type 2 diabetic patients

with renal involvement
P. Hans, M. Kumar, India

180
609 Age-rage and markers of bone metabolism in patients with
diabetes type 1 after successful pancreas-kidney transplantation and
kidney transplantation alone
A. Severina, I. Larina, I. Maganeva, A. Eremkina, M. Shamkhalova, M.
Shestakova, I. Dmitriev, A. Pinchuk, Russian Federation

610 The risk of hip fracture according to the diabetic kidney disease

Short Oral Discussions

status in the Korean population
S. Lee, H. Choi, J. Yoo, K. Han, K.-A. Kim, Korea, Republic of

611 Reduced levels of the anti-ageing hormone Klotho are associated

with increased aortic stiffness in people with type 2 diabetes and
kidney disease
N. Fountoulakis, P.-M. Psefteli, R. Siow, L. Gnudi, J. Karalliedde, UK

612 Type 2 diabetes and congestive heart failure are mutually

independent predictors of the presence of albuminuria
M. Maechler, A. Vonbank, B. Larcher, A. Mader, L. Sprenger, B.
Mutschlechner, M. Benda, A. Muendlein, A. Leiherer, H. Drexel, C.H. Saely,
Austria, Liechtenstein

613 Long term complications in type 1 diabetes are associated with an

altered inflammatory state: a proteomics approach
M. Ajie, J. Van Heck, R. Stienstra, C.J. Tack, Netherlands

614 Inside CKD: modelling the future global burden of chronic kidney
disease in patients with type 2 diabetes
N. Tangri, J. Ärnlöv, M.C. Batista, S. Chadban, G.M. Chertow, L. De Nicola,
J.-M. Halimi, E. Kanda, G. Li, F.S. Mennini, J.F. Navarro-González, A. Power,
A.A. Sultan, L. Webber, J. Wish, Canada, Sweden, Brazil, Australia, USA,
Italy, France, Japan, China, Spain, UK

615 Inside CKD: modelling the direct economic burden of concomitant

chronic kidney disease and type 2 diabetes
A. Power, J. Ärnlöv, M.C. Batista, J. Card-Gowers, S. Chadban, G.M.
Chertow, L. De Nicola, J.-M. Halimi, E. Kanda, G. Li, F.S. Mennini, J.F.
Navarro-González, J.J. Sanchez, N. Tangri, J. Wish, UK, Sweden, Brazil,
Australia, USA, Italy, France, Japan, China, Spain, Canada

181
 Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 52 Predictors of diabetic kidney disease

Chair: R. Roussel, France

616 Central obesity is associated with the onset of albuminuria in

Short Oral Discussions

type 1 diabetes
S. Mutter, E.B. Parente, E. Valo, V. Harjutsalo, L. Thorn, C. Forsblom, P.-H.
Groop, FinnDiane Study Group, on behalf of the FinnDiane Study Group,
Finland

617 Circulating sphingomyelin: A causal risk-factor of chronic

kidney disease?
T. Suvitaival, P. Rossing, C. Legido-Quigley, Denmark, UK

618 Heparin cofactor II prevents the development of albuminuria in

patients with diabetes
T. Hara, Y. Mitsui, S. Masuda, K. Kurahashi, S. Yoshida, T. Otoda, T. Yuasa, A.
Kuroda, I. Endo, M. Matsuhisa, M. Abe, K.-I. Aihara, Japan

619 Factors associated with occupational sitting in type 1 diabetes

M. Seppälä, H. Tikkanen-Dolenc, C. Forsblom, J. Wadén, M.I. Eriksson, V.
Harjutsalo, P.-H. Groop, L.M. Thorn, On behalf of the FinnDiane Study
Group, Finland

620 Association between central obesity and rapid decline of eGFR in

type 1 diabetes
E.B. Parente, S. Mutter, E. Valo, V. Harjutsalo, C. Forsblom, P.-H. Groop, on
behalf of the FinnDiane Study Group, Finland

621 Correlation of urine copper level and microalbuminuria in type 2

diabetic patients
S. Pattanaik, A. Sinha, R. Rajan, A. Mahapatra, India

182
Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 53 New insights from animal models of complications

Chair: K. Jandeleit-Dahm, Germany

622 Adaption of oxidative phosphorylation machinery compensates

Short Oral Discussions

hepatic lipotoxicity in early stages of fatty liver
P. Fahlbusch, A. Nikolic, N.-K. Riffelmann, S. Jacob, H. Al-Hasani, S.
Hartwig, S. Lehr, B. Knebel, J. Kotzka, Germany

623 Iron aggravates hepatic insulin resistance in the absence of

inflammation in a novel db/db mouse model with iron overload
S. Altamura, K. Müdder, A. Schlotterer, T. Fleming, E. Heidenreich, R. Qiu, H.
Hammes, P. Nawroth, M. Muckenthaler, Germany

624 Impact of lipotoxicity on mitochondrial DNA modifications in liver

and muscle
A. Nikolic, N.-K. Riffelmann, P. Fahlbusch, S. Jacob, H. Al-Hasani, J. Kotzka,
B. Knebel, Germany

625 Yg1699, a novel dual systemic SGLT1 and SGLT2 inhibitor,

decreases blood glucose and improves kidney function in primates
with diabetic kidney disease
C. Li, R. Xu, H. Wang, P. Strumph, J. He, D. Li, China

626 GLP-1 receptor agonists attenuates extracellular matrix secretion

via inhibiting HMGB1 signalling in rat mesangial cells
W.S. Gu, Z.W. Wang, M. Shi, H. Zhang, China

627 The role of Nox4-ROS in driving obesogenic bone marrow

mesenchymal stem cell phenotype in mice
J.M. Bond, A. Benova, M. Ferencakova, B. Prakash, A.K. Addington, K.S.
Specht, S.M. Craige, M. Tencerova, USA, Czech Republic

183
 628 Supplementation of methylglyoxal in drinking water does not affect
the cerebral microvasculature and cognitive function in non-diabetic mice
E. Berends, N. Amiri, M.P. Van de Waarenburg, J.L. Scheijen, D.J. Hermes,
R.J. Van Oostenbrugge, S. Foulquier, C.G. Schalkwijk, Netherlands

629 Upregulation of hepatic ß-oxidation-linked mitochondrial

respiration in experimental models of diabetes and fatty liver disease
Short Oral Discussions

B. Dewidar, M. Reina Do Fundo, C. Englisch, L. Mastrototaro, D. Pesta, F.

Zivehe, C. Ress, I. Esposito, M. Roden, Germany, Austria

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 54 Pathogenic mechanisms of complications

Chair: J.L. Ruas, Sweden

630 Continuous glucose monitoring parameters are related to serum

levels of non-enzymatic glycation products in patients with type 1
diabetes
V.V. Klimontov, M.V. Dashkin, J.F. Semenova, Russian Federation

631 Assessment of healthy people and type 2 diabetes patients on

skeletal muscle with T1ρ MRI of calf muscle
L. Guo, China

632 Dynamics of hexokinase-2 linked glycolytic overload mediating

endothelial cell dysfunction in high glucose concentration in vitro
P. Thornalley, M. Xue, N. Rabbani, Qatar

633 Fructosamine 3-kinase: activity and polymorphisms of important

deglycation enzyme in patients with diabetes
J. Skrha jr, M. Flekac, M. Kalousova, M. Prazny, J. Skrha, Czech Republic

634 Indicies of uric acid metabolism as marker of anabolic - catabolic

balance in men and women with type 2 diabetes with different phenotypes
A.A. Shuprovich, O.V. Zinych, O.V. Prybyla, N.N. Kushnareva, A.V.
Kovalchuk, V.V. Korpachev, Ukraine

184
635 Proton pump inhibitor induced hypomagnesaemia and mortality: a
mediation analyses of the diabetes care system cohort
E.A. Vermeulen, T. Hoekstra, J.J. Rijnhart, J.D. Mackenbach, M.G. Vervloet,
J.W. Beulens, Netherlands

636 Pancreas volume in patients with type 1 diabetes: What does it

depends on?

Short Oral Discussions

M. Ragimov, O. Derevyanko, N. Malysheva, D. Babaeva, L. Ibragimova, T.
Nikonova, M. Shestakova, Russian Federation

637 Nodular goiter increases a risk of neurovascular complications in

adult patients with type 1 diabetes
A. Rogowicz-Frontczak, B. Falkowski, D. Zozulinska-Ziolkiewicz, Poland

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 55 Not so sweet: cancer and diabetes

Chair: J. Gojda, Czech Republic

638 A CT-Scanner to detect cancer in subjects hospitalised for

uncontrolled diabetes and weight loss
M.-A. Barbet-Massin, France

639 The effect of the Danish National colorectal screening program on

detecting cancer for patients with diabetes
T. Laurberg, A. Nannsen, L.B. Hansen, M.B. Larsen, B. Andersen, A.
Sandbaek, Denmark

640 Cancer cachexia is associated with beta cell dysfunction: cross-

sectional study in patients with pancreatic cancer
J. Gojda, E. Vokatý, L. Rossmeislová, P. Tůma, M. Anděl, F. Karpe, Czech
Republic, UK

641 Immune infiltration of CD8+ T cells in patients with diabetic

pancreatic cancer reduces the malignancy of cancer tissues
Z. Ye, Y. Lv, Y. Zhang, J. Bao, L. Li, China

642 Assessment of glucose metabolic disorders in management of

prostate cancer with GnRH agonists
E. Gritskevich, T. Demidova, Russian Federation

185
 Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 56 Looking at the brain and its function

Chair: R. McCrimmon, UK

643 Seeing the brain through the eye: relationship between lower
Short Oral Discussions

retinal thickness and altered grey matter structure

R.B. Rodrigues, H.-T. Nguyen, R.G. IJzerman, F.J. Snoek, F. Barkhof, M.
Klein, A.C. Moll, E. Van Duinkerken, F.D. Verbraak, Brazil, Netherlands, UK

644 Retinal microperimetry: an useful tool for the monitoring of the

cognitive function in patients with type 2 diabetes
A. Rojano Toimil, O. Simó-Servat, A. Ortiz-Zuñiga, I. Hernandez Hernandez,
E. Cordero Vazquez, C. Hernandez Pascual, R. Simó, A. Ciudin, Spain

645 The impact of type 1 diabetes on brain volumes in neurologically

asymptomatic adults
T. Claesson, J. Putaala, S. Shams, E. Salli, D.T. Gordin, R. Liebkind, C.
Forsblom, T. Tatlisumak, P.-H. Groop, J. Martola, L.M. Thorn, on behalf of the
FinnDiane Study Group, Finland, USA, Sweden

646 Reduced cortical gyrification in middle-aged patients with type 1

diabetes is related to lower white matter integrity and worse cognitive
performance
J. Dos Santos Silva, R.G. IJzerman, M. Klein, F. Barkhof, A.C. Moll, F.J.
Snoek, E. Van Duinkerken, Brazil, Netherlands, UK

647 Cerebral and peripheral microcirculation in type 2 diabetes and

obesity, influence of neuropathy and C-peptide
M. Káplár, R. Esze, L. Rajnai, Z. Képes, S. Somodi, M. Emri, I. Garai, Hungary

648 Neuroprotective effects of Zfra 1-31 peptide against high glucose-

induced mitochondrial and autophagy defects
C. Carvalho, P.I. Moreira, Portugal

186
Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 57 All you need to know about atherosclerosis and diabetes

Chair: M. Mraz, Czech Republic

649 Safety, efficacy and feasibility of a modified variable rate

Short Oral Discussions

intravenous insulin infusion regime in treating hyperglycaemia in acute
coronary syndrome
A.L. Liarakos, P. Tran, M. Keegan, T. Robbins, N. Murthy, H. Randeva, N.N.
Gholap, UK

650 Estimated risk of atherosclerotic cardiovascular disease and heart

failure in type 2 diabetes without previous cardiovascular events
R. Cannistraci, M. Pozzoli, S. Ciardullo, E. Muraca, G. Manzoni, S. Perra, F.
Zerbini, E. Bianconi, A. Mortara, G. Lattuada, G. Perseghin, Italy

651 Coronary calcification and HbA1c in the north Staffordshire cohort

of the UK-based national targeted lung health check
S. Raza, I. Hussain, J. Barnett, C. Gidlow, G. Owen, F. Hanna, A. Fryer, UK

652 Disse insulin resistance index is a predictor of hospital outcome of

coronary artery bypass grafting in patients with diabetes type 2,
prediabetes and normoglycaemia
N. Bezdenezhnykh, A. Sumin, A. Bezdenezhnykh, A. Osokina, A. Kuz’mina,
A. Tsepokina, M. Noskov, S. Petrosyan, O. Barbarash, Russian Federation

653 Glucose variability is associated with an adverse vascular profile

but only in the presence of insulin resistance in individuals with
type 1 diabetes
N. Kietsiriroje, R.A. Ajjan, M.D. Campbell, UK, Thailand

187
 Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 58 Brain, kidney and vascular complications

Chair: P. Fioretto, Italy

654 The impact of obstructive sleep apnoea on macro- and micro-

Short Oral Discussions

vascular complications in patients with type 1 diabetes: a population-

based retrospective cohort study
Z. Alshehri, A. Subramanian, N.J. Adderley, K.M. Gokhale, M. Karamat, C.J.
Ray, P. Kumar, K. Nirantharakumar, A.A. Tahrani, Saudi Arabia, UK

655 Cerebral small vessel disease does not associate with blood
glucose control in neurologically asymptomatic individuals with
type 1 diabetes
J. Inkeri, K. Adeshara, V. Harjutsalo, C. Forsblom, R. Liebkind, T. Tatlisumak,
L.M. Thorn, P.-H. Groop, J. Martola, J. Putaala, D. Gordin, Finland, Sweden

656 Assessment of metabolic risk following initial presentation to

transient ischaemic attack clinic
V.C. Shaw, H. Binns, G.A. Doolan, G. Chander, S. Saraf, A. Puttanna, UK

657 Prediction of chronic kidney disease in people with diabetes

N. Afshar, M. Andorra, S. Chittajallu, T. Huschto, V. Babinsky, H. Mikulski, H.
Koenig, C. Ringemann, J. Odegard, I. Singh, USA, Spain, Germany, Austria

658 The ceramide- and phosphatidylcholine- based Coronary Event

Risk Test 2 (CERT2) and cardiovascular mortality in men and women
with type 2 diabetes
A. Leiherer, A. Muendlein, C.H. Saely, B. Larcher, A. Mader, M. Maechler, L.
Sprenger, B. Mutschlechner, M. Benda, R. Laaksonen, M. Laaperi, A. Jylha,
P. Fraunberger, H. Drexel, Liechtenstein, Austria, Finland

659 Type 2 diabetes, chronic kidney disease and major cardiovascular

events in patients with established coronary artery disease
L. Sprenger, A. Vonbank, B. Larcher, A. Mader, M. Maechler, B.
Mutschlechner, M. Benda, A. Leiherer, A. Muendlein, H. Drexel, C.H. Saely,
Austria, Liechtenstein

188
660 Combined dulaglutide-dapagliflozin treatment improves vascular
dysfunction and albuminuria vs DPP4 inhibitors independently of
glycaemic control
E. Korakas, I. Ikonomidis, J. Thymis, A. Kountouri, K. Katogiannis, D. Benas,
V. Prentza, K. Balampanis, L. Pliouta, F. Kousathana, G. Kostelli, G.
Dimitriadis, A. Raptis, V. Lambadiari, Greece Z. Huang, K. Ng, Z. Zhang,
J. Li, W. Deng, Y. Li, China

Short Oral Discussions

Short Oral Discussion Event E, Thursday, 11:45 - 13:15

SO 59 Vascular complications: mechanisms and risk factors

Chair: M. Dubsky, Czech Republic

661 Diabetic retinopathy and skin tissue advanced glycation end

products are biomarkers of vascular events in type 2 diabetic patients:
results of the prospective precised study
A. Planas Vilaseca, O. Simó-Servat, J. Bañeras, C. Hernández, I. Ferreria-
González, R. Simó, Spain

662 Type 2 diabetes and risk of major cardiovascular events in

peripheral artery disease versus coronary artery disease patients
C. Saely, A. Vonbank, B. Larcher, A. Mader, M. Maechler, L. Sprenger, B.
Mutschlechner, M. Benda, A. Muendlein, A. Leiherer, H. Drexel,
Liechtenstein, Austria

663 The role of visceral and subcutaneous adipose tissue distribution

determined by CT in the development of subclinical atherosclerosis in
type 2 diabetes and obesity
R. Esze, L. Rajnai, L. Balkay, Z. Képes, S. Somodi, M. Emri, I. Garai, M.
Káplár, Hungary

664 Elevated serum transferrin may play a vasoprotective role in

individuals with type 2 diabetes
A. Ruban Agarvas, S. Kopf, S. Altamura, N. Volk, P. Nawroth, M.U.
Muckenthaler, Germany, India

189
 665 Long-term palmitate treatment attenuates endothelial barrier via
increased mitochondrial reactive oxygen species and malondialdehyde
A.V. Vorotnikov, M.V. Samsonov, N.V. Podkuychenko, A.Y. Khapchaev, I.S.
Stafeev, M.Y. Menshikov, T.N. Vlasik, E.E. Efremov, V.Z. Lankin, M.V.
Skulachev, M.V. Shestakova, V.P. Shirinsky, Russian Federation

666 Vascular complications in patients with type 2 diabetes and

Short Oral Discussions

associated factors in Maghreb (Algeria and Tunisia cohort of the

DISCOVER study programme)
R. Malek, M. Azzouz, D. Roula, M. Brouri, A. Hadaoui, Algeria

Short Oral Discussion Event F, Thursday, 13:30 - 15:00

SO 60 Hepatic fibrosis: from screening to treatment

Chair: C. Postic, France

667 Non invasive blood based biomarkers as screening tools for

hepatic fibrosis in subjects with type 2 diabetes
A. Meritsi, D. Latsou, E. Manesis, I. Tsorlalis, M. Noutsou, I. Gatos, I.
Theotokas, P. Zoumpoulis, S. Rapti, E. Tsitsopoulos, P. Koussis, H.
Moshoyianni, S. Manolakopoulos, D. Pektasidis, A. Thanopoulou, Greece

668 Anti-fibrotic potential of a novel long-acting glucagon/GIP/GLP-1

triple agonist (HM15211) in preclinical models of fibrosis
J. Kim, J. Lee, S. Lee, H. Kwon, E. Park, S. Bae, D. Kim, Y. Kim, I. Choi,
Korea, Republic of

669 Anti-fibrotic effect of a novel long-acting GLP-1/GCG/FGF21/anti-

cytokine tetra-specific drug (OGB21502) in CCl4-induced liver fibrosis mice
M. Kim, R. Kim, Y. Kim, D. Im, S. Park, Korea, Republic of

670 Therapeutic effect of a novel long-acting GLP-1/GCG/FGF21/anti-

cytokine tetra-specific drug (OGB21502) in MCD diet-fed NASH mice
model
R. Kim, M. Kim, Y. Kim, D. Im, S. Park, Korea, Republic of

671 Growth differentiation factor-15 as a mediating factor in the

association between type 2 diabetes and liver fibrosis in NAFLD
J. Bilson, E. Scorletti, L.B. Bindels, P.R. Afolabi, G. Targher, P.C. Calder, J.K.
Sethi, C.D. Byrne, UK, Belgium, Italy

190
672 Relationship between advanced liver fibrosis using transient
elastography and diabetic complications: data in 684 patients from the
Angiosafe T2D cohort
T. Vidal Trecan, J.-B. Julla, D. Bellili, A.-F. Herrou, J.-P. Riveline, D. Valla, J.-F.
Gautier, L. Castera, France

673 Main determinants of NAFLD based on fibroscan in early stages of

Short Oral Discussions

glucose intolerance
R. Dimova-Draganova, N. Chakarova, M. Serdarova, C. Marinova, L.
Mateva, D. Popov, S. Del Prato, T. Tankova, Bulgaria, Italy

Short Oral Discussion Event A, Tuesday, 11:30 - 13:00

SO 61 Fatty liver always hides some complications

Chair: M.P. Macedo, Portugal

674 Nonalcoholic fatty liver disease, liver fibrosis and cardiovascular

disease in the general US population
G. Perseghin, R. Cannistraci, S. Mazzetti, A. Mortara, S. Ciardullo, Italy

675 Increased risk of hospitalisations in type 2 diabetes (T2D) with non-

alcoholic steatohepatitis (NASH): a prospective study from Hong Kong
Diabetes Register
A. Pik-Shan Kong, E. Lau, E. Chow, A. Luk, R. Ma, J. Chan, Hong Kong

676 Subjects with NASH and diabetes have a more unfavourable

metabolic profile compared to NAFL with and without diabetes: results
from the EPOS study
S. Sabatini, M. Gaggini, M. Allison, R. Younes, C. Rosso, J.M. Schattenberg, V.
Ratziu, E. Bugianesi, Q.M. Anstee, A. Gastaldelli, Italy, UK, Germany, France

677 Non-alcoholic fatty liver disease in overweight subjects related to

impaired glucose control and increased insulin resistance
T. Forst, I. Botz, M. Berse, A. Schultz, M.-E. Strempler, S. Vosswinkel, S.
Baumann, Germany

678 Association between non-alcoholic liver fibrosis scoring systems

and micro-macrovascular complications
H. Ataoglu, Ş. Yıldız Şahin, S. Özkabakçı, Turkey

191
 679 Congestive heart failure and the metabolic syndrome are mutually
independent predictors of non-alcoholic fatty liver disease
B. Mutschlechner, M. Maechler, A. Vonbank, B. Larcher, A. Mader, L.
Sprenger, A. Leiherer, A. Muendlein, M. Benda, H. Drexel, C.H. Saely,
Austria, Liechtenstein

680 Current type 2 diabetes, rather than previous gestational diabetes,

Short Oral Discussions

is associated with liver disease in U.S. women

S. Ciardullo, E. Bianconi, F. Zerbini, G. Perseghin, Italy

681 Non-alcoholic fatty liver indices and their association with glucose
metabolism in pregnancy
D. Eppel, T. Linder, G. Kotzaeridi, I. Rosicky, G. Yerlikaya-Schatten, K.
Weisshaupt, W. Henrich, A. Tura, M. Roden, C.S. Göbl, Austria, Germany,
Italy

Short Oral Discussion Event B, Tuesday, 13:15 - 14:45

SO 62 Cardiovascular complications and drugs

Chair: J. Petrie, UK

682 Lipid-lowering in diabetes is not intensified beyond 3-months if

coronary angiography with fractional flow reserve (FFR) suggests
non-obstructive coronary artery disease
R.S. Vasudevan, I. Xu, H. You, R. Xu, P.R. Taub, M.J. Wilkinson, USA

683 The rate of decline in nocturnal interstitial glucose concentrations

influences some electrocardiogram parameters in type 1 diabetes
M. Smallman, O. McCarthy, J. Pitt, R.M. Bracken, UK

684 Empagliflozin ameliorates obesity-induced cardiac dysfunction via

activating SIRT3-mediated autophagy
J. Zhang, N. Hou, F. Han, Y. Ma, T. Ye, X. Sun, China

192
685 Efficacy of intravenous ferric carboxymaltose in patients with iron
deficiency following acute heart failure, by diabetes status: a subgroup
analysis of the AFFIRM-AHF trial
G. Rosano, P. Ponikowski, C. Vitale, S.D. Anker, J. Butler, V. Fabien, G.
Filippatos, B.-A. Kirwan, I.C. Macdougall, M. Metra, F. Ruschitzka, S.
Waechter, P. Van der Meer, E.A. Jankowska, on behalf of the AFFIRM-AHF
investigators, UK, Poland, Germany, USA, Switzerland, Greece, Italy,

Short Oral Discussions

Netherlands

686 Effect of saxagliptin on LV structure and function in patients with

type 2 diabetes and heart failure: results of measure-HF
P. Bertram, B. Reicher, R.E. Gilbert, S.B. Morgan, K. Swedberg, A.M.
Langkilde, J. Monyak, N. Zaozerska, M.N. Kosiborod, USA, Canada,
Sweden, Poland

687 Oleate prevents palmitate-induced abnormalities in insulin

signalling in human cardiac progenitor cells
R. D'Oria, C. Caccioppoli, R. Schipani, V.A. Genchi, A. Leonardini, G.
Santarpino, A. Natalicchio, S. Perrini, A. Cignarelli, A. Milano, L. Laviola, F.
Giorgino, Italy

688 Cardiovascular autonomic neuropathy and risk of heart failure in

participants with type 2 diabetes enrolled in the DEVOTE trial
R. Pop-Busui, L. Ang, S. Hayek, K. Mizokami-Stout, E. Parvaresh Rizi, I.
Lingvay, on behalf of the DEVOTE Study Group, USA, Denmark

689 Meta-analysis of SGLT inhibitors on cardiovascular death or heart

failure hospitalisation based on presence of type 2 diabetes, heart
failure, or chronic kidney disease
K. Charalampidis, T. Karagiannis, A. Liakos, P. Kakotrichi, A. Tsapas, E.
Bekiari, Greece, UK

193
 Short Oral Discussion Event C, Wednesday, 11:45 - 13:15

SO 63 COVID-19: from the known to unknown

Chair: K. Khunti, UK

690 Characteristics and predictors of mortality in diabetes patients

Short Oral Discussions

hospitalised with COVID-19: a single-centre cohort study from Poland

K. Mazur, M. Kania, M. Terlecki, Z. Chaykivska, M. Fiema, M. Kopka, M.
Kostrzycka, M. Wilk, J. Hohendorff, T. Klupa, P. Witek, M. Rajzer, B. Katra,
M.T. Małecki, Poland

691 The impact of acute-to-chronic glycaemic ratio as a predictor of

COVID-19 severity and mortality
J. Ramon, G. Llauradó, R. Güerri, J.-J. Chillarón, E. Climent, S. Ballesta, D.
Benaiges, H. Navarro, N. Fernández, M. Carrera, J.A. Flores-Le Roux, on
behalf of COVID-MAR study group, Spain

692 Bamlanivimab + etesevimab for the treatment of COVID-19 in high-

risk ambulatory patients including those with diabetes
A. Tahbaz, M. Dougan, A. Nirula, R. Gottlieb, M. Azizad, B. Mocherla, P.
Chen, G. Huhn, A. Adams, A. Schade, J. Sabo, D. Patel, P. Klekotka, L.
Shen, D. Skovronsky, USA

693 The effectiveness of selected temporary testing protocols for

gestational diabetes during the COVID-19 pandemic
M. Kania, M. Kwiatkowska, K. Cyganek, M. Szopa, Poland

694 How COVID-19 has impacted diabetes management in the United

States (iNPHORM study)
A. Ratzki-Leewing, S. Harris, J.E. Black, B.L. Ryan, G. Zou, Canada

695 Effects of COVID-19 lockdown on health care for persons with

type 2 diabetes in Germany: results from an electronic medical
record database
B. Kowall, K. Kostev, R. Landgraf, H. Hauner, R. Bierwirth, W. Rathmann,
Germany

194
Short Oral Discussion Event D, Wednesday, 13:30 - 15:00

SO 64 Cardiac complications in diabetes and prediabetes

Chair: K. Strojek, Poland

696 Obesity and decreased vibration perception associated with

Short Oral Discussions

premature cardiovascular mortality in a single centre prospective of
study of people with diabetes
D.S. Tesic, D. Andric, M.T. Tomic, S. Andric, M.D. Tomic, Serbia

697 Impact of prediabetes in heart failure with preserved ejection

fraction: the NetDiamond cohort
M. Borges-Canha, F. Vasques-Nóvoa, F. A. Saraiva, A. Leite, A. Oliveira, J.
Neves, M. Von Hafe, C. Vale, D. Carvalho, A. Leite-Moreira, Portugal

698 Respective role of NT-proBNP and coronary artery calcium score

for the detection of silent coronary disease in asymptomatic patients
with diabetes
S. Pinto, N. Berkane, M. Nguyen, N. Sellier, E. Cosson, P. Valensi, France

699 WITHDRAWN

700 To study the relationship between the mean platelet volume, immature
platelet fraction, and glycaemic control in type 2 diabetes patients
S. Ahsan, R. Roy, M. Prasad, A. Gaurav, India

701 Type 2 diabetes significantly modulates the power of lipoprotein (a)

to predict cardiovascular events and mortality in young coronary artery
disease patients
A. Vonbank, A. Mader, M. Maechler, B. Larcher, L. Sprenger, B.
Mutschlechner, M. Benda, A. Muendlein, A. Leiherer, H. Drexel, C.H. Saely,
Austria, Liechtenstein

702 Remnant cholesterol in patients with established cardiovascular

disease predicts cardiovascular events both among patients with type
2 diabetes and among non-diabetic subjects
H. Drexel, A. Mader, L. Sprenger, A. Vonbank, B. Larcher, M. Maechler, B.
Mutschlechner, M. Benda, A. Leiherer, A. Muendlein, C.H. Saely, Austria,
Liechtenstein

195
 Last Name, Initials, Presentation Number
Abukiwan, A. 291 Baig, A. A. 524
Presenting authors of orals and short oral discussions

Adenis, A. 554 Bain, S. 485

Afi Leslie, K. 217 Bajaj, H. S. 509
Afshar, N. 657 Bally, L. 96
Ahmed, F. 421 Bandet, C. L. 171
Ahmed, M. 81 Banu, B. 529
Ahola, A. J. 283 Bany Bakar, R. 317
Ahsan, S. 700 Bao, J. 376
Ajie, M. 613 Barbet-Massin, M.-A. 638
Akalestou, E. 430 Barchetta, I. 390
Akil, A. A.-S. 301 Barmpagianni, A. 373
Al-Mrabeh, A. 41 Barnard-Kelly, K. 562
Al-Rubeaan, K. 296 Barsby, T. 254
Al-Saoudi, E. F. 55 Basu, A. 227
Al-Sari, N. 157 Battelino, T. 470
Aleppo, G. 214 Bayazit, B. 256
Alshehri, Z. 654 Bazydlo-Guzenda, K. 223
Altamura, S. 623 Beato-Víbora, P. I. 553
Amor, A. 341 Beiglböck, H. 72
Anagnostis, P. 313 Ben-Zvi, D. 249
Anderlova, K. 566 Benhalima, K. 346
Andersen, A. 257 Benson, C. T. 222
Andersen, E. S. 295 Bentzen, M. J. 409
Andreasen, C. R. 258 Berends, E. 628
Andreeva, A. T. 294 Bergman, M. 169
Andriessen, C. 433 Berikov, V. B. 159
Angoulvant, D. 239 Bertram, P. 686
Annersten Gershater, M. 310 Betancort Acosta, J. C. 535
Antikainen, A. A. 302 Bezdenezhnykh, N. 652
Aprile, M. 34 Bhat, B. A. 129
Aroda, V. R. 482 Bianco, E. 240
Arroba, A. I. 604 Bilson, J. 671
Ashik, T. 316 Birukov, A. 312
Asuaje Pfeifer, M. 353 Bishop, K. 579
Atabaki Pasdar, N. 90 Block, T. J. 165
Ataoglu, H. 678 Blüher, M. 335
Avgerinos, I. 148 Bodholdt, U. 450
Awala, O. 567 Bojer, A. S. 178
Ayine, M. L. 131 Bolotskaya, L. 571
Badillo, E. 303 Bond, J. M. 627
Baidya, A. 532 Bönhof, G. J. 56

196
Last Name, Initials, Presentation Number
Bonora, E. 456 Chen, Y. 352

Presenting authors of orals and short oral discussions

Boonpattrawong, N. 18 Cherian, P. 384
Borges-Canha, M. 697 Choi, J. 191
Bosch, A. 490 Christensen, M. H. 403
Bosi, E. 10 Ciardullo, S. 680
Boughton, C. K. 234 Cidade-Rodrigues, C. 275
Bouman, E. J. 285 Cinti, F. 337
Boye, K. 475 Claesson, T. 645
Brahma, M. K. 379 Clemente-Postigo, M. 45
Broe Honoré, J. 448 Coppini, D. 542
Bronczek, G. A. 100 Corbin, K. D. 425
Brønden, A. 177 Cordiner, R. L. M. 175
Brøsen, J. M. B. 516 Coskun, T. 221
Broz, J. 354 Cowan, E. 323
Bruls, Y. M. H. 366 Crabtree, T. S. J. 457
Brun, T. 152 Croosu, S. S. 597
Brüning, D. 399 D'Ippolito, I. 583
Brusco, N. 375 D'Oria, R. 687
Bulkescher, R. 166 Dagogo-Jack, S. 438
Buur Stougaard, E. 606 Dahl, D. 20
Buziau, A. M. 86 Dahlstrom, E. H. 243
Camaya, I. 334 Dal Canto, E. 2
Campos, M. 400 Danne, T. 558
Cannistraci, R. 650 Das, A. 573
Cannon, C. P. 50 Davies, M. J. 22
Canonica, J. 462 de Wit, M. 522
Capehorn, M. 23 de Wit-Verheggen, V. 174
Carlson, A. L. 561 Deanfield, J. E. 479
Carswell, C. 531 Deden, L. N. 250
Carvalho, C. 648 Dejgaard, T. 495
Castillo-Armengol, J. 186 Del Prato, S. 370
Cataldi, S. 46 Delgadillo Silva, L. 363
Cataldo, L. R. 378 Dettmer, R. 328
Cedersund, G. 368 Dewidar, B. 629
Charalampidis, K. 689 Dhayal, S. 330
Charbonnel, B. 439 Di Gioia, L. 534
Charleer, S. 543 di Pietrantonio, N. 270
Charlwood, C. 443 Dimova-Draganova, R. 673
Chawla, P. 9 Dolgin, K. 538
Chen, G. 488 Dong, Z. 416
Chen, L. 200 Dora, N. 590

197
 Last Name, Initials, Presentation Number
dos Santos, R. S. 320 Gallen, I. 424
Presenting authors of orals and short oral discussions

dos Santos Silva, J. 646 Galli, A. 103

Dreher, S. I. 102 Gao, B. 451
Drexel, H. 702 García-Pérez, L.-E. 454
Dubsky, M. 197 Garg, S. 236
Duffus, S. H. 499 Gaspari, S. 386
Dule, S. 42 Gastaldelli, A. 426
Dvir, H. 493 Gaus, B. 156
Edstorp, J. 282 Gehr, B. 137
Ehall, B. 321 Gerstein, H. 434
Ekim Ustunel, B. 170 Geurten, R. J. 263
Ellis, S. L. 549 Gheibi, S. 325
Eppel, D. 681 Ghosh, S. 128
Eriksson, M. I. 164 Gimenez, P. 551
Esze, R. 663 Giovenzana, A. 44
Evans, M. 268 Gjela, M. 600
Fachim, H. 48 Gluud, L. L. 190
Fadhel Dhaher, N. 311 Gmitrov, J. 584
Fadini, G. P. 138 Gojda, J. 640
Fahlbusch, P. 622 Goldenberg, R. 453
Fanni, G. 228 Golubic, R. 460
Farup, J. 374 González-Moro, I. 12
Fauchier, G. 64 Gourdy, P. 505
Fellinger, P. 548 Greene, C. R. L. 146
Ferrannini, E. 501 Greig, M. 59
Ferrannini, G. 5 Gritskevich, E. 642
Ferreira, J. P. 54 Gu, W. Sha. 626
Flor, A. 476 Guja, C. 512
Flores-Guerrero, J. L. 95 Guo, L. 631
Flotynska, J. 360 Guo, X. 515
Forlenza, G. P. 564 Gurgul Convey, E. 331
Forst, T. 677 Hadad, R. 588
Fountoulakis, N. 611 Hagemann, C. A. 37
Fragoso-Bargas, N. 205 Hamaguchi, M. 496
Franey, B. 466 Han, D. J. J. 121
Franzén, S. 70 Han, L. 411
Frias, J. 134 Hannelius, U. 242
Frier, B. M. 299 Hans, P. 608
Fryer, A. A. 526 Hansen, C. 589
Fuchs, J. 233 Hansen, T. 188
Galiyeva, D. 262 Hara, T. 618

198
Last Name, Initials, Presentation Number
Harmsen, J.-F. 246 Irwin, N. 388

Presenting authors of orals and short oral discussions

Harreiter, J. 401 Israeli, T. 377
Hart, H. E. 525 Jacob, P. 259
Hasebe, M. 500 Janiszewski, M. 461
Hashimoto-Kameda, R. 585 Jensen, M. H. 68
Hatem, G. 271 Jensen, N. J. 114
Haugaard, S. B. 187 Jin, Q. 66
Haukka, J. 127 Jodar, E. 481
He, L. 284 Johansen, O. 112
Hedegaard Andersen, J. 193 Johansen, R. F. 520
Heimbürger, S. M. N. 494 Jones, J. 415
Hein Zobel, E. 6 Kabisch, S. 113
Heise, T. 511 Kader, T. 563
Heller, S. 557 Kakotrichi, P. 491
Henriksen, M. M. 519 Kalaidzidis, I. 115
Hentilä, J. 97 Kalra, S. 140
Hernández, I. 582 Kaneko, M. 581
Hernandez, M. 215 Kania, M. 693
Herzig, D. 429 Káplár, M. 647
Herzog, K. 74 Karasik, A. 445
Hill, T. G. 116 Kashima, K. 607
Hiller, J. 580 Katoh, S. 92
Hindsø, M. 387 Kazda, C. 216
Hirani, D. 342 Keuthage, W. 550
Hjortkjær, H. 94 Kgosidialwa, O. 528
Hoelting, L. 361 Khamis, A. 274
Hoene, M. 98 Khan, D. 184
Höhn, A. 77 Kietsiriroje, N. 653
Holland, D. 30 Kim, J. 668
Hompesch, M. 224 Kim, M. 669
Hu, X. 518 Kim, R. 670
Huang, M. 306 Kim, S. 297
Huang, W. 324 Kim, Y. 273
Huang, Z. 410 Kjeldsen, S. A. S. 365
Hughes, A. E. 160 Klar, R. 230
Husain, M. 21 Klimontov, V. V. 630
Husakova, J. 576 Knop, F. K. 480
Ignaut, D. 507 Knorr, S. 17
Inkeri, J. 655 Knudsen, L. 527
Inzucchi, S. E. 489 Kogot-Levin, A. 231
Iqbal, Z. 252 Korakas, E. 660

199
 Last Name, Initials, Presentation Number
Kosiborod, M. 440 Liebmann, M. 351
Presenting authors of orals and short oral discussions

Kosinski, M. 347 Lietzén, M. S. 358

Kotzaeridi, G. 348 Lilja, E. 198
Kountouri, A. 565 Linder, T. 349
Kowall, B. 695 Lingvay, I. 508
Kowluru, A. 155 Linkens, A. 280
Krebs, M. 266 Linnenkamp, U. 276
Kristensen, K. B. 498 Lithovius, V. 253
Krogh, J. 442 Liu, J. 161
Ku, E. 53 Liu, S. 28
Kullmann, S. 38 Liu, X. 340
Kuo, F.-C. 122 Llanera, D. 307
Kuo, M.-L. 196 Llaurado, G. 167
Kurzbach, A. 369 Lobanova, K. G. 391
Lachal, S. 552 Löffler, D. 405
Lambers Heerspink, H. J. 51 Loghin, C. 427
Lampousi, A.-M. 73 Löhnert, M. 13
Lanzinger, S. 300 López-Cano, C. 189
Laurberg, T. 639 Lopez-Pascual, A. 11
Lauritsen, K. M. 204 Loureiro, L. M. 536
Laursen, J. C. 232 Ludvik, B. 472
Layne, J. E. 541 Ludwig, L. 309
Le Marois, M. 57 Lui, D. T. W. 132
le Roux, C. W. 455 Lunati, M. E. 49
Le Solliec, M.-A. 380 Luong, T. V. 372
Leal, E. C. 195 Lyngfelt, L. 142
Leanza, G. 168 Maalmi, H. 595
Lecube, A. 290 Maasen, K. 111
Lee, C. J. 473 MacCalman, A. 272
Lee, E. 395 Maechler, M. 612
Lee, S. 412 Magrill, J. 269
Lee, S. 610 Mahmoud, E. A. 575
Leete, P. 75 Mai, K. 83
Lehmann, V. 260 Maina, J. G. 208
Leiherer, A. 658 Malek, R. 666
Lemaitre, M. 404 Malowicka, M. 574
Leohr, J. 504 Mangelis, A. 150
Li, C. 625 Mann, P. A. 199
Li, H. 106 Mao, D. 144
Li, T. 417 Marku, A. 120
Liarakos, A. L. 649 Marqués, P. 318

200
Last Name, Initials, Presentation Number
Marrano, N. 383 Nakasone, Y. 287

Presenting authors of orals and short oral discussions

Marroqui, L. 329 Nangia, C. 147
Martinez-Sanchez, A. 304 Nash, K. 25
Mastrototaro, L. 101 Natalicchio, A. 469
Matafome, P. 389 Nerild, H. H. 422
Matejko, B. 359 Newman, C. 402
Mathiesen, E. R. 16 Nguyen, C. 544
Mathieu, C. 220 Nikolic, A. 624
Matthews, D. R. 336 Nimgaonkar, A. 431
Mattila, M. 278 Nirmalakumaran, A. 570
Mazur, K. 690 Niskanen, L. 444
McInnes, N. 436 Nøkleby, K. 29
Meek, C. L. 15 Nolan, S. 91
Meier, J. J. 458 Noor, M. A. 464
Meiffren, G. 133 Nunes, S. 428
Mellor, J. 31 O'Harte, F. P. M. 315
Menduni, M. 35 O'Reilly, J. E. 69
Meng, R. 545 Ojala, R. 356
Meritsi, A. 667 Olaniru, O. 255
Mertens, J. 364 Oost, L. J. 209
Messaaoui, A. 27 Orioli, L. 251
Meulebrouck, S. 207 Ortega, F. J. 414
Mezza, T. 119 Owens, D. R. 238
Mocciaro, G. 192 Pafili, K. 88
Mody, R. 449 Palacios-Marin, I. 419
Moffett, C. R. 465 Paldánius, P. M. 292
Mohamed, S. A. 149 Parente, E. B. 620
Monroy, G. 406 Pariz, C. G. 533
Montanya, E. 492 Pasula, D. J. 104
Moon, S. 319 Pattanaik, S. 621
Morales-Villegas, E. C. 484 Paul, S. 143
Morpurgo, P. S. 555 Pedersen, M. G. B. 432
Mosenzon, O. 180 Pedersen, S. D. 19
Moyers, J. 502 Peijs, L. 398
Muraca, E. 93 Pekkarinen, L. 420
Murata, T. 235 Perlman, J. E. 547
Musale, V. 413 Perreault, L. 452
Mutschlechner, B. 679 Perrier, J. 397
Mutter, S. 616 Perseghin, G. 674
Nakamura, N. 599 Persson, S. 26
Nakanga, W. 281 Petersen, E. 60

201
 Last Name, Initials, Presentation Number
Petersen, G. B. 162 Roberts, B. K. 136
Presenting authors of orals and short oral discussions

Petkovic, M. 194 Rodrigues, R. B. 643

Picconi, F. 598 Roeikjer, J. 592
Pietschner, R. 203 Rogowicz-Frontczak, A. 637
Pigeyre, M. 158 Röhling, M. 1
Pik-Shan Kong, A. 675 Rojano Toimil, A. 644
Pina, A. F. 79 Romeres, D. 396
Pinto, S. 698 Rönkkö, T. K. E. 202
Pitt, J. P. 357 Rosano, G. 685
Planas Vilaseca, A. 661 Rosenstock, J. 474
Pletsch-Borba, L. 279 Rotbain Curovic, V. 572
Plum-Mörschel, L. 510 Roumans, K. H. M. 87
Polonsky, W. H. 24 Ruban Agarvas, A. 664
Pomares-Millan, H. 67 Rubino, D. M. 478
Pop-Busui, R. 688 Ruchi, R. 385
Power, A. 615 Rudofsky, G. 447
Pratley, R. E. 52 Ryder, R. E. J. 568
Prystupa, K. 225 Sabatini, S. 676
Puginier, E. 339 Saboo, S. 540
Pylypchuk, R. 62 Saely, C. 662
Qi, L. 80 Saito, T. 367
Qiu, R. 173 Sakaguchi, M. 418
Quezada, E. 108 Sanchez, G. 151
Quinn, L. M. 559 Sandholm, N. 210
Qvigstad, E. 14 Sarsenbayeva, A. 408
Ragimov, M. 636 Scarale, M. 288
Raimundo, A. F. 381 Schaarup, J. F. R. 63
Ramon, J. 691 Schiavon, M. 569
Raoux, M. 117 Schimpfle, L. 591
Ratter, J. M. 43 Seguí, N. 345
Ratzki-Leewing, A. 694 Selig, J. I. 371
Raza, S. 651 Selvais, C. 185
Rebec, M. 546 Selvarajah, D. 601
Recio-López, P. 182 Seppälä, M. 619
Reis-Costa, A. 172 Serhiyenko, V. 586
Ren, H. 118 Seufert, J. 483
Ricciardi, C. 130 Severina, A. 609
Ringqvist, E. E. 218 Shaw, A. C. 245
Risovic, I. 459 Shaw, V. C. 656
Rittig, N. 423 Shi, J. 47
Rix, I. 226 Shi, M. 229

202
Last Name, Initials, Presentation Number
Shuprovich, A. A. 634 Tesic, D. Sreten. 696

Presenting authors of orals and short oral discussions

Siah, Q. 602 Thadani, P. 537
Silver, R. 135 Thakarakkattil Narayanan Nair, A. 286
Simanenkova, A. 3 Thennati, R. 467
Simo, R. 61 Thewjitcharon, Y. 293
Simo-Servat, O. 36 Thomas, R. L. 289
Sivalingam, S. 587 Thomsen, M. N. 109
Skrha jr., J. 633 Thornalley, P. 632
Slieker, R. C. 206 Thorning, T. K. 468
Sloan, G. 58 Tibballs, K. L. 139
Smallman, M. 683 Tirosh, A. 506
Smith, M. P. 84 Tittel, S. R. 261
Soares, G. M. 338 Toczyska, K. W. 327
Spigoni, V. 487 Torchio, S. 305
Spinelli, R. 126 Tore, E. C. 82
Sprenger, L. 659 Trescoli, C. 212
Sridhar, A. 392 Trico, D. 40
Stensen, S. 179 Tsilingiris, D. 523
Stewart, Z. A. 350 Ukropec, J. 99
Stichling, S. 308 Ullrich, S. 326
Stistrup Lauritzen, E. 248 Valensi, P. 237
Stone, V. M. 298 Vambergue, A. 76
Stratmann, B. 394 Van, J. 435
Strelitz, J. 264 van Gennip, A. C. E. 141
Su, Q. 181 van Heck, J. I. P. 163
Sulaj, A. 605 van Nes, F. 497
Suleiman, M. 7 van Netten, J. J. 577
Sun, X. 594 Van Ruiten, C. C. 176
Suvitaival, T. 617 Vandenbempt, V. 332
Svedbo Engström, M. 539 Vanherwegen, A.-S. 578
Syreeni, A. 244 Vanweert, F. 39
Szabo, M. I. M. 437 Vasudevan, R. S. 682
Tahbaz, A. 692 Venkataraman, K. 593
Tahrani, A. A. 78 Vergès, B. 407
Tandon, N. 277 Verhulst, C. E. M. 517
Tang, Y. 105 Verma, S. 486
Tangri, N. 614 Vermeulen, E. A. 635
Tarasov, A. 362 Viana, S. D. 603
Taylor, R. 110 Vidal Trecan, T. 672
Teh, K. 596 Viggers, R. 71
Téllez, N. 322 Visentin, R. 560

203
 Last Name, Initials, Presentation Number
Voigt, J. H. 201 Zhou, Y. 154
Presenting authors of orals and short oral discussions

Vonbank, A. 701 Zijlstra, E. 514

Vorotnikov, A. V. 665 Zou, Y. 107
Vranic, M. 125 Zurawska-Klis, M. 344
Vuori, N. 32
Waddell, T. 89
Wagner, R. 382
Wang, Y. 463
Wei, Y. 241
Weng, X. 124
Wernicke, C. 85
Wernroth, M.-L. 267
Westerink, J. 65
Wharton, S. 477
Wheeler, D. C. 441
Whyte, M. 265
Wilbek Fabricius, T. 521
Wild, S. H. 145
Wilk, M. 343
Winter, H. R. 33
Wittbrodt, E. 314
Wolters, J. 211
Wong, W. K. M. 8
Wright, E. 213
Wyatt, R. C. 219
Xiao, P. 333
Yadav, Y. 247
Yale, J.-F. 446
Yan, Y. 556
Yao, J. 513
Ye, E. R. 530
Ye, Z. 641
Yu, G. Z. 123
Yu, M. 471
Yu, Y. 503
Zabala, A. 4
Zaïmia, N. 153
Zemva, J. 183
Zhang, J. 684
Zhang, X. 393
Zhao, T. 355

204
 Improve your
diabetes knowledge
with the world’s
leading academics

Access is FREE
Modules added monthly
Multimedia and interactive content

EASD has a long and proud history of

postgraduate education and the organisation
is delighted now to be able to offer online
learning as part of this. We are building a suite
of e-learning modules designed to educate,
inform and engage healthcare professionals
around the world.

The wide range of diabetes modules that will

populate this platform have been designed
with international experts in the field and they
use innovative multimedia and challenging
knowledge checks to help you to learn more
about this fast-moving area.

Create your free account at

easd-elearning.org/register
easd-elearning.org

EASD-Conf-2019-A5-AD-v3.indd 2 27/07/2020 15:21

205
 Last Name, First Name, Page Last Name, First Name, Page
Aas, Anne-Marie 59 Freckmann, Guido 103
Agarwal, Rajiv 109 Gemmink, Anne 58
Ajjan, Ramzi A. 125 Georgiadi, Anastasia 82
Amiel, Stephanie A. 57, 125 Gonder-Frederick, Linda 103
Angwin, Catherine 79 Griffin, Simon J. 56
Anker, Stefan D. 105 Groop, Per-Henrik 109
Aravind, Sosale R. 106 Gubitosi-Klug, Rose A. 57
Invited speakers

Avrahami, Dana 124 Haidar, Ahmad 77

Bairey Merz, C. Noel 102 Hartvigsen, Gunnar 56
Bakris, George L. 109 Hattersley, Andrew T. 79
Basu, Rita 123 Heise, Tim 85
Battelino, Tadej 85 Herrera, Pedro L. 53
Bergman, Richard N. 123 Hesselink, Matthijs K.C. 78
Birkenfeld, Andreas L. 109 Hess-Fischl, Amy 122
Bjerre Knudsen, Lotte 102 Hirsch, Irl B. 122
Bonnefond, Amélie 101 Hoeks, Joris 124
Bornfeldt, Karin E. 102 Holt, Richard I.G. 122
Brunak, Søren 104 Inzucchi, Silvio E. 76
Buse, John B. 125 Iqbal, Ahmed 57
Butler, Javed 105 Jensen, Michael D. 77
Chen, Shuibing 76 Jude, Edward B. 81
Choudhary, Pratik 77 Kahn, Barbara B. 77
Cusi, Kenneth 85 Kazak, Lawrence 77
Danne, Thomas 104 Khunti, Kamlesh 107
Davies, Melanie J. 85 Kirkman, Sue 122
De Zoysa, Nicole 125 Kistorp, Caroline M. 79
DeFronzo. Ralph A. 109 Klupa, Tomasz 122
Del Prato, Stefano 85 Knop, Filip K. 102
Dennis, John 56 Kretzler, Matthias 81
DeVries, J. Hans 122 Kuo, Chia-Hua 59
Dotta, Francesco 76 Lambers Heerspink, Hiddo J. 51, 106
Drucker, Daniel J. 83 Lickert, Heiko 124
Eastell, Richard 84 Lingvay, Ildiko 83, 108
Eriksson, Jan W. 85 Loh, Kim 84
Eringa, Etto 58 Ludwig, Barbara 122
Evans-Molina, Carmella 57 Mader, Julia 107
Færch, Kristine 80 Malik, Rayaz A. 56
Fejfarova, Vladimira 81 Mallone, Roberto 57
Filippatos, Gerasimos 105 Marbán, Eduardo 123
Fioretto, Paola 58 Markus, Hugh S. 103

206
Last Name, First Name, Page Last Name, First Name, Page
Marso, Steven P. 83 Shulman, Gerald I. 103
Marx, Nikolaus 83 Sinclair, David A. 124
Mathieu, Chantal 104 Skyler, Jay S. 122
Matthews, David R. 125 Sluijter, Joost P.G. 123
McGill, Janet B. 109 Snoek, Frank J. 122
McMurray, John J. 76 Stehouwer, Coen D.A. 80
Meier, Christian 84 Stocks, Ben 55

Invited speakers
Mirmira, Raghavendra 57 Storkey, Amos J. 106
Mittendorfer, Bettina 106 Sumithran, Priya 108
Mosenzon, Ofri 83 Susztak, Katalin, 81
Müller, Timo. 82 Tabák, Adam G. 80
Nair, Gopika G. 124 Tack, Cees J. 78
Najjar, Sonia M. 106 Theis, Fabian 56
Napoli, Nicola 84 Tiktin, Margaret A. 125
Nathan, David M. 125 Todd, John A. 75
Nauck, Michael A. 107 Tuomi, Tiinamaija 80
Newsome, Philip N. 102 Udler, Miriam S. 56
Nørgaard, Kirsten 122 Ullrich, Susanne J. 58
Norhammar, Anna 105 Valenti, Luca V.C. 58
Nuutila, Pirjo 58 Van Acker, Kristien 81
Otonkoski, Timo 124 van den Berghe, Greet 107
Packer, Milton 105 Van der Schueren, Bart 108
Pearson, Ewan R. 79 van Duinkerken, Eelco 103
Pesta, Dominik H. 59 Villarroya, Francesc 82
Peters, Anne 122 Vilsbøll, Tina 78
Petrie, John 80 Viñuela, Ana 56
Pettus, Jeremy 122 Wang, Sheila 56
Pieber, Thomas R. 102 Wanner, Christoph 106
Pirzgalska, Roksana 55 Weinstock, Ruth 122
Pruijm, Menno 81 Wheeler, David 76
Puhka, Maija 123 Wilding, John P.H. 107
Renard, Eric M. 122 Yabe, Daisuke 59
Rogers, Helen 125 Yki-Järvinen, Hannele 108
Ruilope, Luis M. 109 Younes, Naji 125
Sanyal, Arun 58 Zaharia, Oana Patricia 55
Sattar, Naveed 102 Zeigerer, Anja 103
Schlesinger, Sabrina 107 Ziegler, Dan 80
Schmid, Sebastian M. 123 Zierath, Juleen R. 33, 78
Sen, Ilke 55
Shields, Beverley M. 79

207
 The European Foundation for the Study of Diabetes (EFSD) was created
by the European Association for the Study of Diabetes (EASD) in order to
support more actively diabetes research in Europe and to serve the goals of
EASD. The EFSD began its work in 2000 and has become a significant
Invited

European funding agency for diabetes research, and is continually striving to

enhance diabetes awareness in Europe.
EFSD

Since inception, EFSD has committed over €100 million to European

speakers

diabetes research by way of a wide range of grant and fellowship funding

initiatives.

BOARD
S. Del Prato, IT President
C. Mathieu, BE Senior Vice-President
F. Gribble, UK Board Member
P.-H. Groop, FI Board Member
H. Mulder, SE Board Member
M. Roden, DE Board Member
M. Rydén, SE Board Member
P. Schrauwen, NL Board Member
M. Solimena, DE Board Member
C.D.A. Stehouwer, NL Board Member
P. Wilson, BE Board Member
W. Winzer, DE Board Member

EFSD Scientific Board

M. Roden, DE (Chair) M. Federici, IT

T. Battelino, SI P. Fioretto, IT
M. Blüher, DE H. Al-Hasani, DE
A.J.M. Boulton, UK N. Lalic, RS
F. Bosch, ES M. Nauck, DE
M. Donath, CH U. Smith, SE
F. Dotta, IT A. Tsapas, GR
G.P. Fadini, IT J. Zierath, SE

208
EFSD Grant and Fellowship Programmes

EFSD is greatly indebted to the following companies and organisations for

their most generous support of European diabetes research:

Boehringer Ingelheim:

EFSD
EFSD/Boehringer Ingelheim European Research Programme
on “Multi-System Challenges in Diabetes”
This Programme is intended to stimulate and accelerate European research
on the interrelation and crosstalk of different organs (e.g. heart, kidney,
pancreas, gut, liver and brain) and related pathophysiology in diabetes and
its complications and the impact of therapeutic interventions for this complex
condition.

EUDF:

EFSD and EUDF Digitalisation in Diabetes Care Research Grant

This Programme is intended to stimulate and accelerate European research
aimed at optimising the use of technology, digital health and innovative
treatments to support self-care by people with diabetes, to prevent
complications and support quality of life.

Japan Diabetes Society:

EFSD/JDS Reciprocal Travel Research Fellowships

The objective of these Fellowships is to encourage collaborative research
between Europe and Japan in the field of diabetes.

JDRF and Lilly:

EFSD/JDRF/Lilly European Programme in Type 1 Diabetes Research

This Programme aims to increase awareness and promote the highest
quality of basic biomedical and clinical research in Europe and its associated
countries applicable to type 1 diabetes.

209
 Lilly:

EFSD/Lilly European Diabetes Research Programme

This Programme aims to promote increased European diabetes research
and to raise public awareness and political understanding of the disease.
Grants are offered for any area of basic or clinical diabetes research.
EFSD/Lilly Young Investigator Research Award Programme
EFSD

The objective of these Young Investigator Research Awards is to encourage

innovative research in the field of diabetes and its complications, and to
promote excellence in medical education.

EFSD/Lilly EXPLORING AND APPLYING NEW STRATEGIES IN

DIABETES (EXPAND) Programme
This Programme aims to assess with dedicated research projects, potential
strategies that could be implemented in Europe and rolled out in low-and
middle income countries to favour the improvement of quality of care for all
people living with diabetes.

Merck Sharp & Dohme:

EFSD European Research Programme on “New Targets for Diabetes or

Obesity-related Metabolic Diseases” supported by MSD
This Programme is intended to stimulate and accelerate European research
focusing on the identification and molecular understanding of new targets for
the treatment of type 2 diabetes or obesity-related metabolic diseases.

Novo Nordisk A/S:

EFSD/Novo Nordisk Programme for Diabetes Research in Europe

This Programme aims to promote high-quality diabetes research in Europe,
and accepts applications from all fields of clinical and basic diabetes
research.
EASD Rising Star Symposium & EFSD Research Fellowship
Programme supported by Novo Nordisk
This combined EASD/EFSD initiative aims to identify promising and
innovative young researchers in basic and clinical diabetes research.

210
Novo Nordisk Foundation:

EFSD/Novo Nordisk Foundation Future Leaders Award Programme

This Programme is intended to identify outstanding clinical and basic
scientists in European diabetes research in the transition from
postdoctoral/clinical fellow to a tenured academic appointment in diabetes
research in Europe and support them though significant career development

EFSD
awards over 5 years and fostering their development into the leaders of
tomorrow.

EFSD/Novo Nordisk Foundation Precision Diabetes Medicine Award

Programme
This Programme is based on scientific quality, innovation potential and a
clear translational focus; bringing basic knowledge to use at the patient level
in terms of e.g. disease prognosis, treatment prediction or patient
stratification.

EFSD Anniversary Fund:

Supported by Boehringer Ingelheim, Lilly and Novo Nordisk

This multi supported programme joins in the celebration of the 100-Year
Anniversary of the discovery of insulin with the aim at supporting the most
talented investigators in the fields of diabetes research in Europe. Projects
may be basic, translational and/or clinical research on diabetes or its
comorbidities and complications.

In addition, the EFSD Albert Renold Travel Fellowships are available

throughout the year, and enable young scientists to stay at other institutions
in order to learn new techniques in basic or clinical diabetes research.

EFSD awards are strictly competitive and decisions are based upon a
rigorous and fully independent peer-review process.

Further information on EFSD programmes can be found under:

www.EuropeanDiabetesFoundation.org

211
Symposia

SYMPOSIA
ON THE OCCASION
OF THE
57th ANNUAL MEETING
OF THE
EUROPEAN ASSOCIATION
FOR THE STUDY
OF DIABETES

212
 IDF EUROPE SYMPOSIUM:
THE USE OF DATA IN DIABETES - A PATIENT-
CENTRED APPROACH

Symposia
Monday, 27 September 2021 14:30 - 15:45

Berlin Hall

Moderator: N. Pall, UK

Panelists:

B. Hauck, Germany

H. van Haastert, Belgium

S. Shepered, UK

N. Klazinga, Nertherlands

T. Ross, Bahrain

M. Chlebus, Belgium

K. Kivinen, Finland

213
 DIABETIC FOOT STUDY GROUP SYMPOSIUM:
WHAT DO I NEED TO KNOW ABOUT
DIABETIC FOOT TODAY?

Tuesday, 28 September 2021 08:30 - 10:00

Symposia

Berlin Hall

Chairs: N. Papanas, Greece; F. Game, UK

R. Anichini, Italy:
Epidemiology and COVID-19

N. Petrova, UK:
Charcot osteoarthropathy

E. Brocco, Italy:
Diagnosis and prevention of peripheral arterial disease

S. Bus, Netherlands:
Prevention and preventative offloading

J.L. Lázaro-Martínez, Spain:

Physician and surgeon hand-in-hand

Discussion

214
 DIAB IMAGE - BIOMEDICAL IMAGING IN DIABETES
STUDY GROUP SYMPOSIUM

Tuesday, 28 September 2021 10:30 - 12:30

Symposia
Berlin Hall

Chairs: O. Eriksson, Sweden; M. Gotthardt, Netherlands; V. Schrauwen, The

Netherlands

O. Eriksson, Sweden:
Welcome address and update on the study group activities

P. Iozzo, Italy:
Investigation of metabolism by PET-CT

M. Krssak, Austria:
Magnetic Resonance Spectroscopy as a tool to investigate metabolic
changes in insulin resistance and diabetes

Closed session - annual study group meeting

215
 D&CVD STUDY GROUP SYMPOSIUM:
TOWARDS HEART FAILURE AND CARDIOMETABOLIC
MANAGEMENT IN TYPE 2 DIABETES

Tuesday, 28 September 2021 13:00 - 15:00

Symposia

Berlin Hall

Chairs: D. Catrinoiu, Romania; O. Schnell, Germany

A. Ceriello, Italy:
Welcome

P. Valensi, France:
An homage to 100 years of insulin therapy: What has been achieved
regarding cardiovascular complications?

A. Ceriello, Italy:
How can we compromise between gluco- and cardio-centric
management of diabetes?

N. Lalic, Serbia:
Heart failure in diabetes mellitus: the role of the diabetologist in the
interdisciplinary diagnostic assessment

B. Itzhak, Israel:
Heart failure management: a perspective from diabetes care

E. Standl, Germany:
Heart failure outcomes and COVID-19

General discussion and close

216
 RMSG SYMPOSIUM:
REACTIVE METABOLITES AND INCREASED RISK
OF SEVERE COVID-19 DISEASE IN OBESITY
AND DIABETES

Tuesday, 28 September 2021 16:00 - 17:00

Symposia
Berlin Hall

Chairs: N. Rabbani, Qatar; M. Al-Asmakh, Qatar

A. Ceriello, Italy:
Could increased reactive oxygen species (ROS) contribute to severe
COVID-19 in obesity and diabetes?

P.J. Thornally, Qatar:

Increased methylglyoxal in obesity and diabetes – friend or foe of
SARS-CoV2?

217
 EDNSG SYMPOSIUM:
HOT TOPICS IN DIABETES KIDNEY DISEASE

Wednesday, 29 September 2021 08:00 - 10:30

Symposia

Berlin Hall

Chair: L. Gnudi, UK

H. L. Heerspink, Netherlands:
Clinical trials in DKD – from one size fits all to one fit for everyone

S. Satchell, UK:
Mechanisms of glomerular filtration and disruption in diabetic kidney
disease

R. Schmieder, Germany:
Devices based interventions for CKD and DKD

N. Montserrat, Spain:
Stem cells and organoids: new avenues in diabetic nephropathy
research

L. Gnudi, UK:
Close

218
 STUDY GROUP ON METABOLIC SURGERY
SYMPOSIUM:
CREATING A NETWORK ON METABOLIC SURGERY
FOR THE TREATMENT OF METABOLIC DISEASE

Wednesday, 29 September 2021 11:00 - 12:00

Symposia
Berlin Hall

Chairs: G. Mingrone, Italy; G. Casella, Italy

G. Mingrone, Italy:
Introduction to the MSSG study group

G. Angelini, Italy:
Molecular mechanism of metabolic surgery

M. F. Russo, Italy:
Relationship between body composition and NASH

D. Tsilingiris, Greece:
Long-term effects of bariatric surgery on gut peptide responses and
markers of insulin resistance; association with appetite and weight loss

W. Al-Najim, Ireland:
How can IMI SOPHIA benefit to our understanding of predictors of
response to metabolic surgery?

T. Le Roy, France:
Gut microbiota, bariatric surgery and diabetes resolution

219
 DESG SYMPOSIUM:
THERAPEUTIC PATIENTS’ EDUCATION - ONE YEAR
EXPERIENCE DURING COVID-19 PANDEMIC

Wednesday, 29 September 2021 12:30 - 14:30

Symposia

Berlin Hall

Chairs: F. Toti, Alania; M. Hassanein, UK

F. Toti, Albania; I. Alimehmeti, Albania; E. Nelaj, Albania; D. Doracaj,

Albania:
Impact of COVID-19 in diabetes and other chronic diseases
management

M. Hassanein, UK:
Inpatient management during COVID time: Can technology help?

A. Gupta, India; R. Gupta, India:

Diabetes democracy through digital patient education and training

B. Stepanow, Poland:
The effectiveness of the Diabetofon hotline during COVID-19

Questions and answers

Round table: Therapeutic patients' education in COVID time

D. Rahelic, Croatia; J. Raposo, Portugal; T. Milenkovic, North
Macedonia; T. Tankova, Bulgaria; B. Saboo, India; A. Majchrzak,
Poland; I. Vlasenko, Ukraine; S. P. Montesinos

T. Milenkovic, North Macedonia; F. Toti, Albania:

Closure

220
 EGIR SYMPOSIUM:
WHAT’S THE MATTER WITH ADIPOSE TISSUE AND
INSULIN RESISTANCE?

Wednesday, 29 September 2021 15:00 - 15:45

Symposia
Berlin Hall

Chairs: M. Manco, Italy; A. Gastaldelli, Italy

P. Scherer, USA:
Adipose tissue as a major determinant of systemic insulin sensitivity

T.V. Puig:
Adipose tissue expandability, lipotoxicity and metabolic syndrome

Discussion

221
 NAFLD STUDY GROUP SYMPOSIUM:
WHAT’S THE MATTER WITH ADIPOSE TISSUE AND
HEPATIC STEATOSIS?

Wednesday, 29 September 2021 16:15 - 17:00

Symposia

Berlin Hall

Chairs: C. Postic, France; A. Gastaldelli, Italy

S. Klein, Germany:
Alterations in adipose tissue biology in people with hepatic steatosis

M. Roden, Germany:
Differences in hepatic steatosis and metabolic features of novel
diabetes subtypes

Discussion

222
 PCDE SYMPOSIUM:
RESEARCH OUTPUT DURING THE COVID-19
PANDEMIC

Thursday, 30 September 2021 08:00 - 09:30

Symposia
Berlin Hall

Chair: P. Topsever, Turkey

P. Topsever, Turkey:
Introduction

S. Kunutsor, UK:
Indirect effect of COVID pandemic on cardiovascular hospitalisations

S. van Grondelle, Netherlands:

Impact of COVID pandemic on primary care workforce

S. Seidu, UK:
Combined effect of SGLT-2 Is and RAAS Blockage on cardio-renal
outcomes

L. i Arboix, Spain:
Diabetes foot risk assessment in primary care

P. Topsever, Turkey:
Concluding remarks

223
 NEURODIAB SYMPOSIUM:
DIABETIC NEUROPATHY - THE UNATTENDED
BORDERLINE

Thursday, 30 September 2021 10:00 - 12:00

Symposia

Berlin Hall

Chairs: P. Kempler, Hungary; S. Tesfaye, UK

U. Alam, UK:
Neuropathy in prediabetes

S. Frontoni, Italy:
Diabetic neuropathy: a new vision

A. Körei, Hungary:
Do we still need all five standard tests in the diagnosis of
cardiovascular autonomic neuropathy?

D. Ziegler, Germany:
Evidence based pharmacotherapy of diabetic polyneuropathy

M. Yorek, USA:
Is there an experimental evidence for the neuroprotective role of
insulin?

224
 HSRHE SYMPOSIUM:
HEALTH CARE, HEALTH OUTCOMES AND COSTS 
FOR PEOPLE WITH DIABETES DURING THE COVID-19
PANDEMIC AND BEYOND

Thursday, 30 September 2021 12:30 - 14:30

Symposia
Berlin Hall

Chairs: A. Icks, Germany; W. Jeffcoate, UK

M. Narres, Germany:
Hospitalisation rate and mortality among people with and without
diabetes during the COVID-19 pandemic year 2020 in comparison to
previous years

N. Sattar, UK:
The effects of COVID-19 on the health of people with diabetes

G. Booth, Canada:
Diabetes and COVID-19 severity: a systematic review of the literature

R. Geurten, Netherlands:
Delineating the type 2 diabetes population in the Netherlands using an
all-payer claims database: specialist care, medication utilisation and
expenditures 2016–2018

A. Icks, Germany:
The future plans of the study group

225
 INTERNATIONAL HYPOGLYCAEMIA STUDY GROUP
SYMPOSIUM:
LONG-TERM COGNITIVE CONSEQUENCES OF
SEVERE HYPOGLYCAEMIA

Thursday, 30 September 2021 15:00 - 17:00

Symposia

Berlin Hall

Chair: S. Heller, UK

S. Heller, UK:
Welcome and introduction

B. Frier, UK:
Hypoglycaemia and cognition in type 1 diabetes: new perspectives
from the DCCT/EDIC cohort

R. McCrimmon, UK:
Hypoglycaemia and cognition in type 2 diabetes

E. Seaquist, USA:
Blood glucose and cognition: mechanism of the long-term
consequences of severe hypoglycaemia

L. Gonder-Frederick, USA:
Prevention of cognitive impairment

T. Jones, Australia:
Hypoglycaemia in the paediatric population

Panel discussion: Implications & call to action

S. Heller, UK:
Closing

226
Industry Sessions
on the occasion of the
57th EASD Annual Meeting

www.easd-industry.com

Organised by

INTERPLAN
media & service gmbh
 INDUSTRY SESSION SCHEDULE

INDUSTRY SESSION SCHEDULE

Industry Day
Industry Symposia

Moscow Novo Nordisk

Hall 14:30-16:10

Paris SANOFI
Hall 10:30-12:00

London AstraZeneca
Hall 14:30-16:00

Madrid Abbott Diabetes Care

Hall 14:30-15:30

Barcelona MSD
Hall 14:30-15:30

Saint
Dexcom
Petersburg
12:30-13:30
Hall

Meet the
Expert

228
 INDUSTRY SESSION SCHEDULE

INDUSTRY SESSION SCHEDULE

Monday, 27 September 2021

Industry Symposia
Novo Nordisk Novo Nordisk
16:30-17:30 19:00-19:30

SANOFI
16:30-17:45

AstraZeneca Insulet
17:00-18:00 19:00-20:30

SANOFI
18:00-18:30

229
 INDUSTRY SESSION SCHEDULE
INDUSTRY SESSION SCHEDULE

Morning

Moscow MESI, Ltd.

Hall 09:00-09:10
Industry Symposia

Paris Novo Nordisk

Hall 09:15-09:45
London AstraZeneca
Hall 09:35-09:45
Boehringer Ingelheim &
Madrid
Hall Eli Lilly and Company Alliance
09:35-09:45
Barcelona Eli Lilly and Company
Hall 09:35-09:45

Evening

Moscow Novo Nordisk

Hall 17:40-18:40

Paris SANOFI
Hall 17:40-18:40

London AstraZeneca
Hall 17:40-18:40

Boehringer Ingelheim & Eli Lilly and Company Alliance /

Madrid
Hall PACE-CME
17:40-18:10

Barcelona Ypsomed AG
Hall 17:40-19:10
Saint
Medtronic
Petersburg
17:40-19:10
Hall
Berlin Roche Diabetes Care GmbH
Hall 17:40-19:10

Athens Bayer AG
Hall 17:40-18:40

Milan Tandem Diabetes Care, Inc.

Hall 17:40-18:40

230
 INDUSTRY SESSION SCHEDULE
INDUSTRY SESSION SCHEDULE

Tuesday, 28 September 2021

Industry Symposia
Eli Lilly and Company
19:30-21:00

Sciarc GmbH
19:30-20:00

DIABELOOP SA
19:30-20:00

231
 INDUSTRY SESSION SCHEDULE
INDUSTRY SESSION SCHEDULE

Morning

London AstraZeneca AstraZeneca

Hall 09:20-09:30 09:35-09:45
Industry Symposia

Boehringer Ingelheim &

Madrid
Hall Eli Lilly and Company Alliance
09:35-09:45
Eli Lilly and
Barcelona
Hall Company
08:45-09:15

Evening

Moscow Novo Nordisk Eli Lilly and Company

Hall 18:30-19:00 19:15-19:25

SANOFI
Paris Hall
18:30-19:30

London AstraZeneca
Hall 18:30-19:00

Madrid Boehringer Ingelheim & Eli Lilly and Company Alliance

Hall 18:30-19:30

Barcelona MSD
Hall 18:30-19:30
Saint
Dexcom
Petersburg
18:30-19:30
Hall
Berlin Medtelligence
Hall 18:30-19:30

Athens Bayer AG
Hall 18:30-19:30

Meet the
Expert

232
 INDUSTRY SESSION SCHEDULE
INDUSTRY SESSION SCHEDULE

Wednesday, 29 September 2021

Industry Symposia
Eli Lilly and Company Amryt Pharmaceuticals
19:30-19:40 20:00-21:00

Eli Lilly and Company

20:00-21:00

Medtronic
19:30-20:00

Eli Lilly and Company

20:00-20:30

Bayer AG
19:45-20:45

233
 INDUSTRY SESSION SCHEDULE
INDUSTRY SESSION SCHEDULE

Morning
Moscow Novo Nordisk
Hall 09:15-09:45
Paris Eli Lilly and Company
Industry Symposia

Hall 09:35-09:45
Meet the LifeScan
Expert 09:15-09:45

Evening

Moscow AstraZeneca
Hall 18:05-18:15
Boehringer Ingelheim
Paris & Eli Lilly and
Hall Company Alliance
18:05-18:15
London LifeScan
Hall 18:15-19:15
Madrid CPC Clinical Research
Hall 18:15-19:15
Barcelona MSD
Hall 18:15-18:45
Saint
Medscape Education
Petersburg
18:15-19:15
Hall
Berlin SANOFI
Hall 18:15-18:45

Morning Friday, 1 October 2021

London Medscape Education

Hall 08:15-09:15

Evening
Moscow Novo Nordisk
Hall 17:40-18:40

Paris SANOFI
Hall 18:45-19:15

Madrid Eli Lilly and Company

Hall 19:00-19:30

234
 INDUSTRY SESSION SCHEDULE
INDUSTRY SESSION SCHEDULE

Thursday, 30 September 2021

Industry Symposia
Nestle Health Science
20:00-21:30

All stated times in CEST

Status September 2021, details are subject to change.

235
 MONDAY, 27 SEPTEMBER 2021 10:30 – 12:00
PARIS HALL

CONNECTIONS AND COMBINATIONS:

SUPPORTING PEOPLE TO HELP CONTROL THEIR DIABETES

Session 1: Combining insulin with technology:

Industry Symposia

Towards connected care solutions

10:30 – 10:40 Symposium introduction

Richard Bergenstal (USA)

10:40 – 10:55 Keynote lecture: A turning point in diabetes management

Richard Bergenstal (USA)

10:55 – 11:15 Insulin as part of the treatment journey: Across diabetes

populations and moments
Alice Y.Y. Cheng (CAN)
Jeremy Pettus (USA)

11:15 – 11:35 Advances in glycemic metrics: The value of time-in-range

for people with diabetes
Richard Bergenstal (USA)

11:35 – 11:50 Integrating therapy and care for people with diabetes:
The value of connected solutions (roundtable discussion)
David Kerr (USA)
Jeremy Pettus (USA)
Lori Berard (CAN)

11:50 – 12:00 Q&A and session summary

Richard Bergenstal (USA) and all speakers

Organised by: SANOFI

236
MONDAY, 27 SEPTEMBER 2021 12:30 – 13:30
SAINT PETERSBURG HALL

DEXCOM REAL-TIME CGM INTEROPERABILITY –

THE FOUNDATION FOR PATIENT CHOICE & SUCCESS
IN DIABETES MANAGEMENT

Industry Symposia

Organised by: Dexcom

237
 MONDAY, 27 SEPTEMBER 2021 14:30 – 15:30
BARCELONA HALL

LATEST CLINICAL UNDERSTANDING FROM VERTIS CV FOR

PATIENTS WITH DIABETES, CARDIOVASCULAR AND RENAL
DISEASE: A CROSS-SPECIALTY DISCUSSION
Industry Symposia

Chairs: Chris Cannon (USA), Sam Dagogo-Jack (USA)

14:30 – 14:35 Opening Remarks

Chairs (USA)

14:35 – 14:45 Ertugliflozin and VERTIS CV – New Data Expanding Our

Understanding for the Treatment of Patients With Type 2
Diabetes and Cardiovascular Disease
Sam Dagogo-Jack (USA)

14:45 – 14:55 Recent Data on the Efficacy and Safety of Ertugliflozin

Using Insulin in Patients with Type 2 Diabetes Mellitus
and Established Cardiovascular Disease
Ildiko Lingvay (USA)

14:55 – 15:05 The Latest VERTIS CV Heart Failure Results - Adding to

Our Clinical Understanding From a Cardiologist’s View
Francesco Cosentino (SWE)

15:05 – 15:15 New VERTIS CV Kidney Protection Results - Adding to

Our Clinical Understanding From a Nephrologist’s View
David Cherney (CAN)

15:15 – 15:28 What Does It All Mean For Our Patients?

A Cross-Specialty Faculty – Roundtable Discussion
Faculty

15:28 – 15:30 Closing Remarks

Chairs (USA)

Organised by: MSD

238
MONDAY, 27 SEPTEMBER 2021 14:30 – 15:30
MADRID HALL

CRITICAL ADVANCES IN FLASH-BASED CGM: A FOUNDATIONAL

APPROACH TO OPTIMIZING HEALTH METRICS AND COSTS
ACROSS THE ENTIRE SPECTRUM OF DIABETES CARE
14:30 – 14:40 Program Chair Welcome and Introduction

Industry Symposia
Mainstreaming CGM Across the Spectrum of Diabetes
Care: What Groups Will Benefit?
Type 2 Diabetes? Newly Diagnosed Patients? A Roadmap
to Clinical Success and Patient Satisfaction
What Parameters Do We Follow with Ambulatory Glucose
Profiling (AGP): Applications of CGM to Both Lifestyle and
Pharmacologic Interventions – An Overview
Tadej Battelino (SVN)
14:40 – 14:55 Real World and Prospective Trials Supporting CGM as a
Foundational Approach to Management of Diabetes:
How Does Flash-Based CGM Optimize Time in Range,
Reduction in Hypoglycemia, and Improve Personalized,
A1c Target Goal Attainment?
Real World Data for Optimizing Multiple, Glycemic/Metabolic
Control and Patient Safety Metrics in the Covid-19 Era and
Beyond
Ramzi Ajjan (UK)
14:55- 15:10 Pharmacoeconomic Benefits of Deploying Flash-Based
CGM Across the Diabetes Population: Reducing
Hospitalizations, Cost Neutrality, and Comparative Costs
Among CGM Device Platforms
Comparing Health Economic Data, Hospitalization Rates, and
Clinical Outcomes with Flash-Based CGM
Partha Kar (UK)
15:10 – 15:25 Applying Flash-Based CGM to the Front Lines of Diabetes
Care in the Real World: Patient Case Management Session
A Case-Based Master Class Using Flash Glucose Monitoring
Technology to Improve Glycemic Metrics, Target Goal Attainment,
and Therapeutic Safety of Diabetic Treatment Regimens
Tadej Battelino (SVN)
15:25 – 15:30 Program Summary and Vision Statement
The Evolving Foundational Role of Flash-Based Glucose
Monitoring Technology in Optimizing Cost Containment
and Clinical Outcomes in Persons with Diabetes
A Practical Roadmap for the Application of New Advance-
ments in Flash-Based Glucose Monitoring
Tadej Battelino (SVN)
Organised by: Abbott Diabetes Care

239
 MONDAY, 27 SEPTEMBER 2021 14:30 – 16:00
LONDON HALL

FROM SCIENCE TO PATIENTS:

MECHANISMS OF ORGAN BENEFIT WITH SGLT2 INHIBITION
STATE OF THE ART LECTURE:
NASH, DISEASE BURDEN AND NEW OPPORTUNITIES
Industry Symposia

Chair: Hiddo Heerspink (NLD)

Co-Chair: Nayyar Iqbal (AstraZeneca)

14:30 – 14:35 Welcome

Hiddo Heerspink (NLD)
Elisabeth Björk (AstraZeneca)
Nayyar Iqbal (AstraZeneca)

14:35 – 14:50 Role of water conservation and metabolism in SGLT2

inhibitor mediated organ protection
Jens Marc Titze (SGP)

14:50 – 15:10 Cracking the code in CKD: Mechanisms of renoprotection

Hiddo Heerspink (NLD)

15:10 – 15:30 SGLT2 inhibitors in HF: Piecing together the puzzle of

preserved ejection fraction
Sanjiv Shah (USA)

15:30 – 15:40 Panel discussion

All faculty

15:40 – 15:55 State of art lecture: NASH, disease burden and new
opportunities – Emerging new modalities to manage NASH
Arun Sanyal (USA)

15:55 – 16:00 Closing remarks

Regina Fritsche-Danielson (AstraZeneca)

Organised by: AstraZeneca

240
MONDAY, 27 SEPTEMBER 2021 14:30 – 16:10
MOSCOW HALL

CHANGING PARADIGM THROUGH HOLISTIC APPROACHES

HOLISTIC APPROACHES TO T2D TREATMENT AND WEIGHT
MANAGEMENT IN PEOPLE WITH OBESITY

Chair: Tina Vilsbøll (DNK)

Industry Symposia
14:30 – 14:35 Welcome
Tina Vilsbøll (DNK)
14:35 – 14:47 Should we have a more holistic treatment approach
to improve healthy lifespan in people living with T2D?
Vanita Aroda (USA)
14:47 – 15:10 Panel discussion
Vanita Aroda (USA), Melanie Davies (UK),
John Buse (USA), Nikolaus Marx (GER)
15:10 – 15:20 Treatment intensification in T2D with high-dose
semaglutide: SUSTAIN FORTE
Juan Pablo Frias (USA)
15:20 – 15:25 Questions from the audience

15:25 – 15:27 Break

15:27 – 15:29 Welcome back

Tina Vilsbøll (DNK)
15:29 – 15:37 The potential of semaglutide 2.4 mg for weight
management
Rachel Batterham (UK)
15:37 – 15:47 Changing the paradigm in obesity care: the STEP 1–4 data
Melanie Davies (UK)
15:47 – 15:57 The clinical impact of double-digit weight loss
John Wilding (UK)
15:57 – 16:10 Questions from the audience

16:10 – 16:12 Thanks and wrap-up

Tina Vilsbøll (DNK)

Organised by: Novo Nordisk

241
 MONDAY, 27 SEPTEMBER 2021 16:30 – 17:30
MOSCOW HALL

CONTINUING BEYOND 100

INSULIN INNOVATIONS – 100 YEARS AND BEYOND

Chair: Tina Vilsbøll (DNK)

Industry Symposia

16:30 – 16:35 Welcome

Tina Vilsbøll (DNK)
16:35 – 16:45 Insulin innovations – the past: journey so far
Andreas Liebl (GER)
16:45 – 16:55 Insulin innovations – the present: current scenario
Lena Landstedt-Hallin (SWE)
16:55 – 17:05 Patient case study
Andreas Liebl (GER)
Lena Landstedt-Hallin (SWE)
17:05 – 17:20 Insulin innovations: roadmap to the future
Ronald Goldenberg (CAN)
17:20 – 17:28 Panel discussion

17:28 – 17:30 Thanks and wrap-up

Tina Vilsbøll (DNK)

Organised by: Novo Nordisk

242
MONDAY, 27 SEPTEMBER 2021 16:30 – 17:45
PARIS HALL

CONNECTIONS AND COMBINATIONS:

SUPPORTING PEOPLE TO HELP CONTROL THEIR DIABETES

Session 2: Combining efficacy and simplicity to help improve

Industry Symposia
glycemic control

16:30 – 16:35 Session 2 introduction

Julio Rosenstock (USA)

16:35 – 16:55 Simultaneous approach to therapeutic intensification:

Who, when and why
Yehuda Handelsman (USA)
Leigh Perreault (USA)

16:55 – 17:15 Guiding personalized care with injectable therapies:

Considering the needs of your patient
Stewart Harris (CAN)
Davida Kruger (USA)

17:15 – 17:35 Advancing insulin therapy in adults with T2D:

Outcomes from the SoliMix trial
Julio Rosenstock (USA)

17:35 – 17:45 Q&A and session summary

Julio Rosenstock (USA) and all speakers

Organised by: SANOFI

243
 MONDAY, 27 SEPTEMBER 2021 18:00 – 18:30
MEET THE EXPERT

Chair: Julio Rosenstock (USA)

Industry Symposia

Speaker: Rory McCrimmon (UK)

Organised by: SANOFI

244
MONDAY, 27 SEPTEMBER 2021 19:00 – 19:30
MOSCOW HALL

INTERWOVEN BEYOND TODAY

HIGHLIGHTS AND LEARNINGS: CURRENT DIABETES AND OBESITY
MANAGEMENT AND FUTURE OPPORTUNITIES

Industry Symposia
Chair: Tina Vilsbøll (DNK)

19:00 – 19:05 Welcome

Tina Vilsbøll (DNK)
19:05 – 19:30 Highlights and learnings: current diabetes
and obesity management and future opportunities

Organised by: Novo Nordisk

245
 MONDAY, 27 SEPTEMBER 2021 19:00 – 20:30
LONDON HALL

BEYOND GLYCEMIA: CAN NOVEL TECHNOLOGY ALLEVIATE

THE BURDEN OF DIABETES?

Chair: Trang Ly
Industry Symposia

Speakers: Alice Cheng

William Polonsky
Peter Jennings

Organised by: Insulet

246
TUESDAY, 28 SEPTEMBER 2021 09:00 – 09:10
MOSCOW HALL

TIMELY PAD DETECTION IN DIABETIC PATIENTS.

HOW THE LATEST ABI AND TBI TECHNOLOGY CAN HELP PREVENT
LOWER LIMB ADVERSE EVENTS.

Speaker: Petra Balažic (Brand Manager at MESI, SVN)

Industry Symposia
1. Prevalence of PAD in diabetic patients

2. Guidelines and good medical practice for arterial

assessment

3. Introduction of MESI mTABLET ABI – the automated

wireless device for measuring ABI

4. Discovering PAD in cases of non-compressible by

measuring Toe-Brachial Index (TBI)

5. Introduction of MESI mTABLET TBI – the simplest

wireless device for measuring TBI

Organised by: MESI, Ltd.

247
 TUESDAY, 28 SEPTEMBER 2021 09:35 – 09:45
LONDON HALL

ARTIFICIAL INTELLIGENCE MEET HUMAN INTELLIGENCE:

POWERING PRECISION DECISIONS
Industry Symposia

Organised by: AstraZeneca

248
TUESDAY, 28 SEPTEMBER 2021 09:15 – 09:45
PARIS HALL

CHANGING PARADIGM BY THINKING AHEAD

ORAL SEMAGLUTIDE – WHERE AND HOW DOES IT FIT?

09:15 – 09:20 Overview of oral semaglutide and PIONEER trials

Industry Symposia
Filip K Knop (DNK)
09:20 – 09:30 Case scenarios based on clinical evidence
Filip K Knop (DNK)
Vanita Aroda (USA)
09:30 – 09:35 Patient-centric practicalities
Vanita Aroda (USA)
09:35 – 09:45 A patient-centered approach with oral semaglutide
Panel discussion and Q&A (live)

Organised by: Novo Nordisk

249
 TUESDAY, 28 SEPTEMBER 2021 09:35 – 09:45
MADRID HALL

YOUR TIME TO ACT IS NOW:

BREAKING BARRIERS IN T2D CARE

Speaker: John Buse (USA)

Industry Symposia

Organised by: Boehringer Ingelheim & Eli Lilly and Company Alliance

250
TUESDAY, 28 SEPTEMBER 2021 09:35 – 09:45
BARCELONA HALL

GIP & GLP-1 IN PATHOPHYSIOLOGY & TYPE 2 DIABETES

09:35 – 09:37 Welcome and introduction

Industry Symposia
09:37 – 09:45 T2D Pathophysiology and GIP and GLP-1 Dual Receptor
Agonism

Organised by: Eli Lilly and Company

251
 TUESDAY, 28 SEPTEMBER 2021 17:40 – 18:10
MADRID HALL

TEAMING UP TO TACKLE CARDIORENAL RISK IN DIABETES

ROLE OF SGLT2I: HOW TO OVERCOME CLINICAL INERTIA

17:40 – 17:45 The case challenge

Industry Symposia

Teaming up to tackle cardiorenal risk in diabetes

Melanie Davies (UK)
17:45 – 17:55 Defining treatment goals: SGLT2i, implications from
clinical trials and guidelines
Nikolaus Marx (GER)
17:55 – 18:05 Practical Challenges: SGLT2i in the spectrum of diabetes,
CVD & CKD: Who and how to manage?
Melanie Davies (UK)
18:05 – 18:10 Discussion: How to overcome clinical inertia?
Nikolaus Marx (GER)
Melanie Davies (UK)

Organised by: Boehringer Ingelheim & Eli Lilly and Company Alliance /
PACE-CME
252
TUESDAY, 28 SEPTEMBER 2021 17:40 – 18:40
MOSCOW HALL

COLLECTIVELY TOWARDS MORE

A STEP FORWARD: WEIGHT LOSS AND IMPROVED
CARDIOVASCULAR RISK FACTORS

Industry Symposia
17:40 – 17:55 Introduction: obesity, weight loss and CV risk
Kim Connelly (CAN)

17:55 – 18:10 STEPping forward: cardiovascular risk factors in patients

with overweight or obesity
Ildiko Lingvay (USA)

18:10 – 18:25 STEPping into the future: managing cardiovascular

outcomes in people with overweight or obesity
Subodh Verma (CAN)

18:25 – 18:40 Live Q&A

Chaired by Kim Connelly (CAN)

Organised by: Novo Nordisk

253
 TUESDAY, 28 SEPTEMBER 2021 17:40 – 18:40
PARIS HALL

THE ENDURING POTENTIAL OF INSULIN:

A LEGACY OF LIFE-CHANGING INNOVATION

17:40 – 17:45 Symposium introduction

Industry Symposia

Jay Skyler (USA)

17:45 – 18:00 100 years of insulin therapy for diabetes: From discovery
to innovation
Hertzel Gerstein (CAN)

18:00 – 18:10 Basal insulin and the challenge of hypoglycemia:

A real-world perspective
Stewart Harris (CAN)

18:10 – 18:25 Using 2nd-generation basal insulins:

Lessons from clinical trials to the real world
Emma Wilmot (UK)

18:25 – 18:35 Celebrating 100 years – recognizing insulin’s role in

diabetes management
(roundtable discussion)
All speakers

18:35 – 18:40 Summary and close

Jay Skyler (USA)

Organised by: SANOFI

254
TUESDAY, 28 SEPTEMBER 2021 17:40 – 18:40
LONDON HALL

TIPPING THE SCALES –

REBALANCING CKD IN T2D MANAGEMENT

Industry Symposia
17:40 – 17:45 Welcome and introductions
Silvio Inzucchi (USA)

17:45 – 18:05 Why think about CKD?

Paola Fioretto (ITA)

18:05 – 18:20 Rebalancing T2D management with SGLT2 inhibitors

Peter Rossing (DNK)

18:20 – 18:35 Collaboration in the management of T2D –

a nephrologist’s perspective
Patrick Mark (UK)

18:35 – 18:40 Summary

Silvio Inzucchi (USA)

Organised by: AstraZeneca

255
 TUESDAY, 28 SEPTEMBER 2021 17:40 – 18:40
ATHENS HALL

TESTOSTERONE TREATMENT FOR MEN

WITH HYPOGONADISM AND PREDIABETES/DIABETES

17:40 – 17:50 The perspective of the patient with hypogonadism

Geoff Hackett (UK)
Industry Symposia

17:50 – 18:05 Timely detection of hypogonadism:

The importance of searching proactively
Janine David (UK)

18:05 – 18:20 Health benefits of treating men with hypogonadism and

prediabetes/diabetes
Mathis Grossmann (AUS)

18:20 – 18:35 How to treat functional hypogonadism:

challenges on the long term
Abraham Morgentaler (USA)

18:35 – 18:40 Conclusions and Q&A

Geoff Hackett (UK)

Organised by: Bayer AG

256
TUESDAY, 28 SEPTEMBER 2021 17:40 – 18:40
MILAN HALL

RETHINKING PATIENT SELECTION IN THE ERA

OF ADVANCED HYBRID CLOSED-LOOP SYSTEMS

Industry Symposia

Organised by: Tandem Diabetes Care, Inc.

257
 TUESDAY, 28 SEPTEMBER 2021 17:40 – 19:10
SAINT PETERSBURG HALL

TECHNOLOGIES LEADING TO IMPROVEMENTS

IN CLINICAL OUTCOMES AND BURDEN REDUCTION IN
PEOPLE WITH TYPE 1 DIABETES
Industry Symposia

Chair: Ohad Cohen (CHE)

17:40 – 18:00 Optimizing outcomes with the MiniMedTM 780G system:

evidence from real-world usage
Ohad Cohen (CHE)

18:00 – 18:20 Best practices with the MiniMedTM 780G System

Tadej Battelino (SVN)

18:20 – 18:40 Combining InPen and CGM to Improve Glycemic Outcomes

in MDI Users
Robert Vigersky (USA)

18:40 – 18:55 Next Steps in the Advancement of technologies for the

treatment of diabetes
Ali Dianati (USA)

18:55 – 19:10 Questions & Answers

Ohad Cohen (CHE)

Organised by: Medtronic

258
TUESDAY, 28 SEPTEMBER 2021 17:40 – 19:10
BERLIN HALL

PERSONALISING DIABETES CARE ALONG

THE WHOLE PATIENT JOURNEY

Chair: Rolf Hinzmann (Roche Diabetes Care, GER)

Industry Symposia
17:40 – 17:45 Introduction

17:45 – 18:15 Integrated Personalised Diabetes Management drives

improved patient-reported outcomes
Kamlesh Khunti (UK)

18:15 – 18:35 Screen, triage and treat – a digital paradigm for risk
stratification in CKD
Navdeep Tangri (CAN)

18:35 – 18:55 Innovative therapies and future integrated solutions can

enhance management of diabetic eye disease
Praveen Patel (UK)

18:55 – 19:10 Discussion and Closing

Organised by: Roche Diabetes Care GmbH

259
 TUESDAY, 28 SEPTEMBER 2021 17:40 – 19:10
BARCELONA HALL

TAKING ANDROID APS MAINSTREAM:

A WORKSHOP FOR CLINICIANS

17:40 – 17:45 Welcome

Industry Symposia

James Mayjor (Ypsomed AG, AUS)

17:45 – 18:00 What is Android APS

Neale Cohen (AUS)

18:00 – 18:10 Published data

Martin de Bock (NZL)

18:10 – 18:25 Contemporary use

Neale Cohen (AUS)

18:25 – 18:40 Learning and contemporary use

Martin de Bock (NZL)

18:40 – 19:10 Wrap up and Q&A

James Mayjor (Ypsomed AG, AUS)
Neale Cohen (AUS)
Martin de Bock (NZL)

Organised by: Ypsomed AG

260
TUESDAY, 28 SEPTEMBER 2021 19:30 – 20:00
PARIS HALL

UNDERSTANDING BIOSIMILAR INSULINS:

YOUR PATIENTS’ FUTURE

Chairs: Tina Vilsbøll (DNK), Lutz Heinemann (GER)

Industry Symposia
19:30 – 19:33 Introduction
Tina Vilsbøll (DNK)

19:33 – 19:43 Biosimilar Insulin Manufacturing:

Why the process is the product?
Lutz Heinemann (GER)

19:43 – 19:53 Why do patient and HCP perceptions about biosimilar

insulin matter?
Philip Home (UK)

19:53 – 20:00 Discussion and closure

All

Organised by: Sciarc GmbH / Supported by a medical education grant

from Gan & Lee
261
 TUESDAY, 28 SEPTEMBER 2021 19:30 – 20:00
ATHENS HALL

WHERE DO WE STAND IN TERMS OF CLINICAL EVIDENCE

WITH CLOSED LOOP SYSTEMS?

Chair: Pierre-Yves Benhamou (FRA)

Industry Symposia

19:30 – 19:35 Introduction

Pierre-Yves Benhamou (FRA)

19:35 – 19:43 Germany:

Experience from Germany with DBLG1 w Accu-Chek
Insight: point of view of a diabetologist and an expert
patient
Bernhard Gehr (GER)

19:43 – 19:53 Spain:

Early experience in Spain with Accu-Chek Insight:
outcomes and key learnings
Ana Chico (ESP)
Rosa Corcoy (ESP)

19:53 – 20:00 Next steps:

Future developments: future developments and
improvements, Kids, DBLG1 with Vicentra in France,
other partnerships …
Erik Huneker (FRA)

Organised by: DIABELOOP SA

262
TUESDAY, 28 SEPTEMBER 2021 19:30 – 21:00
MOSCOW HALL

WHAT CAN A FASTER MEALTIME INSULIN MEAN FOR

GLUCOSE CONTROL?

19:30 – 19:35 Welcome and Introductions

Industry Symposia
Carolina Piras de Oliveira

19:35 – 20:10 Review of Lyumjev (insulin lispro) multi-daily injection

clinical studies in T1 and T2 diabetes and Patient Case #1
Emma Wilmot (UK)

20:10 – 20:45 Review of Lyumjev (insulin lispro) CSII clinical studies in

T1 diabetes and Patient Case #2
Andreas Reichel (GER)

20:45 – 21:00 Q&A and Closing Remarks

Organised by: Eli Lilly and Company

263
 WEDNESDAY, 29 SEPTEMBER 2021 08:45 – 09:15
BARCELONA HALL

INCRETIN INSIGHTS: GIP & GLP-1

08:45 – 08:52 Incretin Hormones

Industry Symposia

Overview of Pleiotropic Effects of GIP and GLP-1

08:52 – 08:55 Intro to Pathophysiology Animation Video

08:55 – 09:13 Q&A

09:13 – 09:15 Conclusion

Organised by: Eli Lilly and Company

264
WEDNESDAY, 29 SEPTEMBER 2021 09:20 – 09:30
LONDON HALL

EARLY DIAGNOSIS IS KEY WHEN IT COMES TO CKD –

A PATIENT PERSPECTIVE

Industry Symposia

Organised by: AstraZeneca

265
 WEDNESDAY, 29 SEPTEMBER 2021 09:35 – 09:45
LONDON HALL

DAPA-CKD: REDUCING CARDIO AND RENAL RISK

WITH DAPAGLIFLOZIN IN PATIENTS WITH CKD
Industry Symposia

Organised by: AstraZeneca

266
WEDNESDAY, 29 SEPTEMBER 2021 09:35 – 09:45
MADRID HALL

YOUR CHOICE AFTER METFORMIN:

SGLT2 INHIBITORS OR GLP-1 RECEPTOR AGONISTS?

Speakers: Merlin Thomas (AUS)

Silvio Inzucchi (USA)

Industry Symposia
Francesco Giorgino (ITA)

Organised by: Boehringer Ingelheim & Eli Lilly and Company Alliance

267
 WEDNESDAY, 29 SEPTEMBER 2021 18:30 – 19:00
LONDON HALL

TIPPING THE SCALES –

REBALANCING CKD IN T2D MANAGEMENT

18:30 – 18:35 Welcome and introductions

Industry Symposia

Silvio Inzucchi (USA)

18:35 – 19:00 Tipping the scales – rebalancing CKD in T2D
management: Fireside chat
Silvio Inzucchi (USA)
Patrick Mark (UK)
Peter Rossing (DNK)

Organised by: AstraZeneca

268
WEDNESDAY, 29 SEPTEMBER 2021 18:30 – 19:00
MOSCOW HALL

CONTINUING BEYOND 100

ONCE-WEEKLY INSULINS: THE EXPERTS’ EXPERIENCES

18:30 – 18:32 Welcome

Industry Symposia
Athena Philis-Tsimikas (USA)
Simon Heller (UK)

18:32 – 18:35 A retrospective look:

100 years since insulin was discovered
Simon Heller (UK)

18:35 – 18:47 Once-weekly basal insulins:

From innovation to RCTs
Athena Philis-Tsimikas (USA)

18:47 – 18:53 Patient-centric care:

How once-weekly options may help get patients to target
Simon Heller (UK)

18:53 – 18:58 Questions from the audience

Facilitated by:
Athena Philis-Tsimikas (USA)
Simon Heller (UK)

18:58 – 19:00 Wrap-up

Athena Philis-Tsimikas (USA)
Simon Heller (UK)

Organised by: Novo Nordisk

269
 WEDNESDAY, 29 SEPTEMBER 2021 18:30 – 19:30
PARIS HALL

ADVANCING INJECTABLE THERAPY IN ADULTS WITH T2D:

FINDINGS FROM THE SOLIMIX TRIAL

18:30 – 18:35 Introduction

Julio Rosenstock (USA)
Industry Symposia

18:35 – 18:55 Glycemic goals and overcoming barriers: Unmet needs

for people with T2D
Roundtable discussion
Presentation: Francesco Giorgino (ITA)
Roundtable: Francesco Giorgino (ITA), Julio Rosenstock (USA)

18:55 – 19:15 Advancing basal insulin therapy in the SoliMix trial:

What does it mean for adults with T2D?
Rory McCrimmon (UK), Katherine Whitmire (USA)

19:15 – 19:25 Panel discussion

Moderator: Julio Rosenstock (USA)
and all speakers

19:25 – 19:30 Summary and close

Julio Rosenstock (USA)

Organised by: SANOFI

270
WEDNESDAY, 29 SEPTEMBER 2021 18:30 – 19:30
MADRID HALL

DOES YOUR CLINICAL MANAGEMENT MATCH THE EVIDENCE?

TREATMENT DECISIONS AFTER METFORMIN IN T2D

Speakers: John Buse (chair, USA)

Industry Symposia
Nikolaus Marx (GER)
Naresh Kanumilli (UK)
Maria Jose Soler Romeo (ESP)

18:30 – 18:35 Introduction

18:35 – 19:15 Does your clinical management match the evidence?

Treatment decisions after metformin in T2D

19:15 – 19:30 Panel discussion and Q&A

Organised by: Boehringer Ingelheim & Eli Lilly and Company Alliance

271
 WEDNESDAY, 29 SEPTEMBER 2021 18:30 – 19:30
BARCELONA HALL

CLINICAL TREATMENT OF PATIENTS WITH DIABETES AND

CARDIOMETABOLIC DISEASE - A CONVERSATION WITH AN
ENDOCRINOLOGIST, CARDIOLOGISTS AND A NEPHROLOGIST
Industry Symposia

Chairs: Ofri Mosenzon (ISR), Rich Pratley (USA)

18:30 – 18:33 Opening Remarks

Chairs (ISR, USA)

18:33 – 18:41 Highlighting the Patient with Diabetes and Cardiometabolic

Disease
Rich Pratley (USA)

18:41 – 18:49 Answering Unmet Needs – Clinical Understanding of

Recent Heart Failure Data for Patients with Diabetes and
Cardiovascular Disease
Chris Cannon (USA)

18:49 – 18:57 Adding to the Clinical Understanding for Patients with

Diabetes and Cardio-renal Disease
David Cherney (CAN)

18:57 – 19:27 A Cross-Specialty Faculty Roundtable on Meeting the

Needs of Patients with Diabetes and Established Cardio-
metabolic Disease: Are SGLT2is Best Utilized as a
Cardiovascular Drug? A Kidney Drug? A Glycemic
Lowering Agent? Or All of the Above?
Faculty

19:27 – 19:30 Closing Remarks

Chairs (ISR, USA)

Organised by: MSD

272
WEDNESDAY, 29 SEPTEMBER 2021 18:30 – 19:30
SAINT PETERSBURG HALL

DEXCOM REAL-TIME CGM FOR ALL INSULIN REQUIRING

PATIENTS – THE EMERGING STANDARD OF CARE

Industry Symposia

Organised by: Dexcom

273
 WEDNESDAY, 29 SEPTEMBER 2021 18:30 – 19:30
BERLIN HALL

INTEGRATING NEW EVIDENCE ON ASCVD AND MICRO-

VASCULAR RISK REDUCTION WITH OMEGA-3 FATTY ACIDS
18:30 – 18:35 Welcome, Introductions, Program Overview
Dirk Müller-Wieland (GER)
Industry Symposia

18:35 – 18:55 New Clinical Evidence of Omega-3 Fatty Acids on ASCVD

Event Reduction
Dirk Müller-Wieland (GER)

18:55 – 19:15 Real-world Clinical Implications on Reducing ASCVD Events

Handrean Soran (UK)

19:15 – 19:30 Panel Discussion and Q&A

Handrean Soran (UK), Dirk Müller-Wieland (GER)

Closing Comments
Dirk Müller-Wieland (GER), Handrean Soran (UK)

Organised by: Medtelligence / Supported by an unrestricted

educational grant from Amarin Pharma, Inc.
274
WEDNESDAY, 29 SEPTEMBER 2021 18:30 – 19:30
ATHENS HALL

NEW PERSPECTIVES AND INTERDISCIPLINARY INSIGHTS ON

THE BENEFITS OF MR ANTAGONISM IN CKD AND T2D

Chair: Paola Fioretto (ITA)

Industry Symposia
18:30 – 18:35 Welcome and introductions
Paola Fioretto (ITA)

18:35 – 18:45 Addressing unmet needs in CKD and T2D with nonsteroidal
MR antagonists
Roland Schmieder (GER)

18:45 – 19:00 MR antagonism confers benefits irrespective of

anti-diabetic agents or metabolic status: Insights from
FIDELIO-DKD
Paola Fioretto (ITA)

19:00 – 19:15 FIGARO-DKD: Expanding the benefit of MR antagonism

in CKD and T2D
Samy Hadjadj (FRA)

19:15 – 19:25 Q&A

All faculty

19:25 – 19:30 Summary and close

Paola Fioretto (ITA)

Organised by: Bayer AG

275
 WEDNESDAY, 29 SEPTEMBER 2021 19:15 – 19:25
MOSCOW HALL

THE INCRETIN JOURNEY: PAST, PRESENT AND FUTURE

19:15 – 19:16 Introduction

19:16 – 19:24 The incretin journey: Past, present and future

Industry Symposia

19:24 – 19:25 Summary

Organised by: Eli Lilly and Company

276
WEDNESDAY, 29 SEPTEMBER 2021 19:30 – 19:40
MOSCOW HALL

GIP & GLP-1 IN PATHOPHYSIOLOGY & TYPE 2 DIABETES

19:30 – 19:32 Welcome and introduction

19:32 – 19:40 T2D Pathophysiology and GIP and GLP-1 Dual Receptor

Industry Symposia
Agonism

Organised by: Eli Lilly and Company

277
 WEDNESDAY, 29 SEPTEMBER 2021 19:30 – 20:00
LONDON HALL

COMBINING INPENTM SYSTEM AND CGM

TO IMPROVE GLYCEMIC OUTCOMES IN MDI USERS

Chair: Robert Vigersky (USA)

Industry Symposia

19:30 – 19:40 The need for smart pen for MDI users
Robert Vigersky (USA)

19:40 – 20:00 Case Presentation in Type 1 and Type 2 diabetes

Anders Carlson (USA)

Organised by: Medtronic

278
WEDNESDAY, 29 SEPTEMBER 2021 19:45 – 20:45
MEET THE EXPERT

PEOPLE WITH CKD AND T2D;

HOW FINERENONE REDUCES THE RISK OF PROGRESSION
OF KIDNEY DISEASE AND CV OUTCOMES?
JOIN THE SESSION AND ASK OUR EXPERTS!

Industry Symposia
Speakers: Paola Fioretto (ITA)
Roland Schmieder (GER)
Samy Hadjadj (FRA)

Organised by: Bayer AG

279
 WEDNESDAY, 29 SEPTEMBER 2021 20:00 – 20:30
MADRID HALL

EVALUATION OF THE INCRETIN EFFECT IN HUMANS

20:00 – 20:02 Evaluation of the incretin effect in humans

20:02 – 20:12 Contribution of GLP-1 to the incretin effect

Industry Symposia

20:12 – 20:22 Contribution of GLP-1 to the incretin effect

20:22 – 20:30 Discussion and Closing

Organised by: Eli Lilly and Company

280
WEDNESDAY, 29 SEPTEMBER 2021 20:00 – 21:00
MOSCOW HALL

THE DIFFERENTIAL DIAGNOSIS OF ATYPICAL CASES OF

SEVERE INSULIN RESISTANCE –
SUSPECTING AND DIAGNOSING LIPODYSTROPHY

Industry Symposia
Chair: Matthias Laudes (GER)

20:00 – 20:10 Welcome and introduction

Matthias Laudes (GER)

20:10 – 20:30 Diagnosis of severe insulin resistance and atypical

diabetes and when to suspect lipodystrophy
Francesco Giorgino (ITA)

20:30 – 20:50 The management of lipodystrophy: clinical challenges

and treatment opportunities
Vaia Lambadiari (GRC)

20:50 – 21:00 Q&A, conclusions

Matthias Laudes (GER)

Organised by: Amryt Pharmaceuticals

281
 WEDNESDAY, 29 SEPTEMBER 2021 20:00 – 21:00
PARIS HALL

INTRODUCING TEMPO:
A CONNECTED PEN SYSTEM TO SIMPLIFY
DIABETES MANAGEMENT

20:00 – 20:10 Welcome and instructions

Industry Symposia

20:10 – 20:25 The complexities of insulin management

20:25 – 20:35 Introducing the Tempo Connected Pen System

20:35 – 20:50 Insulin dosing data for more informed treatment

conversations

20:50 – 21:00 Q&A and closing remarks

Organised by: Eli Lilly and Company

282
THURSDAY, 30 SEPTEMBER 2021 09:15 – 09:45
MOSCOW HALL

IMAGINE THE FUTURE,

TODAY THE GLOBAL RISE OF NASH AND LIVER FIBROSIS –
WHAT CAN WE DO?

Industry Symposia
09:15 – 09:35 How and why to identify high-risk patients:
lessons from the clinic
Elmar Jaeckel (GER)
Lise Lotte Gluud (DNK)

09:35 – 09:45 The future of NASH: the importance of interdisciplinary

collaboration
(interactive Q&A)
Elmar Jaeckel (GER)
Lise Lotte Gluud (DNK)

Organised by: Novo Nordisk

283
 THURSDAY, 30 SEPTEMBER 2021 09:15 – 09:45
MEET THE EXPERT

GLUCOSE MONITORING DEVICE INTERFERENTS:

AN UNDER-RECOGNIZED ISSUE
WITH IMPORTANT CLINICAL CONSEQUENCES.
Industry Symposia

Speaker: Andreas Pfützner (GER)

Glucose monitoring interferences when using BGM/CGM.

Organised by: LifeScan

284
THURSDAY, 30 SEPTEMBER 2021 09:35 – 09:45
PARIS HALL

THE INCRETIN JOURNEY:

PAST, PRESENT AND FUTURE

09:35 – 09:36 Introduction

Industry Symposia
09:36 – 09:44 The incretin journey: Past, present and future

09:44 – 09:45 Summary

Organised by: Eli Lilly and Company

285
 THURSDAY, 30 SEPTEMBER 2021 18:05 – 18:15
PARIS HALL

RESULTS OF EMPAGLIFLOZIN IN PATIENTS WITH HFREF

Speaker: Javed Butler (USA)

Industry Symposia

Organised by: Boehringer Ingelheim & Eli Lilly and Company Alliance

286
THURSDAY, 30 SEPTEMBER 2021 18:05 – 18:15
MOSCOW HALL

COFFEE BREAK SESSION:

WHOSE PATIENT IS THIS?

Industry Symposia

Organised by: AstraZeneca

287
 THURSDAY, 30 SEPTEMBER 2021 18:15 – 18:45
BERLIN HALL

THE REAL-WORLD BURDEN AND COST OF DIABETES:

RESULTS FROM THE INPHORM STUDY

18:15 – 18:30 The real-world burden and cost of diabetes:

Industry Symposia

Results from the iNPHORM study

Stewart Harris (CAN)
Alexandria Ratzki-Leewing (CAN)

18:30 – 18:45 Live Q&A

Stewart Harris (CAN)
Alexandria Ratzki-Leewing (CAN)

Organised by: SANOFI

288
THURSDAY, 30 SEPTEMBER 2021 18:15 – 18:45
BARCELONA HALL

CROSS-TALK BETWEEN THE HEART, KIDNEYS &

THE ENDOCRINE SYSTEM – UNDERSTANDING FOR TYPE 2
DIABETES AND CARDIORENAL DISEASE

Industry Symposia
18:15 – 18:20 Opening Remarks
Sam Dagogo-Jack (USA)

18:20 – 18:43 Cross-talk between the Heart, Kidneys & the Endocrine
System – Understanding for Type 2 Diabetes and
Cardiorenal Disease
David Cherney (CAN)
Kim Connelly (CAN)
Sam Dagogo-Jack (USA)

18:43 – 18:45 Closing Remarks

Sam Dagogo-Jack (USA)

Organised by: MSD

289
 THURSDAY, 30 SEPTEMBER 2021 18:15 – 19:15
LONDON HALL

CLINICAL PRACTICE EXPERIENCES USING

A PROFESSIONAL DIABETES MANAGEMENT /
TELEMEDICINE ECOSYSTEM DURING COVID
OUTCOMES OF AN EU ADVISORY BOARD ON DIGITAL
Industry Symposia

THERAPEUTICS AND A LOOK AT ONETOUCH REVEAL

REMOTE MONITORING USAGE IN REAL LIFE
18:15 – 18:20 Introductions
Elizabeth Holt (USA)

18:20 – 18:35 Best practices managing people with diabetes using

telemedicine
Elizabeth Holt (USA)

18:35 – 18:45 Understanding the clinical value of the OneTouch eco-

system for HCPs from multiple EU countries during COVID
Elizabeth Holt (USA)

18:45 – 18:55 Personal stories from HCPs using the OneTouch ecosystem
during COVID

18:55 – 19:05 Real world evidence using the OneTouch ecosystem

Mike Grady (UK)

19:05 – 19:15 Live Q&A

Elizabeth Holt (USA)
Mike Grady (UK)

Organised by: LifeScan

290
THURSDAY, 30 SEPTEMBER 2021 18:15 – 19:15
MADRID HALL

WALKING INTO THE FUTURE – MULTIFACETED CARE

TO REDUCE VASCULAR RISK IN DIABETES
Chair: Cecilia Low Wang (USA)
Co-Chair: Mark Nehler (USA)

Industry Symposia
18:15 – 18:20 Introduction to faculty and program
Cecilia Low Wang (USA)
18:20 – 18:22 Introduction to the Case
Justin Morrison (USA)
18:22 – 18:25 Peripheral Artery Disease Background
Cecilia Low Wang (USA)
18:25 – 18:28 Progression of Case
Justin Morrison (USA)
18:28 – 18:38 Panel Discussion
Rupert Bauersachs (GER), Marc Bonaca (USA), Naomi Hamburg
(USA), Mikhail Kosiborod (USA), Mark Nehler (USA), Subodh
Verma (CAN), Cecilia Low Wang (USA)
18:38 – 18:44 Antithrombotic therapy
Marc Bonaca (USA)
18:44 – 18:53 Glucose-lowering therapy
Mikhail Kosiborod (USA), Subodh Verma (CAN),
Cecilia Low Wang (USA)
18:53 – 18:58 Lipid-modifying therapy
Justin Morrison (USA)
18:58 – 19:02 When is surgery needed?
Mark Nehler (USA)
19:02 – 19:05 Walking into the future – Therapies on the horizon
Marc Bonaca (USA)
19:05 – 19:15 Panel Discussion: Multifaceted management of PAD
and Diabetes and Conclusion
Rupert Bauersachs (GER), Marc Bonaca (USA), Naomi Hamburg
(USA), Mikhail Kosiborod (USA), Justin Morrison (USA), Mark
Nehler (USA), Subodh Verma (CAN), Cecilia Low Wang (USA)

Organised by: CPC Clinical Research

291
 THURSDAY, 30 SEPTEMBER 2021 18:15 – 19:15
SAINT PETERSBURG HALL

A CALL TO COLLABORATIVE ACTION – SHIELDING THE

DIABETES PATIENT FROM MICRO- AND MACROVASCULAR
RISKS WITH GLP-1 RECEPTOR AGONISTS
Industry Symposia

Chair: Naveed Sattar (UK)

18:15 – 18:30 The Endocrinologist in the Lead
The Right Drug for the Right Patient at the Right Time
Panel Discussion: lead by Naveed Sattar (UK)

18:30 – 18:45 The Cardiologist in the Lead

Primary and Secondary Cardiovascular Protection
Panel Discussion: lead by Mark Petrie (UK)

18:45 – 19:00 The Primay Care Physician in the Lead

Implementing Proactive Diabetes Care across the Stages
Panel Discussion: lead by Kamlesh Khunti (UK)

19:00 – 19:15 Panel Discussion and Live Q&A

All Faculty

19:15 Adjourn

Organised by: Medscape Education / Supported by an independent

educational grant from Novo Nordisk
292
THURSDAY, 30 SEPTEMBER 2021 20:00 – 21:30
MADRID HALL

POSTPRANDIAL GLYCAEMIC EXCURSIONS:

IMPLICATIONS FOR HEALTH AND EFFECTS OF
NONPHARMACOLOGICAL INTERVENTIONS

Industry Symposia
20:00 – 20:05 Welcome and Introductions
Bo Ahrén (SWE)

20:05 – 20:40 Health risks associated with elevated postprandial

glucose or increased glycaemic variability
Louis Monnier (FRA)

20:40 – 21:15 Nonpharmacological interventions for postprandial

glucose management
Bo Ahrén (SWE)

21:15 – 21:30 Live Q & A and close

Interactive discussion with speakers

Organised by: Nestle Health Science

293
 FRIDAY, 1 OCTOBER 2021 08:15 – 09:15
LONDON HALL

SURPASSING STANDARDS IN DIABETES CARE –

NOVEL DUAL INCRETIN RECEPTOR AGONISTS

08:15 – 08:25 Better Metabolic Health with Incretin-based Therapies –

Industry Symposia

Achievements and Ambitions

Michael Nauck (GER)

08:25 – 08:40 The Power of novel dual GIP/GLP-1 Receptor Agonists

Tina Vilsbøll (DNK)

08:40 – 09:00 The Clinical Evidence for GIP/GLP-1 Receptor Agonists –

Assessing the Emerging Profile
Melanie Davies (UK)

09:00 – 09:15 Panel Discussion and Q & A

All Faculty

09:15 Adjourn

Organised by: Medscape Education / Supported by an independent

educational grant from Lilly
294
FRIDAY, 1 OCTOBER 2021 17:40 – 18:40
MOSCOW HALL

CHANGING PARADIGM BY THINKING AHEAD:

NEW HORIZONS IN TYPE 2 DIABETES CARE
WITH ORAL SEMAGLUTIDE

Industry Symposia
17:40 – 17:43 Welcome
Adie Viljoen (UK)
17:43 – 17:51 Early treatment: what are the benefits of early initiation of
GLP-1RAs?
Tina Vilsbøll (DNK)
Juris Meier (GER)
17:51 – 18:01 Discussion and Q&A
Tina Vilsbøll (DNK)
Juris Meier (GER)
18:01 – 18:09 Spotlight on: type 2 diabetes management for those with
renal impairment
Tina Vilsbøll (DNK)
Peter Rossing (DNK)
18:09 – 18:19 Discussion and Q&A
Tina Vilsbøll (DNK)
Peter Rossing (DNK)
18:19 – 18:27 Spotlight on: Medical management in individuals with
T2D and CV risk
Matt Cavender (USA)
David Strain (UK)
18:27 – 18:37 Discussion and Q&A
Matt Cavender (USA)
David Strain (UK)
18:37 – 18:40 A look at what is up and coming
Adie Viljoen (UK)

Organised by: Novo Nordisk

295
 FRIDAY, 1 OCTOBER 2021 18:45 – 19:15
PARIS HALL

SUBTYPE CLASSIFICATION OF T2D: ARE WE THERE YET?

18:45 – 19:00 Subtype Classification of T2D: Are We There Yet?

Industry Symposia

Hertzel Gerstein (CAN)

19:00 – 19:15 Live Q&A

Hertzel Gerstein (CAN)

Organised by: SANOFI

296
FRIDAY, 1 OCTOBER 2021 19:00 – 19:30
MADRID HALL

THE INCRETIN EFFECT REVISITED

19:00 – 19:02 The incretin effect revisited

Industry Symposia
19:02 – 19:12 Contra: Can the incretin effect be restored in people with
diabetes?

19:12 – 19:22 Pro: Can the incretin effect be restored in people with
diabetes?

19:22 – 19:30 Discussion and Closing

Organised by: Eli Lilly and Company

297
 3D WORLD / INDUSTRY EXHIBITION

MADRID HALL

EASD Plaza
Industry Symposia

Landing
Point

Eli Lilly A. Menarini

Dexcom
and Company Diagnostics
Eli Lilly
Medtronic and Company
Eli Lilly
i-SENS Insulet
and Company

Undermyfork

Panda Insight
Industry Exhibition Abbott Diabetes Care

DIABELOOP SA

SANOFI
Boehringer Ingelheim
SOOIL & Eli Lilly and Company
Amarin
DEVELOPMENT Alliance

298
 LIST OF SPONSORS
A.Menarini Diagnostics*
Abbott Diabetes Care*
Amarin*
Amryt Pharmaceuticals
AstraZeneca

Industry Symposia
Bayer AG
Bionime Corporation
Boehringer Ingelheim & Eli Lilly and Company Alliance*
CPC Clinical Research
DIABELOOP SA*
Dexcom*
Eli Lilly and Company*
Gan & Lee Pharmaceuticals
Insulet*
i-SENS*
LifeScan
LumiraDx
Medscape Education
Medtelligence
Medtronic*
MESI, Ltd.
MSD
Nestle Health Science
Novo Nordisk
Panda Insight*
Proteomics International
Roche Diabetes Care GmbH
SANOFI*
Sciarc GmbH
SOOIL DEVELOPMENT*
Tandem Diabetes Care, Inc.
Undermyfork*
Ypsomed AG
*This sponsor can also be visited at their virtual booth in the 3D World.
Status September 2021, details are subject to change.

299
WELCOME ADDRESS

On behalf of the EASD Board and the 2022

Scientific Programme Committee, I have the
pleasure of inviting you to participate in the 58th
EASD Annual Meeting in Stockholm, Sweden.

I hope that you will enjoy the present virtual

EASD meeting and it might be difficult to focus
already now on next year’s meeting.
Nevertheless, the diabetes research field is
progressing at a very fast pace and I am sure
you are also looking forward to meeting your
colleagues again in person for interdisciplinary scientific exchange,
dialogue and debate.

The 2022 Scientific Programme Committee will develop again an

outstanding programme with a wide choice of topics covering all
aspects of diabetes research and care and you are encouraged to
submit your research for consideration for presentation during the
meeting by submitting your abstract for review.

I also invite you to enjoy Stockholm’s cultural and recreational

offerings. Sweden’s vibrant capital is sure to be a memorable
backdrop to our Annual Meeting.

We look forward to seeing you in Stockholm in September 2022.

Mikael Rydén
Honorary Secretary EASD

300
58

19 - 23 SEPTEMBER 2022

2022
FOLLOW THE DISCUSSION
LIVE ON TWITTER

#EASD2021
Tweet live
#EASD2021
and follow
@EASDnews